Clinical, laboratory, and genetic studies of families with Charcot-Marie-Tooth type 2C disease by Landoure, G.
  
 
 
 
 
 
 
 
 
Clinical, laboratory, and genetic studies of families with Charcot-
Marie-Tooth type 2C disease 
 
Guida Landouré 
 
A thesis submitted to the University College London for the degree of 
Doctor of Philosophy 
 
August 2011 
 
Department of Medicine 
University College London 
 
 
 
 
 
 
 
 
 
 1 
„I, Guida Landouré, confirm that the work presented in this thesis is my own. Where 
information has been derived from other sources, I confirm that this has been 
indicated in the thesis.‟ 
 2 
Dedication and acknowledgements 
I dedicate this work to:  
GOD the Almighty, the clement and merciful who gave me the chance and courage to 
accomplish this work, and to his Prophet Muhammad, Peace upon Him. 
My parents: thanks for your unshakable love and support throughout my life. 
All my relatives and friends: thanks for being there whenever I needed you. 
My wife and son for their love and support. 
My friend Addis Taye and our patient Kelly Clever (in memoriam). 
First, my thanks to my supervisor Professor Robert Kleta. You have given me the 
chance to accomplish a dream that would be unlikely in other situations. It has 
sometimes been hard, but you have been patient and understanding to make this 
happen. Your sense of good and high standard work is remarkable. 
I am thankful to my supervisor Professor John Hardy. Your guidance and 
encouragement throughout this work were most helpful. 
To my scientific Godfather Dr. Kenneth Fischbeck: I met you when I did not know 
that a gene was made of exons and introns, but you have trusted me from the 
beginning and gave me an opportunity that not many would give to unskilled people 
like me. Thank you for your continued support. I will always be grateful to you.  
To my mentor Dr. Charlotte Sumner: I still remember the day you handed me this 
project, and I was wondering why to a layperson as me. Thank you for all the 
knowledge learned. 
Thank you for all your teaching, and above all for your friendship. 
A special thanks to Professor Moussa Traoré for his continued support. 
Many thanks to my co-workers at UCL and NIH, in particular Horia Stanescu and 
Barrington Burnett. Your presence and support helped me pass difficult moments. 
I thank all the other people who worked in this project from the beginning to the end: 
Dr. Michael Caterina, Shelly Choo, Dr. Rachelle Gaudet, Dr. Henry Houlden, Hitoshi 
Inada, Lingling Kong, Dr. Christy Ludlow, Tara Martinez, Clare Munns, Rima 
Paudel, Christopher Phelps, Yijun Shi, and Dr. Anselm Zdebik.  
 3 
Abstract 
Charcot-Marie-Tooth disease type 2C (CMT2C) is an autosomal dominant 
neuropathy characterized by limb, diaphragm, and laryngeal muscle weakness. We 
studied five unrelated families with CMT2C, of which two showed significant linkage 
to chromosome 12q24.11. Linkage analysis excluded this locus in one of the 
remaining families, suggesting genetic heterogeneity within this CMT subtype. SNP 
genotyping of samples from affected individuals in the three linked families did not 
reveal any deletion or copy number variation. All genes in this region were sequenced 
and two heterozygous missense mutations were identified in the transient receptor 
potential, subfamily V, member 4 (TRPV4), at positions c.805C>T and c.806G>A in 
two families, predicting the amino acid substitutions R269C and R269H, respectively. 
Two other mutations (R186Q, R232C) and one change of uncertain significance 
(D584N) were subsequently identified. The R269C and R269H variants were not 
present in more than 200 controls. TRPV4 is a well known member of the TRP 
superfamily of cation channels. We confirmed that it is expressed in motor and 
sensory neurons. The R186, R232, and R269 residues are located in the intracellular 
N-terminal portion of the TRPV4 protein in the ankyrin repeat domain (ARD); 
functional domains known to mediate protein-protein interactions. When expressed in 
HEK293 cells and Xenopus oocytes, R269C and R269H TRPV4 trafficked normally 
to the cell surface, but caused increased cell toxicity and increased constitutive and 
activated channel currents compared to wild-type TRPV4. Other mutations in TRPV4 
have been previously associated with inherited forms of skeletal dysplasia. When 
mapped onto the crystal structure of the TRPV4 ARD, the mutations found in bone 
diseases lie on the opposite face of the domain compared to those causing neuropathy. 
Our findings indicate that TRPV4 mutations cause a degenerative disorder of 
peripheral nerves. Thus, there is striking phenotypic variability with different 
mutations in this important channel protein. 
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1 Introduction 
1.1 The nervous system 
The human nervous system consists of a central nervous system, the brain and spinal 
cord; and a peripheral nervous system, including cranial and spinal nerves. The 
autonomic or involuntary system is considered to be part of the peripheral nervous 
system.               
1.1.1 Neuron 
Neurons are the basic constituents of the nervous system, which include brain, the 
spinal cord, and the peripheral ganglia. There are motor, sensory, and inter neurons, 
each divided into three parts: a cell body called soma, dendrites that are filaments that 
arise from cell body and receive the input of the neuron, and an axon that carries the 
nerve signals away from the cell body (Figure 1). Neurons are electrically excitable 
cells, allowing them to produce and conduct the regenerative electrical signals called 
action potentials. 
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Figure 1 Diagram representing a myelinated motor neuron.  
(Crossman 2010a) 
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1.1.2 The central nervous system 
The central nervous system (CNS) consists of the brain and the spinal cord. 
The brain 
Human brain consists of six parts: the telencephalon (cerebral hemispheres), the 
diencephalon (thalamus and hypothalamus), mesencephalon (midbrain), the 
cerebellum, the pons, and the medulla oblongata. 
The cerebral cortex 
The cerebral cortex contains sensory areas and areas concerned with motor activity. 
Sensory areas include primary sensory areas and secondary sensory areas. The 
primary sensory areas are constituted with the cortical regions to which impulses that 
convey specific sensory modalities are projected. These areas play the role of 
integrating the sensory experience and the discriminative qualities of sensation. 
Primary sensory areas include the somesthetic area that consists of the postcentral 
gyrus and its medial extension in the paracentral lobule, the visual or striate area 
located along the lips of the calcarine sulcus, the auditory area located on the two 
transverse gyri, the gustatory area localized to most ventral part of the postcentral 
gyrus, the olfactory area that consists of the allocortex of the prepyriform and the 
periamygdaloid regions. 
Motor areas convey impulses related to motor function, modification of muscle tone 
and reflex activity, modulation of sensory impulses, and the alteration of the sense of 
awareness. Motor areas include the primary motor area, the premotor area, the 
supplementary motor area, and the cortical eye fields. The primary motor area or area 
4 of Brodmann is located on the anterior wall of the central sulcus and adjacent 
portions of the precentral gyrus. Lesions of the primary motor area produce flaccid 
paralysis of the controlateral limbs, marked hypotonia, and loss of superficial and 
myotatic reflexes. 
The diencephalon 
Consisting of the thalamus and hypothalamus, the diencephalon is the most rostral 
part of the brain stem. The thalamus consists of three separate nuclei; the ventral 
posterior nucleus, the ventral lateral nucleus, and the ventral anterior nucleus. All 
sensory impulses terminate in the gray masses of the thalamus, except the olfactory 
impulses. The hypothalamus is involved in the visceral, autonomic and endocrine 
functions. 
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The mesencephalon 
Also known as midbrain, the mesencephalon is divided into three parts: the tectum, 
the tegmentum, and the crura cerebri. The tegmentum and crura cerebri are separated 
by the substantia nigra, a large nucleus in the midbrain. Two cranial nerves, the 
trochlear and oculomotor nerves arise in the midbrain. But, the midbrain contains 
important relay nuclei for the auditory and visual systems.  
The cerebellum 
The cerebellum is the organ of coordination, equilibrium and muscle tone. The 
cerebellum contains a median portion, cerebellar vermis, and two lateral lobes, 
cerebellar hemispheres. The cerebellar vermis controls mostly the posture and the 
cerebellar hemispheres control the equilibrium. 
The pons 
Also known as metencephalon, the pons represents the rostral part of the hindbrain. It 
is divided in to two parts: a dorsal portion, the pontine tegmentum, and a ventral 
portion or the proper pons. Nuclei of cranial nerves including the facial, the abducens, 
the trigeminal and the cochlear are found in this part of the brain stem. 
The medulla 
The medulla or myelencephalon is the most caudal brain stem segment. It is the part 
that links the spinal cord to the brain. The medulla is home of some cranial nerves, 
including the hypoglossal, the spinal accessory, the vagus, and the glossopharyngeal.  
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Figure 2 Representation of different parts of the brain. (Crossman A. R. 2010b)  
 
The spinal cord 
The spinal cord, like all of the central nervous system, is derived from the embryonic 
neural tube. It is the main pathway for information connecting the brain to the 
peripheral nervous system. The spinal cord is surrounded by three layers, dura mater, 
pia mater, and arachnoid mater; and lies loosely in the vertebral canal. It is about 45 
cm long in men and 43 cm in women and extends from the foramen magnum to the 
first or second lumbar vertebra. The spinal cord has an ovoid shape, and has two 
spindle-shaped swellings located in the cervical (C4 to T1) and lumbar (T9 to T12) 
regions. The spinal cord contains 33 segments corresponding to the 31 nerve pairs. 
The last 3 coccygeal segments come together to form a single segment. The cord 
furnishes dorsal and ventral root filaments to form a single pair of nerves. There are 8 
cervical, 12 thoracic, 5 lumbar, 5 sacral and usually 1 coccygeal spinal nerves. 
In transverse section, the spinal cord consists of a peripheral region made of the 
neuronal white matter containing sensory and motor neuron axons and myelin (it is 
white because of the myelin). The central part consists of butterfly-shaped gray 
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substance made of nerve cell bodies and their processes, and surrounds the central 
canal; which is an extension of the ventricules located in the brain.  
The gray substance consists of cell columns which have a posterior (dorsal) column or 
horn, an anterior column, and, in the thoracic segments, a small pointed lateral horn.  
The white matter is divided into three paired funiculi: posterior funiculus (between 
posterior horn and posterior median septum), lateral funiculus (between dorsal root 
entry zone and the ventral root fibres emerging site), and the anterior funiculus 
(between the anterior median fissure and the emerging ventral root filaments). The 
white matter contains ascending and descending fibre bundles called tracts or 
fascicules occupying its particular regions.  
Ascending spinal tracts 
Posterior white columns and medial lemnicus tract convey touch, proprioception and 
vibration sense impulses. In this pathway, a primary neuron‟s axon enters the spinal 
cord and then enters column. Lesions involving the posterior columns diminish or 
abolish discriminating tactile sense and kinesthetic sense, mostly in the distal parts of 
extremities. Loss of position in lower limbs impairs gait, and is called posterior 
column ataxia. 
The anterior spinothalamic tract conveys light touch impulses. This is closely 
associated with the medial lemnicus in the pons and midbrain, and terminates upon 
cells of the ventral posterolateral nucleus (VPL) of the thalamus. 
The lateral spinothalamic tract transmits impulses associated with pain and thermal 
sense. This tract sends branches in the brain stem whereas its main fibres terminate in 
the VPL of the thalamus. Unilateral section of this tract leads to loss of pain and 
thermal sense on the opposite side of the body beginning about one segment below 
the level of the lesion. 
The posterior spinocerebellar tract arises from the large cells of the dorsal nucleus of 
Clarke and does not cross; it ascends along the posterolateral periphery of the spinal 
cord. Impulses transmitted via this tract are related to touch and pressure receptors in 
skin. Impulses conveyed by this tract do not reach the conscious level. 
The anterior spinocerebellar tract ascends along the lateral periphery of the spinal 
cord anterior to the posterior spinocerebellar tract. Other spinal tracts are usually 
involved during anterior spinocerebellar tract injury, making it difficult or impossible 
to clinically differentiate its injury. 
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Descending spinal tracts 
The descending spinal tracts mediate motor function, visceral innervations, muscle 
tone, segmental reflexes, and central transmission of sensory impulses. These tracts 
consist of fibres arising mostly from the cerebral cortex (corticospinal system), the 
midbrain (tectospinal, interstitiospinal, and rubrospinal tracts), and the pons 
(vestibulospinal and reticulospinal tracts). 
The corticospinal system consists of the largest and most important tracts. These 
tracts pass through the medullary pyramid and enter and descend in the spinal cord. 
The corticospinal tract undergoes an incomplete decussation at the junction of 
medulla and spinal cord and divides into three separate tracts: the lateral corticospinal 
tract, the anterior corticospinal tract, and the anterolateral corticospinal tract. The 
lateral corticospinal tract is crossed and is the largest tract. It descends the length of 
the spinal cord, gives off fibres to spinal gray at all levels, and progressively 
diminishes in size at more caudal levels. The anterior corticospinal tract is smaller and 
is uncrossed. It is located in an area adjacent to the anterior median fissure and is 
mostly visible in cervical segments. The anterolateral corticospinal tract is the 
smallest tract descending in a more anterior position than the lateral corticospinal 
tract. Its fibres do not cross and terminate in the base of the posterior horn, the 
intermediate gray and central parts of the anterior horn. The corticospinal tract is 
considered the descending pathway conveying voluntary, discrete, skilled movements. 
Lesions of parts of this tract at any level lead to paresis of variable degrees associated 
with loss of muscle tone followed by gradually increased tone, increased tendon 
reflexes, loss of superficial abdominal and cremasteric reflexes, and the Babinski sign 
(the appearance of an extensor toe response on stroking the sole of the foot). 
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Figure 3 Representation of a transverse section of the spinal cord. (Crossman 2010c) 
1.1.3 The peripheral nervous system 
The peripheral nervous system (PNS), in anatomical terms, consists of those parts of 
the nervous system in which neurons or their processes are related to the peripheral 
satellite cell, the cell of Schwann. It thus comprises the cranial nerves (except for the 
second nerve), the spinal nerve roots, the dorsal root ganglia, the peripheral nerve 
trunks and their terminal ramifications and the peripheral autonomic system. 
Peripheral nerves are divided into two main groups: the somatic nerves and autonomic 
nerves. Somatic nerves comprise of motor nerves that control muscles and sensory 
nerves that carry sensations such as heat, pain, and touch to the central nervous 
system. Autonomic nerves are divided into sympathetic and parasympathetic nerves 
that control autonomic functions including blood pressure, digestion, and bladder 
function. 
Structurally, a peripheral nerve or nerve consists of many axons surrounded by a layer 
called endoneurium. Axons are grouped in a fascicle wrapped in a layer called 
perineurium. Externally, the whole nerve is surrounded by another layer called 
epineurium (Figure 4) (Felten D. L. 2010).  
Axon 
An axon is a wiring of a neuron that conducts electrical impulses away from the 
neuron‟s cell body. Axons are thin in diameter, about 1 µm, but long, attaining in 
some cases several feet. They make contact with other cells such as other neurons, 
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muscles and glands through junctions called synapses. Axons are sheathed in myelin, 
but also contain unmyelinated segments called nodes of Ranvier. Action potentials are 
amplified at the nodes of Ranvier and transmitted down the axon. Myelinated axons 
appear in white, making up the “white matter”. 
Myelin 
Myelin is an electrically insulating material that forms a layer called myelin sheath 
around the axon. In the peripheral nerves it is formed by a type of glial cells called 
Schwann cells, and contributes to a rapid propagation of electrical impulses by a 
mechanism called saltation. The role of the myelin is to increase the speed at which an 
impulse is propagated. 
   
 
Figure 4 Anatomy of a peripheral nerve (Felten D. L. 2010). 
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Peripheral nerves are categorized into groups based on the direction they transmit 
signals and based on where they connect to the central nervous system. Based on the 
direction they conduct signals there are afferent nerves that conduct signals from 
sensory neurons to the central nervous system and efferent nerves that conduct signals 
from central nervous along motor neurons to the peripheral organs such as muscles 
and glands. However, there are also mixed nerves that play both afferent and efferent 
functions. 
Based on where they connect to the central nervous system there are spinal nerves that 
originate from the spinal cord and are formed by the joining of ventral roots (motor) 
and dorsal roots (sensory) (Figure 5) (Parent 1996) and cranial nerves that connect 
directly to the brain, mostly the brain stem. While spinal nerves are numbered 
according to the vertebra through which they connect to the spinal cord, cranial nerves 
are assigned numerals (1 to 12) and have also descriptive names according to the 
muscle they innervate or the function they perform. 
  
Figure 5 Typical thoracic spinal nerve and its branches (Parent 1996). 
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At cervical and lumbar levels, the spinal nerves combine to form a network of 
intersecting nerves called brachial and lumbosacral plexus. Distal to the plexus, nerve 
fibres branch to form individual peripheral nerves such as median, ulnar and radial 
nerves of the forearm and peroneal and tibial nerves of the lower leg (Figure 6) 
(Parent 1996).  
          
 
Figure 6 Diagram showing the brachial plexus and peripheral nerves of the forearm. 
The posterior divisions, posterior cords, and peripheral nerves formed from the 
posterior divisions are shaded. Cords and peripheral nerves formed from the anterior 
divisions of the ventral primary rami are in white (Parent 1996). 
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1.1.4 Histopathological responses of peripheral nerves to injury 
Diverse mechanisms lead to nerve injury: inflammatory, metabolic, toxic, ischemic, 
infectious, traumatic, compressive, inherited, and paraneoplastic. The motor nerves, 
the sensory nerves or both can be affected and either the myelin sheaths or axons, 
separately or concurrently, can be at fault (Figure 7) (Adams 1993). This results in 
axonal degeneration or demyelination or both.  
Wallerian degeneration 
Wallerian degeneration is a sequence of axonal and myelin degeneration. It was 
named after Augustus Holney Waller who, in 1850, observed axonal degeneration and 
myelin disintegration when he severed the glossopharyngeal and hypoglossal nerves 
in frogs. Wallerian degeneration occurs distal to the site of injury, usually within 24-
36 hours after an axonal injury. The part of the axon separated from the cell body 
degenerates distally to the site of injury leading to a phenomenon called anterograde 
degeneration. Within hours, accumulation of organelles and mitochondria in 
paranodal regions near the injury takes place. There is a loss of structure of the 
endoplasmic reticulum and a degradation of neurofilaments associated with calcium 
influx and activation of calpain. The axon becomes fragmented and phagocytosed. 
The myelin sheath does not degenerate and remains as an empty tube towards which 
nerve fibres send out sprouts. Schwann cells proliferate and produce growth factors 
that attract these sprouts until they reach the target tissue which they innervate at a 
pace of 1 mm a day. However, Schwann cells atrophy and disappear in the absence of 
axonal regeneration. The regeneration is faster in the peripheral nervous system than 
in the central nervous system because in the central nervous system, myelin sheaths 
are produced by oligodendrocytes and not Schwann cells. 
Axonal degeneration 
Axonal degeneration can occur independently of Wallerian degeneration such as in 
distal axonopathy. This is seen in polyneuropathies where distal parts of axons are 
first affected leading to the condition called “dying back” axon; leading to symptoms 
in the distal part of the body (stocking-glove). Here too neurofilaments and organelles 
accumulate in the axon, leading to axonal atrophy and breakdown, eventually. As 
axonal degeneration advances, axons will lose their myelin leading to demyelination 
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Segmental demyelination 
As it is called, in segmental demyelination there is a breakdown and loss of myelin 
over a few segments while the axon and neuronal body remain intact. However, a 
long-lasting severe demyelination may lead to axonal loss. Because myelin is 
responsible for salutatory conduction propagation, segmental demyelination leads to 
reduced conduction velocity and conduction block. Repetitive segmental 
demyelinations can lead to formation of concentric layers of Schwann cells and 
collagen around the axon called “onion bulbs”, and thickening of peripheral nerves 
also known as hypertrophic neuropathy. Both processes are histological hallmarks of 
hereditary neuropathies including some Charcot-Marie-Tooth disease sub-types.  
 
Figure 7 Diagram of basic pathologic processes affecting peripheral nerves. 
In Wallerian degeneration, the arrow is showing the site of axonal interruption distal 
to which there is degeneration of the axis cylinder and myelin, and central 
chromatolysis. In segmental demyelination, the axon is spared. Axonal degeneration 
leads to distal degeneration of myelin and axis cylinders resulting to a neuronal 
disease. As seen in the diagram, both Wallerian degeneration and axonal degeneration 
lead to muscle atrophy (Adams 1993). 
1.1.5 Diseases of the peripheral nervous system 
Technically, a peripheral neuropathy can be any disorder, either focal or generalized, 
that causes damage to the nerve fibres within the PNS. The definition is not always 
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clear as disorders that lead to primary degeneration of the anterior horn cells such as 
spinal muscular atrophy are sometimes referred to as motor neuropathies. Conditions 
that lead to loss of the whole neuron (cell body and axons) are referred to as 
neuronopathies. 
There are numbers of ways in which the PNS can malfunction: as part of an isolated 
peripheral nerve disorder (mononeuropathy or mononeuropathy multiplex), a general 
neurological disorder or a systemic condition (polyneuropathy). These conditions can 
be acquired (diabetic, infectious, toxic, and metabolic) or, of interest to our study, 
genetic (inherited motor or sensory neuropathies and inherited motor and sensory 
neuropathies). Symptoms and signs linked to motor fibres involvement are muscle 
weakness and atrophy, fasciculations and muscle cramp, and loss of motor functional 
abilities including walking and fine motor skills. In sensory fibres involvement, 
symptoms and signs differ according to the type of fibres affected. Large fibre 
involvement leads to numbness, inability to determine joint position sense with 
resulting incoordination and ataxia, poor vibration sensibility, and loss of tendon 
reflexes whereas damage to small fibres manifests with paresthesias, numbness, 
burning or cold sensations, “lightening” pains, loss of pinprick and temperature 
sensibility. Because the autonomic nervous system controls involuntary and semi-
involuntary function, damage to autonomic fibres manifests with abdominal bloating, 
constipation, diarrhea, dizziness and fainting associated with a fall of blood pressure, 
urinary hesitancy, sexual dysfunction, decreased sweating and dry mouth. 
Peripheral neuropathies can be classified according to the pattern of their occurrence 
(mono or polyneuropathy), the type of fibre involved (motor, sensory, autonomic), the 
time course (acute, subacute, chronic, very chronic), the pathological features (axonal, 
demyelinating), and the aetiology (diabetic, inflammatory, infectious, toxic, genetic). 
Mononeuropathy 
Mononeuropathy is damage to a single nerve or nerve group, and results in loss of 
movement, sensation or other functions of regions innervated by the nerve or nerve 
group. The most common cause of mononeuropathy is compression also known as 
compression neuropathy. Single nerves susceptible to entrapment or compression are 
the median nerve causing neuropathy called “carpal tunnel syndrome” at wrist, and 
characterized by pain, numbness, and weakness in hand in the 1
st
 three digits, the 
ulnar nerve causing neuropathy at elbow, and characterized by pain, numbness and 
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weakness in hand in the 4
th
 and 5
th
 digits, the radial nerve causing radial palsy, and 
characterized by wrist drop commonly called “Saturday night palsy”, the peroneal 
nerve causing neuropathy at the fibular head and leading to foot drop, and the lateral 
cutaneous femoral nerve causing the so-called “meralgia paresthetica”. Although 
mononeuropathies can be caused by chronic stress at the nerve crossing or route, 
mononeuropathies can also be caused by traumatic injuries.  
Traumatic neuropathies are examples of mononeuropathies. They can be complete 
leading to total loss of motor and sensory function or incomplete with some sparing of 
nerve function. Some examples of traumatic neuropathies are stretch brachial plexus 
injury during birth or motorcycle accident, fracture of humerus resulting in radial 
nerve palsy, fracture or dislocations of hip resulting in sciatic nerve palsy, and 
fracture of fibula resulting in femoral palsy. 
Mononeuropathy multiplex 
Mononeuropathy multiplex is damage to at least two individual nerve distributions 
serially or concurrently in a multifocal pattern. It usually presents with acute or 
subacute loss of sensory and motor function of individual nerves, and is often 
associated with pain. At the beginning, symptoms present in an asymmetrical pattern, 
but become more confluent and symmetrical later as the disease progresses; thus, 
making it difficult to differentiate from polyneuropathy. Mononeuropathy multiplex 
are often axonal neuropathies, and are caused or associated with diverse medical 
conditions, including diabetes mellitus, vasculitides (polyarteritis nodosa, Sjögren‟s 
syndrome, Wegener granulomatosis), infectious diseases (leprosy, HIV), immune-
mediated diseases (sarcoidosis, lupus erythematosus), and genetic disorders 
(hereditary neuropathy with liability to pressure palsy). Leprous neuropathy is an 
example of mononeuropathy multiplex. 
Leprous neuropathy 
Leprosy is an infectious disease caused by Mycobacterium leprae, and leprous 
neuropathy is a leading cause of neuropathy worldwide. It is characterized by an early 
involvement of unmyelinated cutaneous nerve fibres and their Schwann cells resulting 
to a superficial loss of sensation and numbness. If not treated, the disease becomes 
debilitating leading to shortened extremities such as fingers, toes or nose. 
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Polyneuropathy 
Polyneuropathy is a generalized disorder in which many nerve fibres of different parts 
of body are affected. However, not all nerve cells are affected altogether in any case 
of polyneuropathy. For example in distal axonopathy, the most common pattern of 
polyneuropathy, while cell bodies remain intact, only axons are affected in proportion 
to their length. This results in symptoms that occur first and most severely in feet, 
and, eventually, in a “stocking-glove” pattern of symptoms. The second pattern is 
demyelinating neuropathies in which the myelin sheath around axons is affected. 
Although axons are not damaged, their ability to transmit electrical impulses will be 
impaired. In the third pattern, cell bodies are directly affected, leading to situations 
called motor neuron disease or sensory neuronopathy. Polyneuropathies cause diffuse 
often symmetrical symptoms resulting in weakness, atrophy and sensory loss in more 
than one body part. The aetiology of polyneuropathies are diverse, including diabetic, 
toxic (pharmaceuticals, toxins, industrial agents), nutritional or metabolic (e.g., 
alcoholic, vitamin deficiency or excess, uremia, porphyria), infectious (HIV or HIV 
drug-induced neuropathy), inflammatory (Guillan-Barré syndrome) and inherited 
(hereditary motor and sensory neuropathy or Charcot-Marie-Tooth disease). In this 
section, we will review diabetic polyneuropathy and the Guillan-Barré syndrome, and 
in the next section we will review Charcot-Marie-Tooth diseases. 
Diabetic polyneuropathy 
Diabetic polyneuropathy is the most common polyneuropathy affecting up to 50 % of 
patients with polyneuropathy. It can manifest as pure small fibres neuropathy or 
sensorimotor axonal neuropathy. Diabetic polyneuropathy can also occur in the pre-
diabetes status such as in the impaired glucose tolerance. The onset is insidious, and 
distal parts of the body are first affected. Sensory symptoms including numbness, 
sensory loss, dysesthesia and night time pain appear early in a glove-stocking 
distribution fashion while motor ones occur later, and autonomic involvement can 
sometimes be noticed.  
Guillan-Barré Syndrome 
Guillan-Barré syndrome is an acute inflammatory demyelinating neuropathy caused 
by an autoimmune attack against peripheral nerves. It is the most common cause of 
acute neuromuscular paralysis. The disease can be triggered by preceding viral 
infection that may pass unnoticed. Most commonly, the disease progresses in an 
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ascending flaccid paralysis fashion over days. Large fibres are most affected leading 
to loss of tendon reflexes, vibratory sense and proprioception, and conserved 
temperature and pain sensibility. Nerve conduction studies show evidence of 
segmental demyelination at nerve root and peripheral nerve. Most patients make a full 
or substantial recovery. 
1.1.6 Approach to evaluation of peripheral neuropathies 
As reviewed in Adams and Victor‟s Principles of Neurology (Adams 1993), the 
diagnosis of a peripheral neuropathy is based on certain points: 
- Determine whether the central or peripheral nervous systems are affected. History, 
the most important part of the evaluation, contributes to 85 % of a correct diagnosis. 
History taking should be directed at elucidating the anatomical location of the 
complaints, central versus peripheral and systemic versus focal. 
- Determine based on symptoms and signs which nerve fibres are affected; motor or 
sensory (small or large) or autonomic (Table 1). This requires both history and 
examination. 
Table 1 Symptoms and signs seen in peripheral neuropathies  
Affected fibres Positive symptoms Negative symptoms 
Sensory 
Small fibres 
Pain, paresthesias Numbness/lack of sensation 
Sensory 
Large fibres 
Not concerned Poor balance 
Motor Cramps, fasciculations Weakness, atrophy 
Autonomic Diarrhea, hyperhidrosis 
Orthostatic hypotension, 
impotence, anhidrosis 
 
- Localize which part of the peripheral nerve system is affected. Examination can 
conclude to a radiculopathy, plexopathy, mononeuropathy or peripheral neuropathy. 
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- Determine the time course. Here also history is very useful in determining the acute 
pattern of a peripheral neuropathy that occurs in days, the subacute peripheral 
neuropathy that occurs in days to weeks, chronic peripheral neuropathy that occurs in 
months or years, or very chronic peripheral that occurs insidiously in several years. 
- Determine the primary pathological process that led to the peripheral neuropathy. 
This will determine whether it is axonal damage or a demyelinating neuropathy. 
History and examination, except in certain unusual cases such as enlarged nerves in 
some CMT cases, are not useful. Important evaluations are nerve conduction studies 
or nerve biopsy. 
- Determine important contributing factors, including medical history (diabetes 
mellitus, HIV, other immune diseases), medications (vitamins), and family history 
(history of high arches or hammer toes). 
- Characterize neuropathy by further testing such as nerve conduction studies, 
electromyography, skin biopsy, nerve and muscle biopsy, quantitative sensory testing, 
and laboratory testing that include genetic testing. We will be reviewing some 
important diagnostic testing here. 
Nerve conduction studies (NCS) 
Nerve conduction studies are commonly used tests that evaluate the electrical 
conduction ability of motor and sensory nerves. NCS consists of three major 
components; motor NCS, sensory NCS, and F-wave study. Motor NCS measures the 
time an electrical impulse takes from a stimulation site of peripheral nerve to a 
recording site, which is the muscle it supplies. This value is called latency and 
measured in millisecond (ms). The size of the response called motor amplitude is also 
measured, and in millivolts (mV). The velocity of the impulse called nerve conduction 
velocity (NCV) can also be determined by stimulating the same nerve in two or more 
sites. The distance between the different stimulating electrodes and the difference in 
latencies are used for calculations. Measurement of sensory NCS isn‟t different except 
that recording is performed in a purely-sensory portion such as finger. In addition, 
sensory amplitudes are smaller than the motor ones. NCS measures large diameter 
motor and sensory fibres, and can distinguish axonal versus demyelinating neuropathy 
and polyneuropathy versus mononeuropathy. As stated above, axons transmit the 
amplified action potentials and myelin plays a role in the rapid propagation of 
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electrical impulses. As result, damage to axons results in low action potentials while 
demyelinating neuropathy leads low nerve conduction velocity. Routine studies 
include sural, median, ulnar, and radial sensory nerve action potentials, and peroneal, 
tibial, median and ulnar compound motor action potentials. F-wave study also record 
action potentials from a muscle by supramaximal stimulation of the motor nerve that 
supplies it. While motor and sensory nerve conduction velocity evaluates conduction 
in the segment of the limb, F-wave can be used to assess conduction between nerve 
and spine. 
Electromyography (EMG) 
EMG is another electrodiagnostic procedure that measures electrical signals 
transmitted by motor nerves at the muscle. When performing EMG electrical 
activities of muscles can be recorded at the surface or at intramuscular level by 
inserting a needle electrode into the muscle tissue. Measurement is done at rest and at 
smooth muscle contraction. The activity of several motor units and at different 
locations is measured to have an accurate study. EMG is used to evaluate 
radiculopathies, plexopathies, and mononeuropathies.  
Skin biopsy 
Skin biopsy is used for a quantitative evaluation of epidermal innervation (small 
sensory nerve fibres). Three main techniques are used: a shave biopsy, an excisional 
biopsy, and now commonly used punch biopsy. Skin sample is stained with pan-
axonal marker to determine their number. 
Nerve biopsy 
Nerve biopsy plays a small role in diagnosing peripheral neuropathy. However, it is 
important in confirming demyelinating neuropathies, and may play a role in the 
cellular pathology and the diagnosis in some diseases including vasculitis, amyloid 
neuropathy, giant axonal neuropathy, and leprous neuropathy.  
Laboratory studies 
Although not always specific, laboratory testing may contribute to the diagnosis or 
understanding of peripheral neuropathies such as vitamin deficiencies or intoxication, 
Guillan-Barré syndrome, and metabolic disorders. Routine tests include blood 
glucose, vitamin B12 levels, lipid profile, homocysteine, and thyroid function. In 
cases where a particular disease is suspected, specific testing can be performed, e.g., 
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anti-nuclear antibodies, anti-neutrophilic cytoplasmic antibodies, HIV, Lyme disease, 
and most importantly in our case genetic testing. 
In conclusion, the diagnosis of a peripheral neuropathy is mainly based on history and 
examination. Blood testing can identify acquired causes of neuropathy as well as 
testing of the cerebrospinal fluid (CSF), which is important to identify inflammatory 
neuropathies. Neurophysiology is very important to identify which part of the 
peripheral nerve is affected. Nerve biopsy is usually the final test carried out but it is 
often the most important in identifying the more unusual types of neuropathy. The 
advance in the molecular genetics of inherited neuropathy has allowed many patients 
and families to be diagnosed without having to undergo many of these invasive 
investigations. 
1.1.7 Treatment of peripheral neuropathies 
Currently there is no proven disease modifying treatment for peripheral neuropathies 
except for some inflammatory neuropathy types including Guillan-Barré Syndrome 
for which plasmapheresis and/or intravenous immunoglobulins are used. In most 
cases peripheral neuropathies are managed by identifying and treating the underlying 
cause. Symptomatic treatment using non-steroidal anti-inflammatory drugs for back 
pain, and anti-epileptic drugs or tricyclic anti-depressants for neuropathic pain can be 
used to improve patients‟ quality of life. Because peripheral neuropathies often lead to 
disability, it is important to help patients gain maximum independence and self-care 
ability through physical therapy to prevent contractures and falls, and occupational 
therapy. In addition, orthopaedic devices can be used to improve gait and reduce falls. 
1.2 Charcot-Marie-Tooth disease (CMT) 
1.2.1 Historical notes 
In 1886, Jean-Marie Charcot and Pierre Marie in Paris, France (Charcot 1886) first 
described a “particular form of progressive muscular atrophy”. At the same time in 
London, England, Howard Henry Tooth (Tooth 1886) independently described 
patients with a peroneal type of progressive muscular atrophy and contrasted this with 
a “classical” progressive muscular atrophy. Tooth was first to attribute the symptoms 
to a neuropathy rather than a myopathy as physicians had done in earlier descriptions. 
These descriptions led to the term CMT or progressive muscular atrophy being used 
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to describe what was initially thought to be one disease. Over the last century, 
clinical, electrophysiological and pathological descriptions have shaped the 
classification of inherited peripheral neuropathy from the original description of CMT 
to a spectrum of peripheral nerve degenerative disorders known to occur in several 
inherited neuromuscular and central nervous system disorders. 
1.2.2 General findings 
Charcot-Marie-Tooth disease is the most common inherited disorder of the peripheral 
nervous system. The prevalence of CMT disease (all types) has been reported to be 
between 4.7 cases per 100,000 in Newcastle-Upon-Tyne (Davis, Bradley et al. 1978) 
and 36 cases per 100,000 in Western Norway (Brust, Lovelace et al. 1978). The 
estimated prevalence based on several studies is one case per 2,500 individuals (Skre 
1974). The mode of inheritance can be autosomal dominant, autosomal recessive or 
X-linked. The classical clinical presentation of CMT is distal weakness involving first 
the lower limbs, extending to the upper limbs during the disease course; sensory loss, 
decreased reflexes and foot deformities; and the most common presenting symptoms 
are walking difficulties with steppage gait (Shy, Jani et al. 2004). Sensory symptoms 
are usually less prominent than motor ones (Harding and Thomas 1980; Shy, Jani et 
al. 2004). Other less frequent signs include cranial nerve impairment, scoliosis, vocal 
fold and diaphragm paralysis and glaucoma (Dyck, Litchy et al. 1994; Azzedine, 
Bolino et al. 2003; Senderek, Bergmann et al. 2003; Hirano, Takashima et al. 2004). 
Although variable between and within families (Garcia, Malamut et al. 1995; 
Pareyson, Scaioli et al. 2006), symptom onset usually occurs during first decades of 
life, and the disease course is very slowly progressive over decades (Pareyson, Scaioli 
et al. 2006); initial symptoms may occur in infancy (Thomas, Marques et al. 1997; 
Pareyson 2004) or late (Harding and Thomas 1980; Shy, Jani et al. 2004).  
1.2.3 Classification 
CMT disease was thought to be one disease until almost a century after the first 
descriptions. But, with advances in electrophysiological, pathological and genetic 
investigations of this disorder, it is now classified into many different subtypes. The 
differentiation of this heterogeneous condition into two predominant types came with 
Dyck and Lambert‟s work (Dyck and Lambert 1968). In 1968, they found clinical, 
pathological, electrophysiological and genetic heterogeneity among patients with 
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CMT. In their series they found that patients were divided into two main groups and 
then into subgroups: (i) those with diffusely low nerve conductions with hypertrophic 
neuropathy and demyelination (CMT1), and (ii) those with normal or borderline 
abnormal nerve conductions and without hypertrophic neuropathy, but peripheral 
nerve axonal degeneration (CMT2). They also introduced the term hereditary motor 
and sensory neuropathy (HMSN) that includes a broader group of inherited 
neuropathies. Both terms are used interchangeably, but CMT is now preferred. 
Subsequent studies done by Thomas and Calne (Thomas, Calne et al. 1974) and 
Harding and Thomas (Harding and Thomas 1980) reinforced this classification. This 
differentiation was based on the median motor nerve conduction velocity, with 38 m/s 
being the cut-off value to differentiate between the two types (conduction velocity 
(CV) <38 m/s in CMT1 patients, whereas it is >38 m/s in CMT2 patients). But, both 
axonal and demyelinating CMT eventually result in loss of axons and in reduction of 
compound motor action potential (CMAP) and sensory nerve action potential (SNAP) 
amplitudes (Lewis, Sumner et al. 2000). Forms of CMT with intermediate values have 
also been described (Verhoeven, Villanova et al. 2001; Jordanova, Thomas et al. 
2003; Zuchner, Noureddine et al. 2005). 
It is often impossible to distinguish CMT1 and CMT2 based on neurological 
examination because clinical features are similar. As genetic and clinical investigation 
of CMT has continued to improve in recent years, the classification of CMTs has 
continued to evolve and there are now a total of about 40 recognized subtypes. 
1.2.3.1 CMT1 
The disorder that Charcot, Marie and Tooth described in their original papers best fits 
the phenotype of CMT1. Based on the mode of inheritance, and according to the data 
in the Inherited Peripheral Neuropathies Mutation Database (IPNMD, Department of 
Molecular Genetics, University of Antwerp, Antwerpen, Belgium), there are 2 
subtypes of demyelinating CMT: the dominant forms that are divided into two 
subgroups (autosomal dominant: CMT1 and X-linked dominant: CMT1X) and the 
recessive forms also divided into two subgroups (autosomal recessive: CMT4 and X-
linked recessive: CMT4X). 
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Dominant forms of CMT1 
Autosomal dominant (CMT1) 
Six sub-forms have been characterized in this sub-type, and five genes have been 
identified (IPNMD, accessed January 2011). We will review here the two most 
common sub-types: CMT1A and CMT1B. This type is the most common of all CMTs 
in general and CMT1 in particular, with CMT1A alone representing 40-50 % of all 
CMT cases (Nelis, Van Broeckhoven et al. 1996; Dubourg, Tardieu et al. 2001; 
Boerkoel, Takashima et al. 2002). The majority of cases in this type develop 
symptoms during the first decade (Harding and Thomas 1980). Symptoms begin 
insidiously with muscle weakness and atrophy in the foot and leg muscles, especially 
the intrinsic muscles; leading to a gait abnormality or clumsiness in running and foot 
deformities. Later, calf, intrinsic hand, and thigh muscles may become affected. The 
atrophy tends to affect the distal part of the gastrocnemius, soleus, and distal 
quadriceps muscle, giving the characteristic appearance of “inverted champagne 
bottle” of lower limbs seen only in thin patients with fully expressed disease. 
Fasciculations and cramps after exercise are common. Sensory dysfunction affecting 
all modalities can be seen (Dyck P. J. et al., 1993), though less prominent than the 
motors signs. Tendon reflex changes are seen and more marked in this type than the 
type 2. Harding and Thomas found 58 per cent of their patients with HMSN type 1 
had total tendon areflexia (Harding and Thomas 1980).  
Hypertrophic neuropathy characterized as hard enlargement of peripheral nerves is 
usually seen in nerve biopsies (Dyck P.J. 1993). 
CMT 1A 
CMT1A represents the typical form of CMT with an early onset, but milder course 
compared to other types of CMT. About 60 % of patients with CMT1A have a 
positive family history. Symptoms include a childhood or adolescent disease onset, 
slowly progressive disease course, symmetrical demyelinating polyneuropathy, 
variable degree of distal muscle weakness and atrophy, and sensory disturbances. In 
10 % of cases, proximal limbs become affected in late teenage years. Slow nerve 
conduction velocities ranging between 20-25 m/s is a 100 % penetrant phenotype 
independent of age, and may appear within the first months of life (Krajewski, Lewis 
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et al. 2000). Histological studies show hypertrophic neuropathy and “onion bulb” 
formations. 
CMT1A is due to mutations in the peripheral myelin protein 22 gene (PMP22) on 
chromosome 17. Both duplication and point mutation in the PMP22 gene cause 
CMT1A. However, the majority of CMT1A cases are caused by a 1.4-Mb duplication 
in band 17p11.2 (Lupski, de Oca-Luna et al. 1991), although the disease course is 
more severe in point mutation cases. Pentao et al. were first to suggest that unequal 
crossing over due to misalignment at the CMT1A-REP (repetitive elements) repeat 
sequences during meiosis was the cause of de novo duplication in CMT1A (Pentao, 
Wise et al. 1992). 
PMP22 encodes an integral membrane protein, and is mainly expressed in Schwann 
cells. It constitutes the major component of compact myelin in peripheral nerves 
where it plays a role during Schwann cell growth and differentiation (Snipes, Suter et 
al. 1992). CMT1A is suggested to be caused by PMP22 overexpression that leads to 
accumulation in the late Golgi-cell membrane compartment and uncouples myelin 
assembly from the underlying program of Schwann cell differentiation (Niemann, 
Sereda et al. 2000). 
CMT 1B 
The first CMT1B case was reported in 1952 in a family with six individuals in 3 
generations (England and Denny-Brown 1952). These individuals presented with 
footdrop, distal leg weakness, and loss of deep tendon reflexes.  
Although clinically similar to CMT1A, CMT1B appears more severe, and many cases 
are sporadic. In addition, motor NCV, especially in the early-onset cases, are slower, 
in the range of 5-15 m/s. But due to the variability seen in all CMT cases, it can be 
difficult to clearly differentiate CMT1B from CMT1A cases. Onion bulb formation 
and excessive myelin folding and thickness are reported in histological studies. 
CMT1B is caused by mutations in the myelin protein-zero (MPZ or P0) gene 
(Hayasaka, Himoro et al. 1993). Mutations in MPZ account for 5 % of all CMT1 
cases (Nelis, Van Broeckhoven et al. 1996). MPZ is the major structural protein of the 
peripheral myelin, and is expressed in Schwann cells. It accounts for 50 % of the 
protein present in the myelin sheath. MPZ is also an integral membrane glycoprotein 
that is thought to join adjacent lamellae, thus stabilizing the myelin assembly. The 
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MPZ protein contains a highly conserved extracellular domain which plays this role 
and where most of the mutations are located. Animal models have shown that a strict 
dosage of MPZ is required for normal peripheral nerve myelination (Wrabetz, Feltri et 
al. 2000). Mutations in MPZ are predicted to alter myelin adhesion or produce an 
unfolded protein response (Wrabetz, D'Antonio et al. 2006). In transfected cells, 
Grandis et al. found that mutations associated with late-onset disease show partial loss 
of protein function while those associated with an early-onset disease show an 
abnormal gain of function (Grandis, Vigo et al. 2008). 
Other variants of this sub-type include CMT 1C caused by mutations in the 
lipopolysaccharide-induced tumor necrosis factor-alpha factor (LITAF) gene (Street, 
Bennett et al. 2003), CMT 1D caused by mutations in the early growth response 
protein 2 gene (EGR2) (Warner, Mancias et al. 1998), CMT 1E caused by point 
mutations in the PMP22 gene (Kovach, Lin et al. 1999), and the CMT1F/CMT2E 
complex caused by mutation in the neurofilament protein, light chain gene (NEFL) 
(Jordanova, De Jonghe et al. 2003). 
X-linked dominant (CMT1X) 
CMT1X is the second most common variant of all CMTs. This subtype is 
characterized by weakness and wasting in distal limbs. The onset occurs before 20 
years of age with gait disorder. Sensory loss is more often described, and absent 
tendon reflexes are noted most often at the knees and ankles. Patients also develop 
hearing loss. Females present with milder signs consistent with absent hypertrophic 
nerves and mildly slow or normal NCVs or are asymptomatic. Some studies have 
reported transient central nervous system symptoms including numbness and paresis 
in the left face and arm with an abnormally increased T2 signal and reduced diffusion 
in the posterior portion of the centrum semiovale bilaterally as well as in the splenium 
of the corpus callosum in MRI (Sakaguchi, Yamashita et al. 2010). Some patients 
show both demyelinating and axonal features. 
CMT1X is due to a mutation in the connexin-32 gene (CX32) also called Gap 
Junction protein Beta-1 (GJB1) (Bergoffen, Scherer et al. 1993). Connexins are 
proteins that span along the cell membrane and assemble to form gap junction 
channels that play a role in facilitating transfer of ions and molecules between cells. 
CX32 is highly expressed in kidney and peripheral nerves. In peripheral nerve CX32 
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is found at the nodes of Ranvier and Schmidt-Lanterman incisures where it may form 
intracellular gap junctions that connect to the folds of Schwann cell cytoplasm; 
allowing the transfer of nutrients, ions, and molecules to the innermost myelin layers 
(Meier, Dermietzel et al. 2004). While some studies proposed a nonfunctional 
chimeric connexin formation by mutant CX32 with wildtype connexins (Omori, 
Mesnil et al. 1996), others have found a trafficking defect that leads to retention of 
mutant proteins in the Golgi apparatus, therefore failure to form gap junctions 
(Kleopa, Zamba-Papanicolaou et al. 2006). 
Recessive forms of CMT1 
Autosomal recessive (CMT4) 
Eleven different clinical forms have been characterized in this sub-type, and ten genes 
have been identified. Although the clinical presentation is quite similar to the 
dominant CMT1 form, the disease course appears to be more severe. Harding and 
Thomas found that autosomal recessive type I cases had more severe weakness in the 
lower limbs, more frequent scoliosis, and a significantly lower motor nerve 
conduction velocities than those with autosomal dominant inheritance (Harding and 
Thomas 1980). Here we will review some of the most frequent forms. 
CMT 4A 
This sub-type is frequent in Hispanic population, Northern Africa and Eastern Europe. 
Symptoms start in childhood, before 2 years, and are characterized by weakness, 
sensory loss, and reduced to absent tendon reflexes. Weakness is rapidly progressive; 
involves distal limbs with lower limbs being more affected, and affects the left more 
than right vocal fold. Because of vocal fold paralysis, patients present with breathing 
difficulties and hoarse voice. There is an earlier involvement of upper extremities and 
proximal muscle weakness. Nerve conduction studies and pathology show the same 
patterns seen in demyelinating CMT. 
CMT4A is caused by mutations in the ganglioside-induced differentiation-associated 
protein 1 (GDAP1) gene (Baxter, Ben Othmane et al. 2002; Cuesta, Pedrola et al. 
2002), and accounts for about 25 % of all CMT4. GDAP1 is a protein that forms a 
homodimer, and contains 2 N-terminal GST domains and 2 C-terminal 
transmembrane domains. It is highly expressed in brain, spinal cord, and dorsal root 
ganglia. In the peripheral nerve, GDAP1 is expressed in both Schwann cells and 
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neurons where it may regulate mitochondrial dynamics that are critical for the proper 
function of myelinated peripheral nerves (Niemann, Ruegg et al. 2005). The same 
study showed that truncating GDAP1 mutations led to mitochondrial targeting defect 
and loss of mitochondrial fragmentation activity, whereas missense mutations in 
GDAP1, although targeted to mitochondria, showed some impaired ability to induce 
fragmentation. 
CMT 4C 
CMT4C affects families from different ethnic background (Kessali, Zemmouri et al. 
1997; Gabreels-Festen, van Beersum et al. 1999; Colomer, Gooding et al. 2006),. 
Skeletal deformities are the main presenting features. Symptoms include delayed 
walking, distal muscle weakness and atrophy, early cutaneous sensory and late 
vibration and joint position loss. Some patients present with cranial nerve 
involvement causing deafness, nystagmus, facial and pupil unresponsiveness, and 
unilateral tongue atrophy. Laboratory studies show similar features to those seen in 
CMT1. 
This sub-type is caused by mutations in the SH3 domain and tetratricopeptide repeat 
domain-2 (SH3TC2) gene (Senderek, Bergmann et al. 2003). The protein encoded by 
SH3TC2 is expressed in the Schwann cells, and localized to the plasma membrane and 
the perinuclear endocytic recycling compartment, which suggest a possible function 
in myelination and/or in regions of axoglial interactions (Arnaud, Zenker et al. 2009). 
The suggested mechanism leading to CMT4C is endocytic and membrane trafficking 
pathway defect. Studies postulate that missense mutations impair communication 
between Schwann cells and axon, leading to myelin malformation (Lupo, Galindo et 
al. 2009). 
Other variants of CMT4 include CMT 4B1 due to mutation in the myotubularin-
related protein 2 (MTMR2) (Bolino, Muglia et al. 2000), CMT 4B2 caused by 
mutations in the SET binding factor-2 (SBF2) gene (Senderek, Bergmann et al. 2003), 
CMT 4D caused by mutations in the N-myc Downstream-Regulated Gene 1 (NDRG1) 
(Kalaydjieva, Gresham et al. 2000), CMT 4F caused by mutations in the periaxin gene 
(PRX) (Guilbot, Williams et al. 2001), CMT 4G due to mutations in the Hexokinase 1 
(HK1) gene, CMT 4H due to mutations in the FYVE, RhoGEF and PH domain 
containing 4 (FGD4) gene (Delague, Jacquier et al. 2007), and CMT 4J which is due 
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to mutations in the FIG4 homolog, SAC1 lipid phosphatase domain containing (S. 
cerevisiae) (Chow, Zhang et al. 2007).  
X-linked recessive (CMT4X) 
Four families have been described in this subtype with at least 3 loci. The clinical 
findings are not much different from the typical CMT presentation except that some 
of these patients have spastic paraparesis, pain and paresthesia. NCS showed both 
demyelination and axonal involvement. 
1.2.3.2 CMT2 
In 1968 Dyck and Lambert (Dyck and Lambert 1968) showed that many CMT 
patients had nerve conduction studies with a normal or borderline conduction 
velocities (CV> 38 m/s), but reduced compound motor and sensory action potentials. 
In addition, pathological studies of nerve biopsies in these patients have showed 
axonal degeneration and regeneration, leading to progressive loss of available nerve 
fibres (Zuchner, De Jonghe et al. 2006). CMT2 is thus defined as forms of CMT 
characterized primarily by axonal loss without demyelination. Like CMT1, CMT2 is 
also clinically and genetically heterogeneous with over fifteen different subtypes 
described, and a disease-causing gene identified in eleven of these subtypes; leaving 
five with no identified gene defect, although regions of interest have been found 
through linkage (IPNMDB). As seen in most CMT cases, the age of onset and the 
severity of the disease in CMT2 cases are variable between and within families. The 
clinical presentation in this type is similar to the type I with some differences: the 
peak age of onset is in the second decade with some developing symptoms even much 
later (seventh or eighth decade) (Harding and Thomas 1980; Klein, Cunningham et al. 
2003), distal weakness in the upper limbs occurs less frequently, sensory loss, foot 
deformity, and scoliosis are less prominent and less common, and nerve enlargement 
is almost always absent (Harding and Thomas 1980; Dyck P.J. 1993). Some studies 
have reported a mean age of onset of 20 years (median 13, range 1-63) (Bienfait, Baas 
et al. 2007). Symptoms more often start in legs with foot deformities and difficulty 
walking (Gemignani and Marbini 2001; Santoro, Manganelli et al. 2002; Bienfait, 
Baas et al. 2007). Based on the mode of inheritance, the classification found in the 
IPNMDB website has this type also divided in 2 subtypes: dominant and recessive 
(autosomal and X-linked) forms. 
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Autosomal dominant forms of CMT2 
Ten genetically different entities have been described in this subtype, and a causative 
gene was identified for 8 of them. We will review the most frequent form, CMT2A2 
and the subtype we are interested in, CMT2C. 
CMT 2A2  
This subtype represents the majority of CMT2A families (Saito, Hayashi et al. 1997), 
and CMT2A2 constitutes 19 to 23 % of all CMT2 cases. The mean age of onset is 15 
years, and symptoms start with weakness in lower limbs and walking difficulties. 
Patients have absent tendon reflexes and mild distal sensory loss. Optic atrophy, 
tremor, pain, and hearing loss may be associated with the disease. CNS involvement 
can be seen in some patients. NCS shows normal NCV but low action potentials. 
Nerve biopsy is consistent with loss of myelinated large fibres with intact myelin. 
CMT2A2 is caused by mutation in the Mutofusin 2 gene (MFN2) (Zuchner, 
Mersiyanova et al. 2004). Mutofusins mediate the fusion of mitochondria contributing 
to the dynamic balance between fusion and fission that determines mitochondria 
morphology (Santel and Fuller 2001). MFN2 is expressed in almost all tissues but its 
highest expression was seen in heart and skeletal muscle. It contains an N-terminal 
GTPase domain and transmembrane domain close to the C-terminal region. In 
transfected cells, MFN2 was shown to colocalize with mitochondrial markers. Studies 
in cells derived from CMT2A2 patients showed that mutations lead to uncoupling of 
mitochondria oxygen consumption and reduced oxygen utilization efficiency, though 
ATP production was normal (Guillet, Gueguen et al. 2010). 
CMT 2C 
CMT2C is a rare, autosomal dominant form of CMT with five families reported in the 
literature, at the time of the start of this study, (two in the United States of America, 
one in New Zealand, one in the United Kingdom and one in Italy) (Dyck, Litchy et al. 
1994; Donaghy and Kennett 1999; Santoro, Manganelli et al. 2002; McEntagart, Reid 
et al. 2005). The disease initially causes distal limb muscle weakness and limb 
atrophy with later involvement of proximal muscles. These symptoms are associated 
with diaphragm, vocal fold and intercostal muscles paralysis; which together are 
distinguishing features of this subtype of CMT, although vocal fold paralysis has been 
reported in other types of CMT, including CMT4A, and CMT2K (Baxter, Ben 
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Othmane et al. 2002; Cuesta, Pedrola et al. 2002; Birouk, Azzedine et al. 2003; 
Zuchner, De Jonghe et al. 2006). Consequently, patients experience hoarseness of 
voice, stridor and shortness of breath aggravated by exertion. Some patients have been 
noted to have facial weakness (Dyck, Litchy et al. 1994). Sensory symptoms are often 
mild and seen more often in most severely affected individuals and include loss of 
touch, vibration sense, and joint position sense in the hands and feet. Some patients 
complain of pain, numbness and paresthesias. Decreased or absent tendon reflexes, 
typical in all CMT types, are seen in this subtype, including mildly affected patients. 
Unlike in most of CMT2 cases, CMT2C manifests more often in the first decade; 
although the age of onset is variable within and between families. This striking 
variability in the disease severity within and between families constitutes another 
characteristic feature of the CMT2C sub-type. Autonomic symptoms have not been 
reported in previous reports of CMT2C. NCS show a pattern of axonal involvement, 
with normal or borderline low nerve conduction velocities and decreased amplitudes. 
Laryngoscopy shows vocal fold paralysis, with the left side being more affected early 
in disease. Chest X-ray shows diaphragm paralysis which affects the left more than 
right side. 
The gene for CMT2C was mapped to 12q23-24 in a large Caucasian-American family 
(Klein, Cunningham et al. 2003). This region was further narrowed down by another 
study that studied two families, one from New Zealand and another from England 
(McEntagart, Reid et al. 2005).  
At the time of this study the gene for this CMT2 subtype had not been identified. 
Three independent studies including the one described here identified the transient 
receptor potential vanilloid superfamily member 4 (TRPV4) as the disease-causing 
gene for this CMT2 sub-type (Auer-Grumbach, Olschewski et al. 2010; Deng, Klein 
et al. 2010; Landoure, Zdebik et al. 2010). We will review this gene in the next 
section. 
A few other autosomal dominant CMT2 subtypes have been described in the 
literature. These include CMT 2A1 caused by mutation in the Kinesin family member 
1β (KIF1B) gene (Zhao, Takita et al. 2001), CMT 2B caused by mutations in RAB7A, 
member RAS oncogene family gene (RAB7), CMT 2D due to mutations in the Glycyl 
tRNA Synthetase (GARS) gene (Antonellis, Ellsworth et al. 2003), CMT 2F due to 
mutations in the heat shock 27 kDa protein 1 gene (HSPB1) (Evgrafov, Mersiyanova 
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et al. 2004), CMT 2G that links to chromosome 12q12-12q13.3 (Nelis, Berciano et al. 
2004), CMT 2L caused by mutation in the heat shock 22kDa protein 8 gene (HSPB8) 
(Tang, Zhao et al. 2005), CMT 2M due to mutations in the dynamin 2 (DNM2) gene 
(Zuchner, Noureddine et al. 2005), and CMT 2N caused by mutation in the Alanyl 
tRNA synthetase (AARS) gene (Latour, Thauvin-Robinet et al. 2010). 
Recessive forms of CMT2 
This subtype is divided into two subforms: autosomal and X-linked recessive. Four 
autosomal recessive subtypes of CMT2 are listed in the IPNMDB website, and 
causative genes were identified in two of them, while about three X-linked recessive 
axonal forms were listed in the same website. Although symptoms are similar to those 
in the dominant form, the disease course and clinical signs in the recessive forms are 
more severe. 
AR-CMT 2A 
Also called CMT2B1, this disease was characterized in Northern Africa families who 
presented with weakness in the legs within the second decade (Bouhouche, Benomar 
et al. 1999). Scapular weakness was also seen. The disease progresses rapidly, and 
can lead to prominent disability over 4 years. 
This sub-type is caused by mutations in the lamin A/C (LMNA) gene (De Sandre-
Giovannoli, Chaouch et al. 2002). Lamins are proteins that compose the structure of 
the nuclear lamina, and form a protein network that constitutes the inner nuclear 
membrane determining the nuclear shape and size. 
AR-CMT 2B 
This sub-type, also known as CMT2B2, was described in a single family (Leal, 
Morera et al. 2001). The mean age of onset is 32 years, and initial symptoms are 
weakness in the ankles. In addition to the classical CMT2 presentation, patients can 
present with cramps and paresthaesias. 
This disease is caused by mutations in the mediator complex subunit 25 gene 
(MED25) (Leal, Huehne et al. 2009). MED25 is ubiquitously expressed but highest 
expression was seen in dorsal root ganglia, cerebellum, cortex, and optic nerve, and 
contains an SD1 domain, and a SD2 domain which contains two putative CAM kinase 
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phosphorylation sites. Heterologous expression studies suggest that mutant MED25 
lose SH3 domain binding specificity. 
AR-CMT 2C is another recessive CMT2 that was mapped to chromosome 8q21.3 
(Barhoumi, Amouri et al. 2001). However, the disease-causing gene is not identified 
yet.  
CMT 2K occurs in both autosomal recessive and dominant patterns, and is caused by 
mutations in the GDAP1 gene (Birouk, Azzedine et al. 2003). The disease starts 
around 2 years with feet weakness and deformities. Some patients present with vocal 
fold paralysis; leading to hoarseness of voice in the second decade of life (Birouk, 
Azzedine et al. 2003). 
X-linked CMT2 
Five sub-types have been described in the literature.  
CMT X-linked Type 1: caused by mutations in the connexion-32 (GJB1) gene 
(Bergoffen, Scherer et al. 1993), this sub-type is semi-dominant. Symptoms are 
similar to the classical CMT associated with hearing loss. NCS show both myelin and 
axonal loss. 
CMT X-linked Type 2: linked to chromosome Xp22.2 (Ionasescu, Trofatter et al. 
1991), this sub-type is recessive, and is associated with mental retardation. 
CMT X-linked Type 3 is linked to chromosome Xq26.3-q27.1 (Huttner, Kennerson et 
al. 2006), and is recessively inherited. The disease starts between age 3 and 13, and is 
characterized by pain and paresthaesias in legs. NCS show an axonal-type CMT. 
CMT X-linked Type 4, also called Cowshock syndrome, is recessive and linked to 
chromosome Xq24-q26.1 (Priest, Fischbeck et al. 1995). Symptoms are axonal-type 
neuropathy, and associated with mental retardation and deafness by age 5. 
CMT X-linked Type 5 is recessive, and is caused by mutations in the 
Phosphoribosylpyrophosphate synthetase I (PRPS1) (Kim, Sohn et al. 2007). The 
disease starts at early age and is associated with sensorineural hearing loss. However, 
sensation is normal. An optic neuropathy starts between 7 and 10 years (Rosenberg 
and Chutorian 1967). 
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1.2.3.3 Charcot-Marie-Tooth disease with intermediate nerve conduction velocities 
This type of CMT can be inherited in both dominant and recessive pattern. As 
indicated, nerve conduction velocities show intermediate values, between 24 and 50 
m/s. 
Dominant intermediate CMT 
DI-CMT, Type B (CMTDIB) 
In addition to typical CMT findings, patients may present with tremor, and none of 
them never use wheelchair (Kennerson, Zhu et al. 2001). 
This sub-type is due to mutations in the dynamin 2 gene (DNM2) (Zuchner, 
Noureddine et al. 2005). DNM2 is a member of a GTPase family, and contains 9 
consensus motifs for CDC2 phosphorylation, making it an important element for the 
G2/mitosis transition. The protein is expressed in a wide range of tissues, but highest 
expression was found in heart and skeletal muscle. DNM2 is thought to regulate actin 
reorganization at the immunologic synapse and links to VAV1 and its downstream 
signalling pathway after TCR engagement (Gomez, Hamann et al. 2005). 
DI-CMT, Type C (CMTDIC) 
This sub-type was described in two families from German and Bulgarian origin 
(Jordanova, Thomas et al. 2003). The age of onset ranges from 7 to 54 years, and 
many patients never need to use a wheelchair. 
CMTDIC is due to mutations in the Tyrosyl-tRNA synthetase (YARS) gene 
(Jordanova, Irobi et al. 2006). Aminocyl-tRNA synthetases catalyze the 
aminoacylation of tRNA by their cognate amino acid. The play an important role in 
linking amino acids with nucleotide triplets contained in tRNAs, suggesting that they 
are among the first proteins that appeared in evolution. 
DI-CMT, Type A (CMTDIA) is another dominant intermediate described in one 
Italian family, the gene for this sub-type was mapped to chromosome 10q24.1-q25.1 
(Verhoeven, Villanova et al. 2001). The disease starts within the first or second 
decade, and manifests like classical CMT. Many of the patients never become 
wheelchair-bound.  
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Recessive intermediate CMT 
RI-CMT, Type A (CMTRIA) 
This sub-type is due to mutations in the Ganglioside-induced differentiation-
associated protein 1 (GDAP1) gene (Nelis, Erdem et al. 2002), and is a variant of the 
CMT 2K form. The disease starts at early childhood with gait disorder. 
RI-CMT, Type B (CMTRIB) 
Due to mutations in the Lysyl-tRNA Synthetase (KARS) gene (McLaughlin, 
Sakaguchi et al. 2010), this sub-type can be dominant or recessive. Symptoms may 
include developmental delay, self abuse, and dysmorphic features. 
1.2.3.4 Other subtypes 
Other subtypes have been added later after Dyck and Lambert‟s initial classification. 
HMSN type III:  
This type was described by Dejerine and Sottas as severe hypertrophic demyelinating 
neuropathy with early onset (Déjérine J. 1893). The clinical features include delayed 
motor development in infancy, generalized muscle weakness and atrophy affecting 
predominantly the distal limbs, areflexia, and sensory loss affecting the touch-
pressure, joint position, and vibration modalities. Difficulties with walking occur in 
childhood and patients become wheelchair-bound by the third decade. Nerve biopsy 
shows lamellar protuberances (the so called onion bulbs; whose origin are the 
Schwann cells) along the axons and segmental demyelination and remyelination 
thereof (Dyck P.J. 1993). 
HMSN type IV:  
Seen in Refsum‟s disease, this subtype is an autosomal recessive hypertrophic 
neuropathy associated with phytanic acid excess. The diagnosis is made with the 
finding of a tetrad of retinitis pigmentosa, peripheral neuropathy (muscle atrophy and 
weakness in the distal parts of lower limbs leading to foot drop, areflexia, sensory 
disturbances), cerebellar signs (ataxia, nystagmus, intention tremor), and increased 
cerebrospinal fluid protein content. Other findings include sensorineural hearing loss, 
anosmia, skin changes, skeletal malformations, cardiac abnormalities, and 
ophthalmologic abnormalities other than the retinitis pigmentosa. The age at onset 
varies from early childhood to the fourth decade, but most of the patients seem to 
have symptoms by the age of 20 years (Ola H Skjeldal 1993).  
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HMSN type V:  
First described as inherited spastic paraplegia with distal limb weakness by Strümpell 
in 1883 (Strümpell 1883), HMSNV is characterized by peroneal atrophy and spastic 
paraplegia. The mode of inheritance is believed to be autosomal dominant. Patients 
manifest symptoms usually in the second decade or later, and the disease course is 
insidiously progressive over many years. Initial stiffness of the legs makes walking 
and running difficult. Later, the spasticity may be so severe that a scissoring-type of 
gait may develop. Although they present difficulty with walking, many patients are 
never confined to a wheelchair and those who are, only are so in the fourth decade or 
later. Clinical examination will show hyperreflexia mainly in the lower limbs, and the 
Babinski sign. Sensory symptoms are absent. NCS show normal conduction velocities 
of motor nerves in the upper limbs and either low normal or only slightly below the 
normal in the lower limbs, and a decrease in amplitude or an absence of the sural 
nerve action potential (Dyck P.J. 1993).  
HMSN type VI:  
In 1879, Vizioli described a family with optic atrophy in association with peroneal 
muscular atrophy (Vizioli 1889). The disease manifests with muscle atrophy and 
weakness first in legs and later in hands, loss of visual acuity progressing to blindness, 
and lancinating pains. The reflexes were normal or decreased. 
HMSN type VII:  
This type is characterized by pigmentary retinopathy associated with distal limb 
muscle atrophy and weakness. Cutaneous sensation was recorded as normal. 
Vibration was decreased at the malleolus, and myotatic reflex of the gastrocnemius 
and soleus muscles could not be obtained (Massion-Verniory L 1946).  
As our knowledge grows there is more and more evidence about clinical, laboratory 
and genetic heterogeneity of CMT disease with about forty different clinical types 
characterized and around twenty six genes reported to cause CMT thus far (IPNMDB) 
(Table 2). Genes implicated in CMTs are involved in the peripheral nerve 
development or function, directly or indirectly (Figure 8) (Patzko and Shy 2011). 
There are genes involved in the structural formation of myelin (PMP22 and MPZ) or 
axonal transport (NEFL) or radial transport (CX32) or Schwann cell differentiation 
(EGR2) or mitochondrial function (MFN2, GADP1) or signal transduction pathways 
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(MTMR2, PRX, SBF2, NDGR1) or endosomal proteins (RAB7) or molecular 
chaperones (HSP22, HSP27) or involved in protein translation (GARS, YARS). With 
all the advances done in understanding the function of these proteins, how mutations 
in these genes cause degeneration of the peripheral nerve is still not known; making it 
difficult to find a treatment.  
However, studying new genes and understanding the process of the disease 
mechanism remains critical to developing therapy for not only these disorders but also 
for the other more common forms of peripheral neuropathy (e.g., leprous neuropathy 
or diabetes neuropathy). 
Because different forms are often clinically indistinguishable in a single patient, the 
diagnostic approach to the identification of the CMT subtype is complex and should 
be based on inheritance pattern, careful clinical examination, electrophysiological 
examination and nerve biopsy together (Pareyson 1999; Pareyson 2003). 
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Table 2 Genetic and clinical features of CMT types 
Type  Inheritance Subtype Locus Gene Age of onset Specific features 
D
e
m
y
e
li
n
a
ti
n
g
 
Dominant 
CMT 1A 
CMT 1B 
CMT 1C 
CMT 1D 
CMT 1E 
CMT 1F 
17p11 
1q22 
16p13 
10q21 
17p11, 1q22 
8p21 
PMP22 
MPZ (P0) 
LITAF 
EGR2 
PMP22, P0 
NEFL 
1st decade 
1st decade 
2nd decade 
2nd decade 
1st decade 
1-40 years 
Classical phenotype 
Classical severe phenotype 
Classical phenotype 
Ptosis 
Deafness 
Ataxia 
Recessive 
CMT 4A 
CMT 4B 
CMT 4B2 
CMT 4C 
CMT 4D 
CMT 4E 
CMT 4F 
CMT 4G 
CMT 4H 
CMT 4J 
8q21 
11q22 
11p15 
5q32 
8q24 
10q21 
19q13 
10q22 
12q12 
6q21 
GADP1 
MTMR2 
SBF2 
SH3TC2 
NDRG1 
EGR2 
Periaxin 
HK1 
FGD4 
FIG4 
Childhood 
2-4 years 
< 20 years 
5-15 years 
1-10 years 
Birth 
1-3 years 
8-16 years 
10-24 months 
Congenital 
Vocal fold paralysis 
Proximal weakness 
Glaucoma 
Delayed walking, cranial nerves 
Hearing loss 
Infant hypotonia 
Motor delay 
Classical phenotype 
Motor delay 
Asymmetric, proximal involvement 
X-linked CMT 1X Xq13 GJB1 2nd decade Encephalopathy, deafness 
A
x
o
n
a
l 
Dominant 
CMT 2A1 
CMT 2A2 
CMT 2B 
CMT 2C 
CMT 2D 
CMT 2E 
CMT 2F 
CMT 2G 
CMT 2I 
CMT 2J 
CMT 2K 
CMT 2L 
CMT 2M 
CMT 2N 
1p36 
1q36 
3q13-q22 
12q24 
7p15 
8p21 
7q11-q21 
12q12 
1q22 
1q22 
8q21 
12q24 
19p12 
16q22 
KIF1B 
MFN2 
RAB7 
TRPV4 
GARS 
NEFL 
HSPB1 
Unknown 
P0 
P0 
GADP1 
HSPB8 
DNM2 
AARS 
7 years 
10 years 
2nd decade 
<1 to 50 years 
16-30 years 
1-40 years 
6-54 years 
15-25 years 
>30 years 
>50 years 
Infant 
15-33 years 
0-50 years 
6-54 years 
Classical phenotype 
CNS, hearing loss 
Acromutilation 
Vocal fold, diaphragm, urinary incontinence 
Arms>legs 
Classical phenotype 
Classical phenotype 
Classical phenotype 
Deafness, photophobia 
Deafness, photophobia 
Vocal fold paralysis 
Classical phenotype 
Ophthalmoparesis 
Classical phenotype 
Recessive 
AR-CMT2A 
AR-CMT2B 
AR-CMT2 
AR-CMT2 (CMT 2B5) 
AR-CMT2C (CMT 2H) 
AR-CMT2 (CMT 2K) 
AR-CMT2 
1q21 
19q13 
9q33 
8p21 
8q21.3 
8q21 
7q11-q21 
Lamin A/C 
MED25 
LRSAM1 
NEFL 
Unknown 
GADP1 
HSPB1 
2nd decade 
30-40 years 
2nd-5th decade 
<2 years 
4-8 years 
<2 years 
6-54 years 
Scapular weakness 
Classical phenotype 
Autonomic symptoms 
Early hypotonia 
Pyramidal involvement 
Vocal fold paralysis 
Fasciculations 
X-linked 
CMT X1 
CMT X2 
CMT X3 
CMT X4 (Cowchock) 
CMT X5 
Xq13 
Xp22.2 
Xq26 
Xq24 
Xq22 
GJB1 
Unknown 
Unknown 
Unknown 
PRPS1 
<20 years 
1st decade 
3-13 years 
<5 years 
8-13 years 
Hearing loss, females 
Mental retardation 
Pain, paresthaesia 
Mental retardation, deafness 
Hearing loss 
In
te
r
m
e
d
ia
te
 
Dominant 
CMT DIA 
CMT DIB 
CMT DIC 
CMT DID 
10q24 
19p12 
1p34 
1q22 
Unknown 
DNM2 
YARS 
P0 
1st-2nd decade 
1st-2nd decade 
7-54 years 
>30 years 
Classical phenotype 
Neutropenia in some patients 
Classical phenotype 
Photophobia, deafness 
Recessive 
CMT RIA 
CMT RIB 
8q21.1 
16q23 
GADP1 
KARS 
2nd decade 
Birth 
Vocal fold paralysis 
CNS, dysmorphic features 
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Figure 8 CMT genes involved in the peripheral nerve structure and function (Patzko 
and Shy 2011).  
1.2.4 Therapeutic approaches for CMT 
To date, no disease modifying treatment has been found for the many CMTs 
described so far because the proteins involved are difficult to target for therapeutics. 
However, therapeutic developments that target the molecular pathway of the proteins 
causing CMTs are underway.  
Transcriptional regulation has been tried as treatment in CMT1A by PMP22 gene 
dosage. In animal models, two compounds have been shown to alter PMP22 mRNA 
levels. The first one, progesterone is produced by both neurons and Schwann cells, 
and has been shown to worsen the disease in PMP22 cDNA overexpressing rats while 
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selective progesterone receptor antagonist, onapristone, reduced the disease and 
PMP22 levels (Sereda, Griffiths et al. 1996). Because opapristone is toxic in humans, 
developing a less toxic progesterone antagonist is ongoing. The second compound, 
ascorbic acid (vitamin C), necessary for peripheral nerve myelination, led to 
improvement in myelination and reduction of PMP22 levels in CMT1A transgenic 
mouse (Passage, Norreel et al. 2004); prompting several studies with different vitamin 
C doses.  
Ions including sodium, calcium, and more importantly potassium play a role in 
depolarization at the nodes of Ranvier. In addition, calcium influx plays a major role 
in axonal degeneration. Therapeutic approaches targeting these ion channels may 
open the road for new treatment of CMTs. Although the first studies that used 
potassium channel blockers did not show improvement in CMT1 patients (Russell, 
Windebank et al. 1995), there is still hope that finding more specific ion channel 
blockers may reverse the disease course in CMT patients. 
Therapeutic approach targeting Schwann cell-axonal signal transduction pathways 
based on the fact that overexpression of neuregulin-1 type III, a protein that expresses 
in axons and binds to ErbB receptors on Schwann cells to initiate myelination, 
induces Schwann cell hypermyelination (Michailov, Sereda et al. 2004). 
Other potential therapeutic approaches include targeting the mitochondrial function 
because genes involved in the mitochondrial function (MFN2, GADP1) cause CMT, 
protein misfolding, membrane trafficking, and gene therapy. 
1.3 Transient Receptor Potential (TRP) Channels 
TRP channels are a superfamily of cation channels that are mostly permeable to both 
monovalent and divalent cations. The first TRP channel was identified in Drosophila 
as a phospholipase C-dependent process gene (Hardie and Minke 1993). The name 
transient receptor potential is based on the transient response pattern of flies carrying 
a mutant in the trp locus to light (Montell and Rubin 1989). Seven TRP-related 
proteins subfamilies have been described based on their amino acid sequence 
similarities: the transient receptor potential canonical (TRPC), the transient receptor 
potential vanilloid (TRPV), the transient receptor potential melastatin (TRPM), the 
transient receptor potential polycystin (TRPP), the transient receptor potential 
mucolipin (TRPML), the transient receptor potential ankyrin (TRPA), and the no 
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mechanoreceptor potential C (TRPN); which is present only in tunicates, flies, and 
worms. About twenty eight mammalian TRP channels grouped into six main 
subfamilies have been cloned in recent years, and many of them are conserved in 
flies, worms, fish and tunicates. However, only a single TRP-related gene, yvc1, has 
been identified in yeast, and none in plants, thus far.  
These subfamilies are subdivided into several members except TRPA that has only 
one member (TRPA1). The TRPC subfamily consists of seven channels (TRPC1-7), 
TRPV has six channels (TRPV1-6), TRPM comprises eight members (TRPM1-8), 
and TRPP and TRPML each contain three members (Table 3). There is approximately 
90 % amino acid sequence similarity among members of one subfamily, but this 
degree of amino acid sequence similarity cannot be found among members of 
different subfamilies. This similarity accounts for heteromerization of TRP channels 
members of one subfamily in native tissues and primary cells. Assembly of channel 
subunits as homo- or heterotetramers results in the formation of cation-selective 
channels. TRP channels are expressed in almost every tissue and cell type including 
peripheral nerves, and play an important role in the regulation of various cell 
functions. Each TRP channel subunit consists of six putative transmembrane spanning 
segments (S1–6), a pore-forming loop between S5 and S6, and intracellularly located 
NH2 and COOH termini. Among other structural features of TRP proteins are ankyrin 
repeats domain (ARD) within the NH2-terminal and coiled-coil domains within the C-
terminal cytoplasmic regions of TRPCs, TRPVs, TRPMs, and TRPA1 (Figure 9) 
(Flockerzi 2007). These structural domains are absent in TRPPs or TRPMLs 
subfamilies. In addition to these structural features, four short amino acid sequence 
motifs, M1-M4, are present in the proteins of some TRP subfamilies. Thus, the M1 
motif, consisting of 38 amino acids is present in TRPC1-7 at the upstream region of 
S1. An alternative M1 motif consisting of 52 to 63 amino acid residues is detectable 
in TRPV1-6, at the corresponding position. The M2 motif resides within the cytosolic 
loop between S4 and S5 of TRPC1-7, and is fairly conserved in the TRPVs and 
TRPMs subfamilies. Motif M3 (consensus sequence ILLLNM-LIAMM) is part of S6 
of all TRPCs, TRPVs, and TRPMs. Finally, the M4 motif which consists of highly 
conserved 26 amino acids and contains the TRP-box domain (WKFQR) follows 
immediately the transmembrane segment S6.  
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The M4 motif is located within the C-terminal cytosolic tail of most TRPs, and is 
followed by proline-rich sequences in some TRP channels (Flockerzi 2007).  
Except TRPM4 and TRPM5, which are only permeable to monovalent cation, all TRP 
channels are permeable to Ca
2+
. Of all TRP channels, only TRPV5 and TRPV6 are 
highly Ca
2+
-selective, with permeability ratio relative to sodium (PCa/PNa) > 100 
whereas this ratio is between 0.3 and 10 in the other Ca
2+
-permeable TRP channels 
(Nilius 2007).  
Different stimuli have been shown to trigger TRP channel gating. These stimuli 
include the binding of intracellular and extracellular messengers, changes in 
temperature, and chemical (e.g., vanilloid compounds, endocannabinoid lipids, IGF-1, 
camphor, 4-alpha-Phorbol) and/or mechanical (hypotonicity) stress. Chemical 
components including ruthenium red, capsazepine, gadolinium, and spermine and 
pharmaceutical molecules (RN1734 and RN1747) have also been described to inhibit 
some TRP channel activity (Flockerzi 2007; Vincent, Acevedo et al. 2009).  
TRP proteins have been shown to play a role in sensory processes such as 
thermosensation, osmosensation, olfaction, taste, mechanosensation, vision, and pain 
perception. Recently, the role of TRP proteins in non-excitable cells including 
endothelial and smooth muscle cells was demonstrated in knock-out mice. 
 
 
Table 3 Classification and pathogenesis of TRP channels 
Subfamily   Member  Locus  Agonists Antagonists Thermo-
sensitive 
Human disease References  
C
a
n
o
n
ic
a
ls
 TRPC1 
TRPC3 
TRPC4 
TRPC5 
TRPC6 
TRPC7 
3q22-q24 
4q27 
13q13.3 
Xq23 
11q21-22 
5q31.1 
↓Ca2+ 
DAG, PLC, IP3 
PLC, ↓Ca2+ 
Gd3+, La3+,↓Ca2+ 
CaM, FFA, 20-HETE 
DAG/PLC, ↓Ca2+ 
Gd3+, CaM 
Gd3+, La3+ 
Gd3+, La3+ 
2APB 
Gd3+, La3+ 
Gd3+, La3+ 
No  
No  
No  
No  
No  
No 
NR 
NR 
NR 
NR 
Focal segmental glomerular sclerosis 
NR 
 
 
 
 
(Reiser, Polu et al. 2005; Winn, Conlon et al. 2005) 
 
V
a
n
il
lo
id
s 
TRPV1 
 
TRPV2 
TRPV3 
TRPV4 
 
TRPV5 
TRPV6 
17p13.2 
 
17p11.2 
17p13.2 
12q24 
 
7q35 
7q33-q34 
Heat, Capsaicin 
 
Heat, IGF-1, 2APB 
Heat  
Heat, 4αPDD, 
hypotonicity 
Calcitropic hormones 
PIP2 
Capsazepine, RR, 
A-425619 
RR, La3+ 
RR 
RR, RN1734 
 
RR 
Mg2+ 
Yes  
 
>52 °C 
22-40 °C 
24-32 °C 
 
No  
No  
NR 
 
NR 
NR 
Skeletal dysplasias, peripheral neuropathies 
 
NR 
NR 
 
 
 
 
(Guilak, Leddy et al. 2010; Nilius and Owsianik 2010) 
M
e
la
st
a
ti
n
s 
TRPM1 
TRPM2 
TRPM3 
TRPM4 
 
TRPM5 
TRPM6 
TRPM7 
TRPM8 
15q13.3\ 
21q22.3 
9q21.11 
9q13.33 
 
11p15.5 
9q21.13 
15q21 
2q37.1 
Constitutively  
ADPR, NAD, AMP 
SPH, ↓Ca2+ 
Heat, ATP, PIP2 
 
Ca2+/PLC 
↓Mg2+ 
Free Mg2+ 
Cold, menthol 
Gd3+, La3+ 
Fenamates, La3+ 
RR, Gd3+, La3+ 
Clotrimazole, 
flufenamic acid 
Acid pH 
RR 
Muscarinic  
Capsazepine  
No  
No 
No 
15-37 °C 
 
No  
No 
No  
23-28 °C 
Congenital stationary night blindness 
NR 
NR 
Progressive familial heart block, type 1B 
 
NR 
Hypomagnesaemia with hypocalcaemia 
ALS-Parkinsonism/Dementia Complex of Guam 
NR 
(Audo, Kohl et al. 2009) 
 
 
(Kruse, Schulze-Bahr et al. 2009) 
 
 
(Schlingmann, Weber et al. 2002) 
(Hermosura, Nayakanti et al. 2005) 
A
n
k
y
r
in
 
TRPA1 8q13 
Pungent, irritants, 
bradykinin 
Gentamicin, 
amiloride, RR, 
Gd3+ 
17 °C (?) NR 
 
P
o
ly
cy
st
in
s 
TRPP1 
TRPP2 
TRPP3 
TRPP5 
16p13.3 
4q21-23 
10q24-q25 
5q31 
NR 
Vasopressin, EGF, ATP 
[Ca2+]ic,ec 
NR 
NR 
↑[H+] 
NR 
NR 
No 
No 
No 
No 
Polycystic kidney disease, type 1 
Polycystic kidney disease, type 2 
NR 
NR 
 
(Peral, Gamble et al. 1995) 
(Mochizuki, Wu et al. 1996) 
 
M
u
c
o
li
p
in
s 
TRPML1 
TRPML2 
TRPML3 
19q13.2 
1q22 
1q22.3 
[Ca2+]ic 
[Ca2+]ic 
[Ca2+]ic 
[Ca2+]ic 
[Ca2+]ic 
[Ca2+]ic 
No 
No 
No 
Mucolipidosis, type IV 
NR 
NR 
 
(Bargal, Avidan et al. 2000) 
 
 
 
Gd3+: gadolinium, CaM: calmodulin, DAG: diacylglycerol, PLC: phospholipase C, IP3: inositol 1,4,5-trisphosphate, La
3+: lantanium, 2APB: 2-aminoethoxydiphenyl borate, FFA: flufenamate, 20-HETE: 20-
hydroxyeicosatetraenoic acid, RR: ruthenium red, PIP2: phosphatidylinositol bisphosphate, ADPR: adenosine 5‟-diphosphoribose, NAD: nicotinamide adenine dinucleotide, AMP: adenosine monophosphate, SPH: D-
erythro-sphingosine, EGF: epidermal growth factor, NR: not reported. 
  
Figure 9 Structures of the mammalian TRP subfamilies.Brackets indicate 
representatives of subfamilies. Protein domains (ankyrin repeats, coiled-coil domain, 
protein kinase domain, and TRP domain) are indicated (Flockerzi 2007). 
1.3.1 The canonical transient receptor potential channels (TRPC) 
TRPC channels are nonselective, Ca
2+
-permeable cation channels, but the 
permeability ratio (PCa/PNa) varies significantly between different members of the 
family. There are seven mammalian TRPC channels (TRPC1-7). We will review one 
member that was implicated in human disease. TRPC channel family can be 
subdivided into three major subfamilies: TRPC1/4/5 activated by calcium store 
depletion; and TRPC3/6/7 activated by diacylglycerol (DAG) (Vazquez, Wedel et al. 
2004). All TRPCs share a structural motif in the COOH-terminal tail called “TRP 
box”. This motif is located close to the intracellular border of S6, and contains the 
invariant sequence EWKFAR. TRPC channels also contain three or four ankyrin 
repeats located in the NH2-terminal (Philipp S 2000). 
TRPC6 
The canonical transient receptor potential 6 gene was first cloned in mouse brain 
(Boulay, Zhu et al. 1997), and later in human placenta (Hofmann, Obukhov et al. 
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1999). The human TRPC6 gene is localized on chromosome 11q21-q22 and has 13 
exons coding for 931 amino acids.  
TRPC6 structural features are similar to those of the other TRP channels with 
intracellular N- and C- terminal regions, six transmembrane helices (S1-S6) and a 
predicted pore forming loop (P) between S5 and S6. Three ankyrin domains are found 
in the amino terminus. The TRPC6 protein also contains an EWKFAR TRP box, 
which is a conserved motif in the TRPC family, and two inositol 1,4,5-trisphospahte 
(IP3) receptor binding domains. The second domain overlaps with a calmodulin 
binding site (Boulay, Brown et al. 1999). Two glycosylation sites were identified in 
the first and second extracellular loop (Asn473, Asn561). The glycosylation sites are 
important determinants for the tightly receptor-operated behaviour of TRPC6 
(Dietrich, Mederos y Schnitzler et al. 2003). 
TRPC6 channels form heteromeric complexes in native environments, but functional 
TRPC6 tetrahomomers were characterized in over-expression studies. As discussed 
earlier in other TRPC channels, over-expression studies and observation in native 
tissues revealed that TRPC6 can form homo- and heterotetramers with TRPC1, 
TRPC3, TRPC4/TRPC5 and TRPC7. 
In human TRPC6 appears to be expressed at higher levels in lung, placenta, ovary and 
spleen (Hofmann, Schaefer et al. 2000). While TRPC6 is found in numerous tissues 
enriched with smooth muscle cells including lung, stomach, colon, oesophagus and 
myometrium (Beech, Muraki et al. 2004), its functional roles were only described in 
vascular and pulmonary arteries. TRPC6 expression in brain is lower than that of 
other TRPCs. 
Gain-of-function mutations of the TRPC6 channel were identified in families with 
focal and segmental glomerulosclerosis (FSGS) by two groups (Reiser, Polu et al. 
2005; Winn, Conlon et al. 2005). These studies showed TRPC6 expression in the 
glomeruli and the tubuli as well as the podocytes. TRPC6 was also implicated in other 
diseases including cardiac hypertrophy (Bush, Hood et al. 2006), idiopathic 
pulmonary hypertension (Yu, Keller et al. 2009), and infantile hypertrophic pyloric 
stenosis (Everett, Chioza et al. 2009). TRPC6 properties show that TRPC6 displays 
double rectification with single-channel conductance of 28-37 pS. The ion 
permeability ratio PCa/PNa is approximately 6 (Hofmann, Obukhov et al. 1999), 
distinguishing it from its closely related channel, TRPC3, which has a significant low 
Ca
2+
 selectivity values, 1.1, and a higher single-channel conductance, 60-66 pS 
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(Owsianik, Talavera et al. 2006). In contrast to TRPC3, TRPC6 is a receptor-operated 
channel (ROC) and shows little basal activity. 
TRPC6 was the first ion channel identified that is activated by diacylglycerol (DAG) 
in a membrane delimitation fashion, independently of PKC. Ca
2+
/calmodulin has a 
stimulatory impact on TRPC6 channel activity (Zhang and Saffen 2001). TRPC6 ions 
channels are also regulated by protein serine and tyrosine phosphorylation. Although 
the PKC activator phorbol 12-myristate 13-acetate (PMA) has no effect on basal 
TRPC6 activity it inhibits carbachol-induced TRPC6 activation by more than 90 % 
(Estacion, Li et al. 2004). Fyn, a member of the Src family of protein tyrosine kinase, 
increases TRPC6 channel activity. 
There are no specific inhibitors for TRPC6. Lanthanum and gadolinium block TRPC6 
at IC50 of 4-6 µM and 1.9 µM, respectively. An arachidonic acid metabolite, 20-
hydroxyeicosatetraenoic acid (20-HETE) and flufenamate (FFA; 100 µM) were 
shown to activate TRPC6. 
1.3.2 Transient receptor potential vanilloid channels (TRPV) 
This family comprises of six members that share the same structural organization 
consisting of an N-terminal region where is located ankyrin repeat domain and a 
transmembrane domain containing six segments. TRPV channels are expressed in a 
wide range of tissues and organs such as sensory neurons (TRPV1, TRPV2, TRPV4, 
TRPV5), smooth muscle cells of blood vessels (TRPV2, TRPV4), kidney, bladder, 
keratinocytes (TRPV4, TRPV5), and digestive apparatus (TRPV4, TRPV6). Some of 
these channels (TRPV1/TRPV2, and TRPV5/TRPV6) interact to form heteromers. 
We will review TRPV1; the first discovered and most studied vanilloid channel, and 
TRPV4 that causes the disease we are studying here. 
TRPV1 
Also called capsaicin receptor, the transient receptor potential vanilloid member 1 
gene was first cloned in rat dorsal root ganglia (DRG) (Caterina, Schumacher et al. 
1997), and was named VR1, for vanilloid receptor subtype 1. This receptor was 
subsequently identified to be a member of the transient receptor potential (TRP) 
family of cation channels, and was thus named TRPV1. TRPV1 has been later cloned 
from human, guinea pig, rabbit, mouse, and porcine tissues. Significant differences 
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are noted in TRPV1 orthologs from different species in their sensitivity to various 
agonists and antagonists. 
TRPV1 is expressed in diverse tissues but high levels are detected in DRG, trigeminal 
ganglia, and nodose ganglia. TRPV1 is predominantly expressed in small- and 
medium-sized peptidergic and non-peptidergic neurons. Peptidergic neurons are 
important in the development of neurogenic pain and inflammation while non-
peptidergic neurons play a critical role in mediating chronic pain. Other regions of the 
brain where TRPV1 is expressed are the hypothalamus, cerebellum, cerebral cortex, 
striatum, midbrain, olfactory bulb, pons, medulla, hippocampus, thalamus, and 
substantia nigra. In non-neuronal tissues, TRPV1 is detected in keratinocytes of the 
epidermis, bladder urothelium and smooth muscles, glial cells, liver, and 
polymorphonuclear granulocytes, mast cells, and macrophages.  
TRPV1 is localized on chromosome 17p13.2 with 17 exons encoding for 839 amino 
acids that form a 95-kDa protein. Mouse Trpv1 has two splice variants, Trpv1α and 
Trpv1β. Trpv1β is not functional by itself, and has a dominant-negative effect on 
Trpv1 by inhibiting Trpv1α function during co-expression (Wang, Hu et al. 2004). 
Human TRPV1 has four transcript variants encoding for the same protein but different 
in their 5‟ untranslated region (UTR). Human TRPV1b splice variant, expressed in 
trigeminal ganglion neurons, is unresponsive to capsaicin or protons, but can be 
activated by high temperature (>47 °C) (Lu, Henderson et al. 2005). TRPV1 consists 
of six transmembrane domains containing a short pore-forming region between the 
fifth and sixth transmembrane domains, 400-amino-acid N-terminus containing three 
ankyrin-repeat domains, and a carboxy-terminus containing a TRP domain. TRPV1 
channels can function as homo- or heteromultimers, and homotetramer TRPV1 
channels are the predominant forms of expression (Kedei, Szabo et al. 2001). TRPV1 
can form with TRPV2 or TRPV3 functional heteromers (Smith, Gunthorpe et al. 
2002; Liapi and Wood 2005). This ability to form functional heteromers with 
different TRPV channels is, at least in part, responsible for the variable responses to 
agonists and antagonists.  
TRPV1 is a non-selective cation channel with near equal selectivity for Na
+
, K
+
, Li
+
, 
Cs
+
, and Rb
+
 ions (Caterina, Schumacher et al. 1997) but moderate selectivity for 
divalent cations. The permeability of Mg
2+
 and Ca
2+
 relative to Na
+
 is higher when 
activated by capsaicin than when activated by heat, 5 and 10 versus 3 and 4. 
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TRPV1 currents exhibit significant outward rectification due to a combined effect of 
voltage on both channel conductance and open probability (Nilius, Talavera et al. 
2005). Upon activation, TRPV1 undergoes desensitization; a phenomenon that can 
occur rapidly during application of an agonist or slowly following repeated agonist 
application. 
TRPV1 is activated by increases in temperature in the noxious range, suggesting that 
it functions as a transducer of painful thermal stimuli in vivo. TRPV1 activates at 
positive potentials and deactivates at negative potentials. These phenomenons depend 
on temperature and ligand concentration, in the absence of which large membrane 
depolarisations are required to activate the channel. TRPV1 is also activated by 
capsaicin, the pungent component of hot chili peppers. Several endogenous fatty acids 
that share structural similarity with capsaicin also activate TRPV1. Those include 
endocannabinoid anandamide, N-arachidonoyl dopamine (NADA) and oleoyl-
dopamine, the 12 hydroperoxyeicosatetraenoic acid (12-HPETE), and 18-20 carbon 
N-acylethanolamines (Movahed, Jonsson et al. 2005). Other TRPV1 regulators 
include extracellular protons and cations, protein kinase A and C, Ca
2+
/calmodulin-
dependent kinase II (CaMKII) or Src kinase.  
Several TRPV1 inhibitors have been described. Capsazepine, which has structural 
similarity with capsaicin, is a competitive antagonist for TRPV1. Ruthenium red also 
blocks TRPV1 activity, though not specific. 
The biological relevance of TRPV1 was shown in some pathological processes such 
as inflammatory pain that can be induced by sensitization of TRPV1, and other 
physiological processes like regulation of normal body temperature. The role of 
TRPV1 in several tissues was reported in several studies. TRPV1 is important in 
regulating normal lower urinary tract function, and maintains mucosal homeostasis, 
and protects against mucosal injury in the gastrointestinal tract. Moreover, in human, 
inflammatory bowel disease is associated with up-regulation of TRPV1 in nerve 
fibres of the colon (Yiangou, Facer et al. 2001). Other tissues and organs where 
TRPV1‟s important role was demonstrated include the vascular system, brain, ear, 
respiratory tract, and skin.  
TRPV4 
The transient receptor potential vanilloid subfamily, member 4 was found by 
screening expressed sequence tag databases for sequences with similarity to other 
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TRPV channels including TRPV1 and TRPV2, and the Caenorhabditis TRPV 
isoform Osm-9. TRPV4 was cloned from kidney, hypothalamus and the auditory 
epithelium. Different names were giving to this newly cloned TRPV: Osm-9-like TRP 
channel 4 (OTRPC4) (Strotmann, Harteneck et al. 2000), vanilloid receptor-related 
osmotically activated channel (VR-OAC) (Liedtke, Choe et al. 2000), transient 
receptor potential channel 12 (TRP12) (Wissenbach, Bodding et al. 2000), and 
vanilloid receptor-like channel 2 (VRL-2) (Delany, Hurle et al. 2001). The human 
TRPV4 is located on chromosome 12q23-q24.1. Five TRPV4 splice variants have 
been described (Arniges, Fernandez-Fernandez et al. 2006). The full-length splice 
variant named TRPV4A encodes an 871-amino acids protein. TRPV4B lacks exon 7 
(Δ384-444), TRPV4C lacks exon 5 (Δ237-284), TRPV4D has a small deletion inside 
exon 2 (Δ27-61), while TRPV4E lacks both exon 5 and 7. Studies have shown that 
only two of these variants, TRPV4A and TRPV4D, traffic to the membrane (Arniges, 
Fernandez-Fernandez et al. 2006). The other TRPV4 variants are retained in the 
endoplasmic reticulum (ER). This lack of trafficking was explained by the loss of 
parts of the ankyrin domains consecutive to the splicing. Ankyrin domains are 
important for TRP channels oligomerization that is a pre-requisite for trafficking. The 
glycosylation site Asn
651
 has been also shown to influence trafficking (Xu, Fu et al. 
2006). Mutation of Asn
651
 to Gln prevented glycosylation and increased both cell 
surface expression of TRPV4 and functional responses mediated by TRPV4. 
As all TRP channels, TRPV4 contains six transmembrane segments (S1-S6) with a 
pore-forming loop between S5 and S6, and intracytoplasmic N- and C-termini. There 
are six ankyrin repeat domains in the N-terminus region. TRPV4 channels are 
believed to form homotetramers. 
TRPV4 is expressed in many tissues with various physiological functions. TRPV4 
mRNA was detected in heart, endothelium, brain, liver, placenta, lung, trachea, and 
salivary gland (Liedtke, Choe et al. 2000; Strotmann, Harteneck et al. 2000; 
Wissenbach, Bodding et al. 2000; Delany, Hurle et al. 2001), but it is in kidney and 
cartilage that TRPV4 has been detected at highest levels. TRPV4 was also found in 
the stria vascularis of the cochlea, in the inner and outer hair cells of the organ of 
Corti, and in the peripheral nervous system (Liedtke, Choe et al. 2000; Suzuki, 
Mizuno et al. 2003; Facer, Casula et al. 2007). 
Heterologous experiments demonstrated that TRPV4 forms a Ca
2+
-permeable, non-
selective cation channels. TRPV4 acts as an outwardly rectifying channel, but has a 
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higher proportion of inward current to outward current than other TRPV channels 
such us TRPV1 and TRPV2. The outward rectification function in physiological 
solutions results from a block by extracellular Ca
2+
 ions resulting from binding to 
negatively charged amino acids, Asp
672
 and Asp
682
, in the pore loop.  
TRPV4 can be activated by a numerous stimuli including heat, extracellular 
osmolarity, mechanical and chemical stimuli. Some studies have shown spontaneous 
TRPV4 activity in some type of cells. Changes in extracellular osmolarity were the 
first TRPV4 modulator found. Increases in osmolarity from 300 mosmol/l reduced 
TRPV4 activity (Nilius, Prenen et al. 2001), whereas hypotonic solutions led to an 
increase in TRPV4 activity (Nilius, Droogmans et al. 2003). Activation of TRPV4 by 
4α-phorbol ester derivatives was shown by several studies. In fact, TRPV4 is strongly 
activated by 4α-PDD, especially in higher than room temperature (Watanabe, Davis et 
al. 2002). Temperature, especially above 25 °C, strongly activates TRPV4. Ca
2+
 
controls both activation and inactivation of TRPV4. 
General TRP channel blockers that block TRPV4 include but not limited to ruthenium 
red and lanthanides. Replacement of Met680 residue by a negatively charged lysine 
reduced TRPV4 divalent permeability. Recently, two TRPV4 blockers were 
discovered (RN-1734 and RN-1747), with one being a specific TRPV4 blocker 
(Vincent, Acevedo et al. 2009).  
TRPV4 plays a role in the mechanosensation, the osmosensation, and nociception 
(Tabuchi, Suzuki et al. 2005; Gevaert, Vriens et al. 2007).  
Prior to our study, TRPV4 had not been implicated in the pathogenesis of a 
neurological disorder. During our study, the gene was involved in inherited skeletal 
dysplasias (Rock, Prenen et al. 2008), and was also associated with hyponatremia 
(Tian, Fu et al. 2009). 
1.3.3 Transient receptor potential melastatin channels (TRPM) 
The mammalian TRPM family consists of eight genes of which three (TRPM2, 
TRPM6, TRPM7) differ from the other ion channels by their C-terminal region that 
contains enzyme domains. The C-terminal region of TRPM2 contains a NUDT9 
domain that has an ADP-ribose pyrophosphatase activity, whereas those of TRPM6 
and TRPM7 contain a serine/threonine protein kinase domain. We will review some 
of the melastatin channels here. 
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TRPM1 
The transient receptor potential melastatin subfamily, member 1, also called 
melastatin 1, is the founding member of the melastatin subfamily of TRP channels. 
Originally discovered as a melanocyte-specific gene that is silenced in aggressive 
mouse melanoma cells (Duncan, Deeds et al. 1998), TRPM1 is expressed in normal 
tissues primarily in the melanin pigment-producing cells melanocytes of the skin and 
eye. TRPM1 is conserved in a wide range of species from mammals to worm. The 
TRPM1 gene is located on chromosome 15q13.3, and contains 27 exons of which 26 
encode a 1,603-amino acids long protein.  
Heterologous experiments have demonstrated that TRPM1 preferentially transports 
Ca
2+
 but the permeability ratio (PCa/PNa) is not determined yet. 
TRPM1 is thought to be constitutively active in overexpression systems and inhibited 
by trivalent ions such as lanthanium (La
3+
) and gadolinium (Gd
3+
) (Xu, Moebius et al. 
2001). 
TRPM1 has been also shown to express in cells responsible for transmitting signals 
from the retina to the ganglions, and mutations in TRPM1 have been associated with 
congenital stationary night blindness (Audo, Kohl et al. 2009; Li, Sergouniotis et al. 
2009; van Genderen, Bijveld et al. 2009; Nakamura, Sanuki et al. 2010). 
TRPM4 
The human TRPM4 is located on chromosome 9q13.33, and consists of 25 exons 
spanning 54 kb. Splicing occurring within TRPM4 leads to two variants, TRPM4a 
and TRPM4b, with TRPM4b being the longest. TRPM4 has the six membrane-
spanning segments with the pore region between S5 and S6, as seen in other TRP 
channels. However, no ankyrin repeats are present in the N-terminal region of 
TRPM4. Nevertheless, TRPM4 variants have important domains or sites, including a 
putative calmodulin binding sites in the N- and C-termini, phosphorylation sites for 
protein kinase A (PKA) and C (PKC), four Walker B motifs, a phosphatidylinositol 
biphosphate (PIP2) binding site (Nilius, Prenen et al. 2005). TRPM4 channels 
homotetramerize to form functional channels. 
Human TRPM4 expresses almost ubiquitously except in brain. Northern blot studies 
have found TRPM4 in a wide range of tissues, including placenta, spleen, prostate, 
skeletal muscle, heart, kidney, pancreas, small intestine, colon, lung and thymus (Xu, 
Moebius et al. 2001; Launay, Fleig et al. 2002; Nilius, Prenen et al. 2003).  
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TRPM4 protein was shown to function as a Ca
2+
-activated channel. In addition to 
Ca
2+
-dependent activation, TRPM4 currents are also strongly voltage-dependent 
(Nilius, Prenen et al. 2003). TRPM4 channel is activated at positive potentials 
whereas it closes at negative potentials. 
TRPM4b constitutes a cation-selective pore that is poorly and selectively permeable 
to monovalent cations (Na
+
, K
+
, Cs
+
, Li
+
), and impermeable to Ca
2+
 (Launay, Fleig et 
al. 2002; Nilius, Prenen et al. 2003). This selectivity filter feature is unique to 
TRPM4b, and was attributed to a 6-amino acids stretch (EDMDVA) found between 
S5 and S6. 
TRPM4b activity is modulated by PKC activity, temperature, and binding of 
intracellular ATP, PiP2 and decavanadate to the channel. Recent studies showed that 
TRPM4b is also a heat-activated channel. 
Among TRPM4 blockers are intracellular spermine and flufenamic acid, and 
extracellular clotrimazole. But these compounds are not selective. 
TRPM4 has been shown to be expressed in the Purkinje fibres of the heart and plays 
an important role in the human heart conductance. Moreover, mutations in TRPM4 
have been implicated in progressive familial heart block, type 1B (Kruse, Schulze-
Bahr et al. 2009). 
TRPM6 
The human TRPM6 is located on chromosome 9q21.13. This gene has 3 splice 
variants containing 39 exons. The longest variants encodes for 2,022 amino acids. The 
TRPM6 gene was first cloned when screening for homologues of elongation factor-2 
kinase (Riazanova, Pavur et al. 2001). TRPM6 is Mg
2+
 and Ca
2+
-permeable channel. 
Structural analysis showed that TRPM6, as most TRP channels, has six 
transmembrane domains with a pore region between S5 and S6. In addition, TRPM6 
has kinase domains at its C-terminal end, conferring it a serine/threonine kinase 
activity. The Mg
2+
 permeability coupled with the kinase activity confers TRPM6 a 
unique status in TRP channels. TRPM6 has highest similarity with TRPM7, and the 
sequence identity increases to more than 80 % in the pore-forming region.  
TRPM6 is predominantly expressed in kidney and intestine, where it might play a role 
in the Mg
2+
 re/absorption.  
TRPM6 channels were shown to homomerize but also to heteromerize with its closest 
TRP channels, TRPM7. Heterologous experiments using Xenopus oocytes suggested 
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that interaction between TRPM6 and TRPM7 is required in order for TRPM6 to be 
trafficked to the cell membrane. But there was no sign that TRPM6 increased TRPM7 
expression (Chubanov, Waldegger et al. 2004).  
TRPM6 is activated by a decrease in the intracellular Mg
2+
 concentration. TRPM6 
channels show outwardly rectifying currents, and reverse close to 0 mV. 
Only one unspecific blocker was identified for TRPM6. In fact, TRPM6 inward 
monovalent currents are strongly inhibited by ruthenium red (10 µM) whereas the 
outward currents remain unaffected (Voets, Nilius et al. 2004). 
Mutations in TRPM6 were shown to cause hypomagnesaemia with secondary 
hypocalcaemia (Schlingmann, Weber et al. 2002). 
TRPM7 
The transient receptor potential melastatin-related subfamily member seven is located 
on chromosome 15q21 and contains 39 exons that encode for 1,865 amino acids. Like 
TRPM6, TRPM7 is also a bifunctional protein that contains both ion channel and 
protein kinase domains (Ryazanova, Dorovkov et al. 2004). TRPM7 has very strong 
outward rectification currents with little inward current in the physiological range of -
70 mV to 0 mV. Its currents are characterized by a reversal potential of approximately 
0 mV. 
TRPM7 activity is controlled by intracellular free Mg
2+
. Other TRPM7 activity 
controllers are magnesium-complexed nucleotides. The role of the kinase domain in 
TRPM7 gating was speculated on in different studies. Others have suggested a 
receptor stimulation of TRPM7 activity.  
TRPM7, unlike TRPM6, is ubiquitously expressed, although expressed in variable 
amounts in different cells. Reports have implicated TRPM7 in the susceptibility for 
Amyotrophic Lateral Sclerosis-Parkinsonism/Dementia Complex of Guam 
(Hermosura, Nayakanti et al. 2005). 
1.3.4 Transient receptor potential ankyrin channel (TRPA) 
There is only one TRPA channel in human known so far, the transient receptor 
potential cation channel, subfamily A, member 1. Also called ankyrin-like with 
transmembrane domains 1 or transformation-sensitive protein p120, TRPA1 is located 
on chromosome 8q13 and contains 27 exons encoding for 1,119-amino acids long 
protein with a molecular weight of 127.4 kDa. As for most TRP proteins, TRPA1 has 
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six transmembrane domains with a presumed pore region between S5 and S6. Two 
potential N-linked glycosylation sites are located in the predicted extracellular four 
short loops. TRPA1 has up to 18 predicted ankyrin repeats domain in its N-terminal 
region. This feature distinguishes the human TRPA1 from the other TRP channels 
since most of them have zero to eight ankyrin repeat domains.  
The expression of TRPA1 was detected in dorsal root, trigeminal, and nodose ganglia, 
and in the inner ear in the vestibular and auditory sensory epithelia. In these tissues, 
TRPA1 mediates pain.  
Many stimuli have been reported to activate TRPA1 channels. These stimuli include 
pungent compounds and environmental irritants (e.g., mustard, wasabi, and 
cinnamon), bradykinin via bradykinin receptor. The role of cold in TRPA1 activation 
is still debated. 
Four antagonist compounds, including gentamicin, ruthenium red, gadolinium, and 
amiloride, have been identified for TRPA1. However, as mentioned earlier, these 
chemicals block other channels.   
1.3.5 Transient receptor potential polycystin channels (TRPP) 
This family is divided into two groups, the polycystic kidney disease 1-like proteins 
and the polycystic kidney disease 2-like proteins. TRPP2, TRPP3 and TRPP5 are 
members of the polycystic kidney disease 2-like group and are called TRPP2-like 
proteins. They are cation-permeable channels with a calcium to sodium ration 
(PCa
2+
/PNa
+
) >1. They do not contain TRP domain nor do they contain ankyrin repeats. 
We will review two of the polycystin channels implicated in diseases. 
TRPP1 
The transient receptor potential polycystin member 1, also called polycystic kidney 
disease gene 1 (PKD1) is localized on chromosome 16p13.3 and encodes for two 
splice variants. The longest splice variant contains 46 exons that encode for 4303 
amino acids with a 460 kDa molecular mass protein. This gene encodes for 
glycoprotein that contain a large extracellular N-terminal region, 11 transmembrane 
domains, and a cytoplasmic C-terminal region.  
TRPP1 is thought to interact with TRPP2 and other TRP channels including TRPC1 
and TRPC4 (Kottgen, Buchholz et al. 2008). Other interactors include cytoskeletal 
proteins. TRPP1 and TRPP2 co-localize at the membrane of the primary cilia of renal 
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epithelial cells and endothelial cells. In these cells, the two genes are proposed to 
transducer luminal shear stress into a calcium signal (Nauli, Kawanabe et al. 2008). 
PKD1 is a membrane integral protein that functions as a regulator of calcium 
permeable cation channels and intracellular calcium homeostasis. This channel is also 
involved in cell-cell/matrix interaction and may modulate G-protein-coupled signal-
transduction pathways. Studies showed that this gene plays a role in renal tubular 
development.  
Mutations in this gene were shown to cause autosomal dominant polycystic kidney 
disease type 1 (ADPKD1) (Peral, Gamble et al. 1995). 
TRPP2 
Also called the polycystic kidney disease gene 2 (PKD2), the transient receptor 
potential polycystin subfamily member 2 is located on chromosome 4q21-23 and 
contains 15 exons that encode for 968 amino acids protein with a molecular weight of 
110 kDa. Structurally, TRPP2, as all other TRP channels contains six membrane-
spanning segments with a pore region between S5 and S6, and intracytoplasmic N- 
and C-terminus regions. There are two predicted motifs in the C-terminal region, a 
coiled-coil domain and a Ca
2+
-binding EF-hand (E and F helices motifs).  
TRPP2 channels are thought to homomerize but also interaction with TRPP1 and 
TRPC1 was also demonstrated in studies. This interaction is mediated by the C-
terminal region (Qian, Germino et al. 1997). This region mediates interaction with 
other proteins including α-actinin, troponin I, IP3 receptor, and PACS-1/PACS-2 
among others. Several studies have established that TRPP2 is a non-selective cation 
channel with a large conductivity averaging 100 pS. TRPP2 is permeable to divalent 
and monovalent ions such as Ca
2+
, Na
+
, and Cs
+
 but not to Cl
-
. Heterologous 
experiments of mouse Trpp2 in Xenopus oocytes showed that most of the protein 
localizes in the intracellular membranes, and its trafficking is induced by chaperones 
and proteasome inhibitors (Vassilev, Guo et al. 2001).  
Several factors directly or indirectly modulate TRPP2 activity. Among those factors 
are interaction with TRPP1, the pH, vasopressin, ATP, hydro-osmotic pressure, and 
the epidermal growth factor (EGF). In fact, TRPP2 activity is inhibited by an 
increased hydrogen ions concentration [H
+
]. Other non-specific TRPP2 inhibitors are 
lanthanium (La
3+
), high Ca
2+
 concentrations, gadolinium (Gd
3+
), and amiloride.  
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PKD2 is mutated in patients with autosomal dominant polycystic kidney disease Type 
2 (Mochizuki, Wu et al. 1996). Mutations in PKD2 have been identified in around 15 
% of these patients (Peters and Sandkuijl 1992). 
1.3.6 Transient receptor potential mucolipin channels (TRPML) 
This family contains three members of which one, TRPML1, has been associated with 
a disease. 
TRPML1 
Also called MCOLN1, this gene encodes the protein mucolipin 1 (MLN1). MLN1 is a 
non-specific Ca
2+
 channel that has a similar putative structure to the TRP superfamily 
for which it was called TRPML1 (Delmas 2004). TRPML1 is located on chromosome 
19p13.2, and contains 14 exons that encode for a 580-long protein. TRPML1, like 
most TRP channels has six transmembrane segments with a pore region between S5 
and S6. However, TRPML1 does not contain ankyrin domains. The MLN1 protein 
functions as calcium channel regulated by cations concentration. But, MLN1 function 
is also regulated by monovalent cations (Na
+
 and K
+
) (LaPlante, Falardeau et al. 
2002) and pH changes (Raychowdhury, Gonzalez-Perrett et al. 2004). MLN1 contains 
a serine-lipase domain in the amino part of the protein between the first two 
transmembrane domains. Studies have localized MLN1 in late endosomal-lysosomal 
organelles (Luzio, Poupon et al. 2003). In addition, MLN1 contains two di-leucine 
motifs, one in the N-terminal region and another in the C-terminal region. The C-
terminal di-leucine motif is responsible for targeting TRPML1 from the plasma 
membrane to early endosomes (Vergarajauregui and Puertollano 2006). Studies have 
shown that TRPML1, TRPML2, and TRPML3 can interact to form functional 
channels that traffic from Golgi to lysosomes. Although TRPML1 and TRPML2 can 
independently transport to lysosomes, TRPML3 requires one of the first two to traffic. 
Heterologous experiments have shown that TRPML1 generates robust outwardly 
rectifying currents. 
Mutations in this gene result in patients with mucolipidosis type IV (Bargal, Avidan et 
al. 2000). 
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1.4 Objectives 
The gene for CMT2C has been mapped in a large Caucasian-American family to 
chromosome 12q23-24 (Klein, Cunningham et al. 2003) spanning about 5 Mb 
between markers D12S105 and D12S1330. This region contains 81 annotated genes. 
Subsequently, two other European families were studied, and their trait showed 
linkage to the same region; they narrowed the region to 3.9 Mb between markers 
D12S105 and D12S1340 (McEntagart, Reid et al. 2005); reducing the number of 
genes to 63. 
However, at the time of this study, the gene causing CMT2C was not yet identified. 
We identified five families with a CMT2C-like phenotype. One of these families is a 
branch of the first large family in which the region was first mapped by Klein et al. 
(Klein, Cunningham et al. 2003). Our goals were to study these new families with the 
following objectives: 
a. Clinical and laboratory characterization of these additional CMT2C families to 
confirm their similarity with the classical CMT2C phenotype. 
b. Perform linkage analysis by fine mapping to see if the trait in these families links to 
the previously published region and moreover to narrow this region. 
c. Compare the haplotypes of these families to see whether there is a common 
haplotype. 
d. Find the gene causing this disease by sequencing all the genes in the region found 
by linkage. Eventually use high-through-put sequencing technology to find the gene 
when it becomes available. 
e. Study the cellular and molecular biology of the causative gene defect by 
heterologous expression comparing mutant to wild-type versions of the gene. 
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2 Materials and Methods 
2.1 Patients 
We evaluated five unrelated families who presented with clinical and laboratory 
findings consistent with CMT 2C disease. All adult subjects and parents or guardian 
for minors gave written consent before participation in studies at the National Institute 
of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health 
(NIH), Bethesda, Maryland (United States of America) and the University College 
London Research Ethics Committee research protocols (London, United Kingdom). 
Permission was obtained from all participating individuals to share their samples with 
other researchers. A separate consent to take and publish pictures for scientific 
purposes was signed by patients. All subjects provided a detailed medical and family 
history, and underwent neurological evaluations and genetic counselling. A subset of 
patients and normal individuals underwent electrophysiological, radiological, 
laryngological, or audiological evaluations. 
Medical and family history 
Family F1 (Figure 10) 
This is a Caucasian American family with German ancestors. Twenty five individuals 
were examined and had peripheral blood collected. Eight members were seen in the 
Neurogenetics Clinic at NIH. The rest of the individuals were seen during field trips 
in their homes. Overall, seven individuals identified themselves as being affected in 
this family based on the symptoms they were experiencing, and/or previous 
electrophysiological and laryngoscopic findings. Fifteen family members did not 
complain of any symptom suggestive of CMT, and three were unaffected, unrelated 
spouses. Of the seven affected, five underwent neuro-electrophysiological studies and 
laryngoscopy during this study. Nerve conduction studies and laryngoscopy were 
performed in one unaffected member who had raspy voice, and revealed no 
abnormalities except vocal cord inflammation; which may explain her raspy voice. 
Two patients who were complaining of hearing loss underwent audiological 
examination. Muscle and peripheral nerve biopsy of the gastrocnemius muscle and 
sural nerve was performed in one patient. 
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Family F2 (Figure 11) 
Currently living in the United States, this family has Scottish ancestors. Twenty-four 
individuals of which six were seen in the Neurogenetics Clinic and the Laboratory of 
Speech and Language at the National Institutes of Health (NIH) were studied. The rest 
of family members were seen during field trips. Ten individuals had symptoms 
consistent with a peripheral neuropathy. Nine described themselves as unaffected and 
five were designated as unknown because of their young age or insufficient symptoms 
or lack of previous neurophysiological and laryngoscopic evaluation for those with 
suspicious symptoms. Of the six individuals seen at the Neurogenetics Clinic at NIH, 
three were affected and three unaffected. Neurological examination, nerve conduction 
studies and laryngoscopy were performed on them.  
 
V 
Figure 10 Pedigree of family F1. 
Note that there is at least one affected in generations III to V. The arrow denotes 
the proband. 
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Figure 11 Pedigree of family F2.  
Note that there is at least one affected in generations II to IV, and two cases of male to 
male transmission. The arrow indicates the proband. 
 
Family F3 (Figure 12) 
This also is a Caucasian family of which 9 individuals were seen in the Neurogenetics 
Clinic at NIH. Three family members identified themselves as being affected or 
showed obvious symptoms of peripheral neuropathy and laryngeal involvement. One 
individual complained of cramps in calves, numbness in hands, and sleep apnea. All 
individuals underwent a complete neurological examination. Laryngoscopy was 
performed in the three people who presented with weakness and breathing difficulties. 
Nerve conduction studies were done in all but one. That individual had clear 
symptoms of CMT, but was too young at time of study to undergo NCS. An 
audiological examination was performed in the most affected patient (IV.3) because 
of complaints of hearing loss.  
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Figure 12 Pedigree of family F3.  
Note the vertical transmission pattern of the disease. The black arrow indicates the 
initial proband. 
 
Family F4 (Figure 13)  
Also living in the United States, this family has European ancestors. All individuals 
were seen in the Neurogenetics Clinic at NIH. Four presented with weakness and 
breathing difficulties. Two family members had no complaints (one unaffected sibling 
and one unaffected unrelated spouse). All four affected family members were seen in 
the Clinic of Speech and Voice department at NIH because of their laryngeal 
symptoms, and neuro-electrophysiological studies and laryngoscopy were performed. 
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Figure 13 Pedigree of family F4.  
Note the vertical transmission of the disease with a male to male transmission. The 
initial proband is indicated by the arrow. 
 
Family F5 (Figure 14) 
This is a small family that is originally from Iran collected by our collaborator Dr 
Henry Houlden in the Institute of Neurology at the University College London, 
London, United Kingdom. Five individuals in this family were affected or reportedly 
had symptoms suggesting that they are affected, a mother and her four children. The 
disease onset was variable, and symptoms included distal weakness and atrophy 
associated with shortness of breath on exertion and hoarseness of voice. No hearing 
loss or urinary incontinence was reported in any of the affected individuals. 
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Figure 14 Pedigree of family F5.  
Note the vertical pattern of the disease transmission. Individuals II.3 and II.4 are 
reportedly affected but were not seen in clinic.  
   
In all five families at least one affected was seen in each generation that followed the 
founder. In two families (F4 and F2), there was evidence of male to male 
transmission, excluding X-linked mode of inheritance. Families F1 and F3 had fewer 
males, and the only affected male does not have offspring. We concluded that this is 
most likely an autosomal dominant disease and the analyses were done accordingly. 
Phenotypic characterization 
The affected status was determined based on clinical findings consistent with a CMT 
2C-type phenotype, with vocal fold and diaphragm involvement being the key 
features. In addition, nerve conduction studies and electromyogram findings 
consistent with axonal degeneration were also considered. However, 
electrophysiological studies and laryngoscopy were not performed in some of the 
individuals we evaluated during our field trips and some individuals declined these 
evaluations.  
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Because of the high variability of the disease in term of age at onset and disease 
severity, we could not completely exclude people without symptoms, and revisited 
them occasionally after the first examination. 
2.2 Laboratory studies 
2.2.1 Muscle and nerve biopsy 
This procedure was performed in an affected individual (Family F1 IV.4) in 1978 
when she was 13 years old. The right gastrocnemius muscle and the right sural nerve 
were biopsies using standard techniques at the Cleveland General Hospital. The 
muscle fragment measured approximately 0.7 x 0.5 x 0.3 cm, the nerve fragment 
measured 0.7 cm in length and 0.2 cm in cross diameter. The muscle fragment was 
put in Zinker‟s solution while the nerve fragment was put in formalin. Samples were 
frozen in dry-ice-cooled isopentane for conservation. For the current study, fragments 
of the first biopsies were requested for further analysis. Samples were sectioned 
transversely in a cryostat for pathology. For muscle general morphology assessment, 
serial sections of 10 µm were picked up on poly-lysinated slides, and stained with 
hematoxylin and eosin. Nerve sections were stained with toluidine blue. Both muscle 
and nerve sections were visualized using a light microscope. In addition, sural nerve 
sections were examined by electron microscopy. My contribution in this part of the 
study was to identify the laboratory where the biopsy was done, obtain material 
release consent from the patient and organize the shipment.  
2.2.2 Nerve conduction studies (NCS) and electromyography (EMG) 
These laboratory examinations were performed in available affected and unaffected 
family members in the Electromyography Section at NIH by Drs. Mary Kay Floeter 
and Tanya J. Lehky or in their local clinics for those who could not make it to NIH or 
had previously had the testing prior to enrolling in this study. My contribution in this 
part of the study was to organize the evaluation and help with interpreting the results 
based on clinical findings. NCS of motor nerves and sensory nerves were obtained 
using standard surface recording techniques.  
Compound motor action potential (CMAP), conduction velocity (CV), and distal 
latency (DL) were recorded at the ulnar and median nerves for upper extremities, the 
peroneal and tibial nerves for lower extremities, and the phrenic nerve.  
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For the ulnar nerve, motor action potentials were recorded at the abductor digiti 
minimi (ADM) muscle, with stimulation sites at wrist, below elbow, and above 
elbow, the conduction velocity was recorded at segments wrist-below and below 
elbow-above elbow while distal latencies were recorded at all segments.  
For the median nerve, motor action potentials were recorded at abductor pollicis 
brevis muscle with the stimulation sites being the wrist and elbow, conduction 
velocity was recorded at the wrist-elbow segment, and the distal latency at all 
segments. For the peroneal nerve, motor action potentials were recorded at the 
extensor digitorum brevis with the ankle being the stimulation site, conduction 
velocity was recorded at segments ankle-fibula neck and fibula neck-popliteal fossa, 
and distal latencies at all sites. Motor action potentials for the tibial nerve were 
recorded at the abductor hallucis muscle and stimulated from the ankle, the 
conduction velocity at the ankle-popliteal fossa segment, and the distal latencies at all 
sites. For the phrenic nerve, motor action potentials and distal latencies were recorded 
at the chest and stimulated from the neck while conduction velocity was not usually 
recorded. In some patients the CMAP and DL of the phrenic nerve were recorded 
during laryngoscopy by fluoroscopy. F-wave studies were also performed. For these 
studies, F-latency and M-latency were recorded at median, ulnar, peroneal and tibial 
nerves.  
Sensory nerve action potential (SNAP), CV, and DL were also recorded from median, 
radial, ulnar, and sural nerves. For the median nerve, sensory amplitude was first 
recorded at the index and stimulated at the wrist, and then at wrist-elbow and elbow-
axilla segments. Conduction velocity was recorded at the index-wrist segment while 
distal latencies were recorded at all segments. The radial nerve sensory amplitude was 
recorded at the base of the thumb and stimulated from the forearm. Conduction 
velocity and distal latency were recorded at the same segment. For the ulnar nerve, 
sensor action potentials were recorded at the little finger and stimulated at the wrist. 
Both conduction velocity and distal latency were recorded at the same site. Sural 
nerve sensory action potentials as well as conduction velocity and distal latency were 
recorded at the ankle and stimulated at the lower leg. 
A concentric needle EMG study was performed in the biceps brachii, the first dorsal 
interosseus, the tibialis anterior, the vastus lateralis, the gastrocnemius (medial head), 
and the diaphragm muscles. Parameters assessed include but not limited to the 
insertional state of muscle fibres including the spontaneous activity (fibrillation, 
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positive waves, fasciculations, and phases), the volitional activity (amplitude, 
duration, and configuration), and the recruitment of motor units (at maximum effort, 
and the maximum pattern). In addition, an interference pattern analysis was 
performed in selected muscles. Not all motor and sensory nerves amplitudes were 
recorded in all individuals that underwent this evaluation nor was needle EMG 
performed in all. 
In addition, short exercise test and a quantitative sensory testing estimating the cold 
and warmth detection threshold and using the CASE IV machine (WR Medical 
Electronics C0., Stillwater, MN) with the 4-2-1 algorithm were done in a subset of 
patients. 
2.2.3 Fiberoptic nasolaryngoscopy  
This laboratory examination was performed by Dr. Christy Ludlow at the National 
Institutes of Health in the Speech and Language Department. Here too I helped 
organize patient visit, and identify those we needed undergo this examination. 
Otolaryngological examinations were performed using a Pentax PNL-10RP3 
fiberoptic nasolaryngoscope (Pentax Precision Instruments, Orangeburg, NY) 
interfaced with the Kay Elemetrics Digital Stroboscope system (Kay Elemetrics 
Corporation, Lincoln Park, NJ) to evaluate the structure and function of the laryngeal 
mechanism. All available patients and unaffected family members with suspicious 
altered voice underwent this examination which included the following gestures to 
examine the vocal folds integrity: 
a. Alternating between sniff and phonation three times to examine for asymmetry in 
abduction and adduction. 
b. Pitch-glide up and pitch-glide down to examine for vocal fold lengthening. 
c. Rapid repetition of syllables containing glottal stops and vowels for speed and 
completion of hyper-adduction. 
d. Rapids repetition of syllables containing voiceless consonants and vowels for speed 
and completion of phonation offset and abduction. 
e. Whistling “Happy Birthday” to examine for symmetry for movement for rapid 
abduction and adduction during non-speech. 
f. Stroboscopy during extended vowel production to examine the symmetry of the 
mucosal wave during vocal fold vibration. 
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2.2.4 Radiological evaluation 
Chest X-rays during inspiration and expiration were performed in a subset of patients 
to look for diaphragmatic movement abnormalities. Vertebral column, long bones, 
hands, and wrists X-rays were also done to evaluate skeletal deformities which are 
seen in CMT patients, and to examine bone morphology and density. Antero-posterior 
and lateral radiographs were obtained for this evaluation. 
2.2.5 DNA extraction 
Peripheral blood was taken from available patients and unaffected relatives for DNA 
extraction. I extracted DNA using the Qiagen PAXgene Blood DNA kit protocol or 
the Puregene Blood Core Kit C (Qiagen, Valencia, CA, USA) per manufacturer‟s 
protocol for genetic analysis. Eight millilitres (ml) of peripheral blood were collected 
in a tube provided by the manufacturer that contains 2 ml of buffer for the PAXgene 
blood DNA Kit whereas blood was collected in a heparin tube for the Puregene Blood 
Core Kit C.  
2.2.6 Skin biopsy 
Skin biopsies were performed by Dr Sumner with my assistance using a 3-mm punch. 
Selected areas of biopsy were cleaned with providone-iodine solution. The areas were 
anesthetized using a subcutaneous injection of 2 percent lidocaine. A 30-gauge needle 
was used to administer the anesthetic to limit discomfort. The skin surrounding the 
biopsy site was stretched with the thumb and index finger of the nondominant hand. 
The punch biopsy instrument was held vertically over the skin and rotated downward 
using a twirling motion created by the first two fingers on the dominant hand. Once 
the instrument had penetrated the dermis into the subcutaneous fat, or once the 
instrument reached the hub, it was removed. This created a cylindrical skin specimen 
which was removed. Scissors held in the dominant hand cut the specimen free from 
the subcutaneous tissues. The cut was made below the level of the dermis. Each 
specimen was placed in a formalin container. In selected patients, skin sections were 
analyzed to look for possible abnormalities. 
2.2.7 Immortal cell lines establishment 
To establish lymphoblast cell lines, peripheral blood was collected in heparin tubes 
and sent to Georgetown University (Washington D.C., USA) for EBV transformation.  
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Skin samples from some patients and unaffected individuals were used to establish 
fibroblast cell lines. 
2.3 Genetic analysis 
We performed fine mapping using STS markers and SNP arrays analysis for whole 
genome scan. 
We then proceeded with the editing, quality control and analysis of the linkage format 
of pedigree, marker and map files (pedigree file .ped, marker data file .dat and mapfile 
.map) on a software installed (and where necessary compiled) on a Windows XP 
workstation and a Unix / Linux (CentOS 5) server.  
2.3.1 Linkage analysis/Fine mapping 
Linkage analysis was done in Professor Robert Kleta‟s laboratory by Dr Horia 
Stanescu. My role was to draw pedigrees, help design the model to use, and data 
interpretation. This analysis involved three families (F1, F2 and F4). Twenty five 
individuals were collected from family F1, 24 from family F2, and 6 from family F4. 
Samples from the three families were combined and sent to deCODE (Reykjavik, 
Iceland) for genotyping. Twelve highly informative STS markers spaced at about 0.04 
to 1.6 cM intervals covering the previously reported region (Klein, Cunningham et al. 
2003) were used to perform fine mapping. Di-, tri-, and tetra-microsatellite loci were 
used in multiplex PCR with fluorescently-labelled primers. The analysis was done in 
capillary electrophoresis ABI 3730 DNA analyzers (Applied Biosystems, Foster City, 
CA USA). Multipoint analysis was performed using both: a parametric model 
(assuming autosomal dominant mode of inheritance with complete penetrance and 
disease allele frequency of 0.001) and a nonparametric model (with no assumptions 
regarding the mode of inheritance) followed by haplotype reconstruction. The 
software used for the analysis was: Genehunter 2.0 (Kruglyak, Daly et al. 1996) and 
Simwalk2 v2.91 (Sobel, Sengul et al. 2001). Mendelian inconsistencies were checked 
using PedCheck (version 1.1). Genotyping data was formatted for Simwalk2 using 
mega2 (v4.0) which is based on a Markov Chain Monte Carlo simulation. The 
haplotypes were reconstructed with Genehunter and Simwalk, and visualized using 
HaploPainter (v.029.5). Data from previously reported studies on this disease were 
compared with our results to re-define the region of interest. 
 77 
2.3.2 Single Nucleotide Polymorphism (SNP) array analysis 
SNP array analysis was also performed to track for possible deletion or duplication in 
the region of interest found through linkage analysis using families F1, F2 and F4, and 
to perform whole genome scan in another family. 
Copy number analysis in the linked region  
The Illumina Infinium II HumanHap550 SNP chips (Illumina Inc., San Diego, CA, 
USA) were used in the families where linkage analysis was done with microsatellite 
markers for this analysis. Samples from one affected individual from each of the 3 
families (F1, F2, and F4) were genotyped. These chips assay 555,352 tagging SNPs 
derived from phase I and II of the international HapMap project. Genotyping was 
performed as per the manufacturer‟s protocol using 750 ng of genomic DNA. Briefly, 
each DNA sample was amplified in an overnight step. The amplified product was then 
enzymatically fragmented, precipitated, and resuspended. The resulting product was 
then hybridized to the chip overnight. The amplified and fragmented DNA samples 
anneal to locus-specific 50-mers during the hybridization step. Each allele at each 
locus is represented by one of two bead-types fixed to the chip. Following 
hybridization, allelic specificity is conferred by enzymatic extension. Products were 
fluorescently stained and visualization of the resulting signal and localization of the 
SNPs was performed with the BeadStation scanner and data collection software 
(v2.3.25, Illumina Inc, San Diego, CA, USA). 
Whole genome scan 
GeneChip Human Mapping 10K array XBa142 2.0 Affymetrix (Affymetrix UK Ltd, 
United Kingdom) was used to perform this analysis. DNA from family F5 was 
genotyped according to manufacturer‟s instruction. Unlikely genotypes were filtered 
using the Merlin software (version 1.1 alpha3). Genotypes were examined as 
described above (linkage analysis).  
2.3.3 Selection of candidate genes 
To select candidate genes I considered different criteria, including the level of 
expression of genes in the nervous system by in situ hybridization or expression 
prediction based on homology with other known CMT genes, and their interaction or 
homology with other known CMT-causing genes. Another criterion considered was 
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the effect on the development, morphology or functioning of the nervous system of 
animal models of the genes in the region of interest.  
Genes that fulfilled all or most of these criteria were considered first. To do this work 
we used different bioinformatics tools and databases including the Online Mendelian 
Inheritance in Man (OMIM) from the National Center for Biotechnology Information, 
NCBI (NIH, Bethesda, MD USA) and the McKusick-Nathans Institute of Genetic 
Medicine (Johns Hopkins University School of Medicine, Baltimore MD USA), 
Unigene and Aceview from NCBI, EMBL-EBI (Hinxton, Cambridge UK), Gene 
Sorter from UCSC (Santa-Cruz, CA USA) and GNF SymAtlas v1.2.4 (San Diego, 
CA USA). Genomic sequences of candidate genes were taken from the NCBI Entrez 
database (RefSeq) but cross-compared with other nucleotide sequences databases, 
e.g., Ensembl (EMBL-EBI and Sanger Institute) and the UCSC genome browser. 
2.3.4 Mutation detection 
I designed intronic primers flanking the donor and acceptor sites up to about 200 bp 
of all exons of candidate genes by visual inspection. The specificity of these primers 
to the chosen genes was checked using NCBI‟s nucleotide BLAST search (Basic 
Local Alignment Search Tool). Coding regions and flanking intronic regions up to 
about 200 bp of candidate genes in the region of interest were sequenced to look for 
eventual sequence variants. From each family, genomic DNA was amplified from an 
affected and an unaffected individual sharing the non-disease-bearing allele in the 
linked region for sequence comparison. Polymerase Chain Reaction (PCR) using 25-
μl total volume containing 25 ng genomic DNA and 10 pmol of each primer were 
processed in PuReTaq Ready-to-go beads (GE Healthcare, Buckinghamshire, HP7 
9NA, UK). PCR was done according to the following protocol: five minutes at 95 ˚C 
for the first step, followed by 35 cycles of 95 ˚C for 30 seconds, 55 ˚C to 60 ˚C for 30 
seconds, and 72 ˚C for 30 seconds to 1 minute, followed by a final 10 minutes 
extension step at 72 ˚C. All reactions were performed in a DNAEngine thermocycler 
from Bio-Rad (Hercules, CA USA). DNA fragments were separated by 
electrophoresis on 1 per cent agarose gels (150 ml TAE buffer for 1.5 g of agarose) 
containing 1.5 µg of ethidium bromide. The gels were cast in 1x TAE buffer, and ran 
at a constant voltage of 140V for 45-60 minutes. A size marker of 200 bp ladder 
(Hyperladder I from Bioline, London, UK) was electrophoresed alongside the samples 
to allow identification of correct DNA fragments.  
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The DNA fragments were purified using GENECLEAN Spin Kit from MP 
Biomedicals, Inc. (Illkirch, France). Sequencing PCR was set up in the same 
thermocycler according to the manufacturer‟s protocol (Beckman Coulter, Fullerton, 
CA USA), and by using their Quick Start Kit. Direct genomic DNA sequencing from 
both forward and the reverse primers was done by dye terminator cycle sequencing 
from Beckman Coulter. Sequences were aligned and compared with the NCBI 
reference sequences using the nucleotide BLAST software. When a sequence variant 
not seen in the NCBI and Ensembl SNP databases was found in the affected 
individual only, segregation was checked within the families, and conservation of the 
mutated amino acid or nucleotide among all available species was checked by 
alignment using the MultAlin software. In addition at least 200 ethnically matched 
controls were sequenced to exclude SNPs. 
2.3.5 Exome sequencing 
This experiment was performed by Dr Bryan Traynor‟s group at the National Institute 
of Aging (NIH). Two families, F4 that linked to the chromosome 12q24 locus but was 
negative for all genes within the region and F3 that was negative for TRPV4 
screening, were used for this analysis. DNA from one affected individual (III:1 for 
family F4 and IV:3 for family F3) was enriched using SureSelect Exome target 
enrichment technology according to the manufacturer‟s protocol (version 1.0, Agilent, 
CA). The enriched DNA was paired-end sequenced on a Genome Analyzer IIx 
(Illumina, CA). Sequence alignment and variant calling were performed against the 
reference human genome (UCSC hg 18) using the Genome Analysis Toolkit 
(http://www.broadinstitute.org/gsa/wiki/index.php/The_Genome_Analysis_Toolkit). 
PCR duplicates were removed prior to variant calling using Picard software 
(http://picard.sourceforge.net/index.shtml). Based on the hypothesis that the mutation 
underlying this rare familial disease was not present in the general population, SNPs 
identified in the 1000 Genomes project (www.1000genomes.org/) or in dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP/, Build 131) were removed. Next, 
synonymous changes were identified and filtered from the variant list using SIFT 
software (version 4.0, http://sift.jcvi.org/). Sanger sequencing using customized 
primers was performed to confirm the variant and determine its presence in the other 
affected family members as well as the unaffected family members to check for 
segregation.  
 80 
As an additional step, variants and indels detected in the genotyped families were 
filtered against exome data generated for 200 neurologically normal control subjects. 
My contribution in this part of the study was to draw pedigrees, help design the 
approach, confirm sequence variants, and check co-segregation. 
2.4 Functional studies of mutants TRPV4 
2.4.1 TRPV4 expression in the nervous system 
- Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR) 
Frozen human spinal cord and trachea tissues isolated at autopsy were obtained from 
the Maryland Brain and Tissue Bank (Baltimore, MD). Human knee cartilage primary 
chondrocytes isolated at the time of knee surgery were a kind gift of Jennifer 
Eisenhoff at John Hopkins University. Spinal cord dorsal horn and ventral horn and 
tracheal cartilage was dissected from the whole tissues and homogenized. RNA was 
isolated from tissues using TRIZol reagent and purified using the QIAGEN RNeasy 
mini kit. RNA was converted to cDNA by using the High Capacity cDNA RT kit 
(Applied Biosystems) as previously described. Primers to amplify different exons of 
the TRPV4 transcript (exons 3-4, exons 5-6, exons 7-8, exon 5, and exon 7) and 18S 
(as internal control) were purchased from Applied Biosystems (ABI). Reactions were 
run in triplicate using the ABI Prism 7900 Sequence Detector System as previously 
described. Data were analyzed in an excel spreadsheet.  
- Standard Polymerase Chain Reaction 
Studies have shown that TRPV4 have five splice variants, some lacking exon number 
5 or exon number 7, and some lacking both. I then designed primers covering exon 5 
and 7 of TRPV4 within exon number 4 and 8 in the human and mouse cDNA 
sequence. These primers were ordered from Integrated DNA Technologies (Leuven, 
Belgium). Human cDNAs from different tissues including lung, brain, trachea, spinal 
cord, heart, and kidney were purchased from Clonetech (Mountain View, CA). Mouse 
spinal cord, peripheral nerves and cartilage cDNAs were also ordered. A regular PCR 
using the protocol described above (mutation detection) was processed. PCR products 
were run on a 1 % agarose gel to identify bands characterizing different splice 
variants. Bands were identified, cut, purified and sequenced to verify the presence or 
absence of exon number 5 and/or exon number 7. 
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2.4.2 Expression of WT and mutant TRPV4 in Xenopus oocytes and mammalian cells 
Xenopus oocytes experiments were completed by Dr Anselm Zdebik in our laboratory 
at UCL. I helped selecting healthy oocytes, inject them, and performed western blot to 
check equal expression. For expression in Xenopus oocytes, cDNA constructs were 
obtained by recombinant PCR from mouse cDNA prepared using Superscript III 
(Invitrogen) primed with polydT according to manufacturer‟s instructions. A 
recombinant 5‟ fragment carrying the R269C mutation was combined with a 3‟ 
fragment carrying the R269H mutation to obtain WT, R269C and R269H through 
proofreading activity. The full-length fragment was then inserted into pTLB via ClaI 
and XbaI sites test digested, and fully sequenced. These mouse WT and mutant 
TRPV4 cDNAs were also subcloned into a modified pIRES-CD8 for transfection in 
mammalian cells.  
Mammalian expression constructs (pcDNA3.1 and pcDNA3.1-FLAG), expressing 
human TRPV4 cDNA, were a gift from Miguel Angel Valverde. I generated the 
R269C and R269H TRPV4 mutants using the QuickChange Site-Directed 
Mutagenesis
 
kit (Stratagene) as per the manufacturer's instructions. For the R269C 
sequence variant we used the following primers: forward primer 5‟-
CCACGCCCAGGCCTGTGGGCGCTTCTTCCAGCCC-3‟ and reverse primer 3‟-
GGGCTGGAAGAAGCGCCCACAGGCCTGGGCGTGG-5‟. For the R269H 
sequence variant we used the following primers: forward primer 5‟-
CCACGCCCAGGCCCATGGGCGCTTCTTCCAGCCC-3‟ and reverse primer 3‟-
GGGCTGGAAGAAGCGCCCATGGGCCTGGGCGTGG-5‟. A PCR reaction using 
50 µl total volume containing 1µg of plasmid DNA, 125 pmol of each primer, 2 µl of 
enzyme, 2 µl of DMSO, 1 µl dNTPs, was completed with water and processed in a 
200-µl tube. PCR was done according to the following protocol: 95 °C for 30 seconds 
followed by 16 cycles of 68 °C for 3 minutes. The PCR product was test-digested 
with DPN1 for up to 6 hours to eliminate wild-type version and purified using the 
Qiagen PCR purification kit as directed. To transform TOP10 supercompetent cells 
(Invitrogen), 5 µl of the PCR product were used. Transformed cells were plated in 
ampicillin-containing agar overnight. Plasmid
 
DNA was isolated from three random 
colonies using the Qiagen Miniprep DNA kit and mutagenesis confirmed
 
by DNA 
sequencing. Mutant plasmid DNA was first used to transfect cells to check for 
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transfection efficiency before transforming Maxi Efficiency DH5α (Invitrogen) for 
maxiprep plasmid DNA extraction.  
Human epithelial cervical cancer cells (HeLa), Human Embryonic Kidney (HEK) 293 
were grown and plated in high glucose DMEM supplemented with fetal bovine serum 
(FBS) (Hyclone) (10 %) and penicillin/streptomycin/glutamine (PSG) (1 %) at 37 °C 
in 5 % CO2, and DRG cell lines were grown in neurobasal medium supplemented 
with glucose (20 %), L-glutamine (0.2 M), FBS (10 %), B-27 supplement (Invitrogen) 
(5 %), and blasticidin (Invitrogen) (1 %). HeLa cells were transfected with the mouse 
cDNA using polyethyleneimine (1 mg/ml) in Optimem I (Invitrogen). HEK 293 and 
DRG cells were transfected with the Human cDNA using lipofectamine 2000 
(InVitrogen).  
2.4.3 TRPV4 blockers 
TRPV4 is an ion channel that is regulated by different stimuli including chemical 
compounds and structural changes. A pore domain mutant M680K, shown to be a 
TRPV4 inhibitor (Voets, Prenen et al. 2002), was generated in WT, R269C and 
R269H mutants TRPV4 using the QuickChange Site-Directed Mutagenesis
 
kit 
(Stratagene) as described above. 
RN1734 is a chemical compound that was shown to be a specific TRPV4 blocker 
(Vincent, Acevedo et al. 2009). This compound is commercially available, and was 
purchased from Menai Organics Ltd. (catalogue number NC1207) (Bangor, United 
Kingdom). 
2.4.4 Cell death quantification 
Part of cell death assays was performed in Dr Charlotte Sumner and I performed part 
of it in our laboratory. HEK 293 cells were grown on cover slips and transfected as 
described above. For indicated samples, ruthenium red (Sigma) or RN1734 (10 μM) 
was added to the media 4 hours after transfection at a concentration of 10 µM. 
Twenty four or 48 hours after transfection, cells were washed once with PBS and 
incubated with 2 µM Calcein AM and 4 µM of ethidium homodimer-1 (EthD-1) 
(Invitrogen) for 30 minutes at room temperature. EthD-1 is used to label and detect 
nucleotides and nucleic acids. Because EthD-1 is highly positively charged and 
cannot cross cell membrane of living cells, it is used to stain dead or dying cells. 
Cover slips were then immediately mounted using ProLong Gold antifade reagent 
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(Invitrogen) and imaged immediately using a Zeiss AxioImager Z1 microscope. Each 
experiment was performed in triplicate and digital pictures were taken at 40X 
magnification of each sample at random. The number of dead cells (red) and live cells 
(green) were counted in each picture using the Zeiss Axiovision 4.6 software, and the 
average percentage of dead cells for 3 separate experiments was quantified. Equal 
expression of TRPV4 was confirmed by protein blot of cells transfected under 
identical conditions. 
2.4.5 Immunohistochemistry 
This experiment was done in Dr Charlotte Sumner‟s laboratory. Cells were 
transfected as above and after 24-48 hours were fixed with 4 % paraformaldehyde 
(PFA)/0.05 % NP-40. They were stained with the following antibodies: polyclonal 
rabbit anti-TRPV4 antibody 1:300 (Sigma reference number T9075), polyclonal 
rabbit anti-TRPV4 1:1000 (gift from Michael Catarina, Johns Hopkins), monoclonal 
anti-Flag 1:500 (Sigma), monoclonal anti-calnexin 1:50 (BD), and acetylated tubulin 
(Sigma). Alexa Fluor conjugated 488, 546, or 594 (Molecular Probes) secondary 
antibodies were used at 1:1000 dilution. Nuclei were counterstained with TOTO-3 
(Molecular Probes) at 1:3000 dilution or mounted in ProLong gold anti-fade reagent 
with or without DAPI (Invitrogen). Images were obtained using a Zeiss LSM-510 
META confocal microscope. Z-stack projections were made from serial scanning 
every 0.5 μm.  
Adult mice (strain C57/B6) were transcardially perfused with 4 % PFA and spinal 
cords and DRGs were isolated, post-fixed in 4 % PFA for 6h, cryoprotected in 30 % 
sucrose, and cut into transverse sections on a cryostat at 50 μm thickness. Polyclonal 
rabbit anti-TRPV4 1:1000 (gift from Michael Caterina, Johns Hopkins) (Guler, Lee et 
al. 2002), anti-Choline acetyltransferase (ChAT) (Chemicon), and anti-Tuj1 
(Covance) were used followed by the appropriate Alexa Fluor-conjugated 488, 546, 
or 594 secondary antibodies (Molecular Probes). Images were obtained with an 
inverted Zeiss LSM 510 META confocal microscope as above. 
2.4.6 Cell surface biotinylation 
This experiment was also done by Dr Anselm Zdebik. For surface biotinylation, cells 
were transfected as above, washed with PBS, and incubated with SulfoLink NHS 
Biotin from Pierce (0.5 mg/ml in PBS+2 mM MgCl2) for 1 h at 4 ˚C. Cells were 
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washed with PBS and TBS to block unincorporated biotin, and harvested into 0.1x 
TBS+300 mM Mannitol, 1 % Triton X-100 supplemented with a complete protease 
inhibitor cocktail (Roche). Cells were incubated on ice for 10 min, centrifuged at 
1000 g for 10 min, and an aliquot of the supernatant saved for Western blotting of the 
input fraction.  
The remaining was incubated with streptavidin-covered agarose beads for 60 min at 
room temperature with gentle shaking. Beads were pelleted at 500 g for 2 min for a 
total of 4-wash steps using TBS 1 % Triton-X100, 0.05 % SDS, 0.1 % sodium 
desoxycholate. Protein was recovered from the beads by incubation with 100 µl 1x 
LDS loading buffer (Invitrogen) supplemented with 100 mM DTT. Five per cent 
input and biotinylated protein was separated on 4-12 % ready-made gels using MOPS 
run buffer (Invitrogen), transferred to PVDF membrane using a Biorad TransCell 
semidry blotter and protein visualized using Sigma anti-TrpV4 (reference number 
T9075) and mouse anti-actin antibodies. Secondary antibodies were from Amersham 
and diluted 1:3000 in block containing 5 % non-fat dry milk and 0.05 % NP-40 in 
TBS. Blots were visualized using homemade ECL reagent on a Syngene cooled CCD 
imaging station. 
2.4.7 Endoplasmic Reticulum (ER) stress experiment 
This work was completed in Dr Charlotte Sumner‟s laboratory. The endoplasmic 
reticulum (ER) is a central organelle of each eukaryotic cell as the place of lipid 
synthesis, protein folding and protein maturation. Proteins of the plasma membrane, 
secreted proteins as well as proteins of the Golgi apparatus and lysosomes fold into 
their tertiary and quaternary structure in the ER. The ER is the major signal 
transducing organelle that senses and responds to changes of the homeostasis. 
Conditions interfering with the function of ER are collectively called ER stress. ER 
stress is induced by accumulation of unfolded protein aggregates (unfolded protein 
response, UPR) or by excessive protein traffic usually caused by viral infection (ER 
overload response, EOR). Several genes including HSPA5 (Grp78), HSP90B1 
(Grp94), and GADD45A have been implicated in protecting against ER stress. As a 
result these genes become over expressed during ER stress. To investigate whether 
TRPV4 mutants induce ER stress, we have measured the expression of these genes in 
WT compared to mutants-expressed HEK293T cells. To measure the expression RNA 
was extracted in cultured HEK293T cells expressing WT and mutants TRPV4, and 
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converted to cDNA by using the High Capacity cDNA RT kit (Applied Biosystems) 
as previously described. Primers to amplify different exons of the Grp78, Grp94 and 
GADD45A transcripts, and 18S were purchased from Applied Biosystems (ABI). 
Reactions were run in triplicate using the ABI Prism 7900 Sequence Detector System 
as previously described.  
2.4.8 Intracellular calcium measurement.  
In this experiment I provided mutant and wild-type constructs. 
Cell calcium imaging  
Calcium imaging was done in Dr Michael Caterina‟s laboratory at Johns Hopkins‟ 
University. HEK293 cells were transfected with 0.1 µg wild type or mutant TRPV4 + 
0.4 µg pcDNA3, or 0.5 µg pcDNA3 alone, plus fluorescent marker (0.02 µg 
mCherry), using Lipofectamine 2000, according to the manufacturer‟s instructions. 
Cells were replated onto polyornithine-coated coverslips approximately 4.5 hours 
after transfection and were maintained at 37 °C in 5 % CO2 until use. A subset of cells 
was cultured in the presence of 10 µM ruthenium red which is a TRP channels 
blocker. Calcium imaging was started approximately 22-24 hours post-transfection. 
Cells were loaded with Fura 2-AM (10 µM Fura + 0.02 % pluronic acid diluted in 
extracellular buffer; Molecular Probes, Eugene, OR) for 1 hour at 37 °C. Coverslips 
were positioned on an inverted microscope (Nikon, Melville, NY), and solutions were 
delivered via a gravity-driven perfusion system using electronically controlled valves 
(Warner Instruments, Hamden, CT). Standard extracellular buffer contained (in mM): 
130 NaCl, 3 KCl, 2.5 CaCl2, 0.6 MgCl2, 10 HEPES, 10 sucrose, 1.2 NaHCO3, pH 7.4 
(NaOH), 295 ± 5 mOsm. Baseline Fura 2 fluorescence was assessed over a period of 
90 seconds and was used as a measure of intracellular calcium levels. Ratiometric 
images were captured at 340 and 380 nm excitation at 2 second intervals, using a 
fluorescent light source (DG4, Sutter Instruments, Santa Rosa, CA), cooled CCD 
camera (Roper, Tucson, AZ) and RatioTool software (ISee Imaging, Raleigh, NC). 
All experiments were done at room temperature. Only transfected (mCherry-positive) 
cells were included in the subsequent analysis. 
Plate-based intracellular calcium assay 
This assay was performed in Dr. Charlotte Sumner‟s laboratory at Johns Hopkins‟ 
University. Intracellular calcium levels were determined using a calcium assay kit 
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according to manufacturer‟s instructions (catalogue number R8041, Molecular 
Devices). The assay was performed with the use of a Fluorometric Imaging Plate 
Reader (FLIPR) calcium assay kit, according to the recommendations of the 
manufacturer (Molecular Devices). HEK293 cells were transfected with wild-type and 
mutants TRPV4 constructs. At 4 h, RN1734 was added at 10 μM, and at 24 h, media 
was removed. Cells were washed once in Hanks balanced saline supplemented with 
2.5 mM probenecid (pH 7.4), and 50 μl of Calcium Assay Reagent was added, and 
cells were incubated at 37 °C for 1 h. After incubation, cells were placed immediately 
in a FlexStation plate fluorometer equipped with a multichannel injector (Molecular 
Devices) and set at λex = 485 nm, λem = 520 nm. Agonist or a vehicle was added in a 
volume of 50 µL/well at an injection speed of 80 µL/ s. Fluorescence measurements 
were taken at 1.52 s intervals before and after agonist addition for a total of 60 s per 
well. Each assay plate included a mock-transfected control, wild-type receptor and a 
test mutant all transfected at the same time and seeded at the same cell density. The 
raw data were analyzed with the SoftmaxPro software package (Molecular Devices). 
The baseline was defined as the average of the first five recordings on each curve. 
Functional responses were measured as peak fluorescence levels after subtraction of 
the baseline. Basal (spontaneous) receptor activity was determined by subtracting the 
baseline in the mock-transfected control from that of the test sample also measured on 
the same assay plate. All measurements were derived from at least three separate 
experiments each performed in sets of three to four replicates. 
2.4.9 Electrophysiology 
Xenopus oocytes whole-cell currents measurement 
This work was done in our laboratory by Dr. Anselm Zdebik. Whole-cell membrane 
current was measured using Xenopus oocytes. Mouse TrpV4 cRNA was transcribed 
from templates linearized with MluI using mMessageMachine Sp6 kits (Applied 
Biosciences) according to manufacturer‟s instructions. We injected 0.5-5 ng of cRNA 
into oocytes prepared according to standard protocols (Thiemann, Grunder et al. 
1992). Oocytes were incubated in nominally Ca
2+
 free solution containing 100 mM 
NaCl, 4 mM MgCl2, 2 mM KCl and 5 mM HEPES, pH 7.5 after injection to prevent 
degradation. Oocyte currents were measured using a npi Tec01 TEVC amplifier (npi, 
Tamm, Germany) in the same solution supplemented with 20 mM CaCl2 after 24-48 
h. Currents were activated by increasing temperature from 17 ˚C to 38 ˚C using a 
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Peltier-based CL-100 solution cooler/heater (Harvard Apparatus, Kent, UK) or by 
preincubation with 4-alpha-phorbol 12,13-didecanoate (4-α-PDD) (Watanabe, Davis 
et al. 2002) obtained from LC laboratories (Woburn, USA) predissolved at 5 mM in 
DMSO at a final concentration of 5 µM. Temperature activated currents were 
measured initially and when the bath had reached 38 ºC. Pre-incubation with 4-α-
PDD rather than acute application was used due to the observed slow activation of 
TRPV4 currents in oocytes. A ramp or pulse protocol was used in clamping oocytes 
from –100 to + 100 mV, and currents from WT and the two mutants compared at –
100 mV. Each experimental condition was replicated in at least 3 to 4 different oocyte 
batches. Recordings were performed in a solution containing 100 mM sodium 
gluconate, 20 mM calcium gluconate, 4 mM MgSO4 and 5 mM HEPES, pH 7.5. 
Human Embryonic Kidney cells (HEK293T cells) whole-cell currents measurement 
This experiment was completed in Dr. Rachelle Gaudet‟s laboratory at Harvard 
University, Cambridge by Dr Hitoshi Inada. 
HEK293 cells were transfected using Opti-MEM and Lipofectamine2000. Cells were 
prepared in 3.5-cm dishes at a cells density of about 1 x 10
6
. Four µg of DNA was 
added into a tube containing 250 µl of Opti-MEM and mixed well. Ten µl of 
Lipofectamine2000 was added into another tube. Samples were incubated for 5 min at 
room temperature. Solutions were combined and incubated for 25 min at room 
temperature. After incubation, 500 µl of DNA/Lipofectamine2000 were added in the 
cells and incubated at 37 °C for 4 to 5 hours. Media was removed by aspiration and 2 
ml of warm PBS was added to wash cells. Cells were resuspended in 2 ml of DMEM 
containing 10 % Fetal Bovine Serum (FBS), and 500 µl of cells were dispersed in 6-
cm dishes, and incubated at 37 °C for 24 to 36 hours. For visual selection of 
transfected cells pNEGFP was added to the cells.  
Whole-cell currents were measured at 25 °C with Axopatch 200B (Molecular 
Devices) using a repeated ramp protocol (−100 to +100 mV, 400 ms, every two 
seconds). The solutions were: standard extracellular, 150 mM NaCl, 5 mM KCl, 1 
mM MgCl2, 2 mM CaCl2, 10 mM glucose, 10 mM HEPES, pH 7.4 with NaOH; 
hypotonic (200 mOsm), NaCl reduced to 80 mM; isotonic (320 mOsm), 120 mM 
mannitol added to hypotonic solution; and pipette solution, 140 mM CsCl, 5 mM 
EGTA, 10 mM HEPES, pH 7.2 with CsOH. 
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2.4.10 Protein structure determination 
This experiment was completed in Dr Rachelle Gaudet‟s laboratory. TRPV4-ARD 
(132-383) was amplified from avian cDNA (provided by Stefan Heller) and cloned 
into pET21-C6H (Jin, Touhey et al. 2006), providing a C-terminal AAAHHHHHH-
tag.  
The protein was expressed in BL21 (DE3) at room temperature, inducing with 0.75 
µM IPTG at OD600=0.6. Cells were lysed in 20 mM Tris pH 8.0, 300 mM NaCl, 20 
mM imidazole pH 8.0, 1 mM PMSF, 7 mM ß-mercaptoethanol (ß-ME), 0.1 % Triton 
X-100, 0.4 mg/mL lysozyme, 0.05 mg/mL RNase A and 0.02 mg/mL DNase I. The 
clarified lysate was loaded onto Ni-NTA agarose (Qiagen), eluted with a stepwise 
imidazole gradient; 7 mM β-ME and 10 mM EDTA were added after elution. 
TRPV4-ARD was further purified on an SP FF column (GE Healthcare) with an NaCl 
gradient in 20 mM HEPES pH 8.0 and 5 mM DTT, dialyzed against 10 mM Tris pH 
8.0, 300 mM NaCl, 5 mM DTT, and 10 % glycerol, concentrated to 7-10 mg/mL with 
a centrifugal concentrator (10,000 MWCO; VivaScience), and stored at -80 °C. 
TRPV4-ARD crystals were grown in hanging drops at 4 °C in 0.1 M sodium citrate 
pH 5.0, 10 % MPD, 2 % PEG8000, 4.3 % trifluoroethanol and frozen in reservoir 
with 20 % PEG4000 (crystal form I), or 0.025 M KH2PO4, 7 % MPD, 7 % PEG8000, 
and 5 mM DTT and frozen in reservoir with 25 % PEG400 (crystal form II). Data 
were collected at 110 K and 1.54 Å on a Micromax007/R-AXIS IV++ system 
(Rigaku/MSC Inc) and processed with HKL2000. The structures were determined by 
molecular replacement using TRPV2-ARD (Jin, Touhey et al. 2006) as search model 
in MOLREP, model building in COOT, and refinement using REFMAC. Data and 
refinement statistics are in Table 7. The coordinates were deposited in the Protein 
Data Bank with entry codes 2JXI and 2JXJ (crystal forms I and II, respectively). 
Crystal form I chain A was used for structural analyses unless otherwise noted. 
Figures were generated using PyMOL. 
2.4.11 TRPV4-ARD expression and purification 
This experiment was also done in Dr. Rachelle Gaudet‟s laboratory. The chicken 
TRPV4-ARD (132-383) was generated by amplification of the cDNA (provided by 
Stefan Heller) and cloned into the Nde I and Not I sites of pET21-C6H, providing a 
C-terminal AAAHHHHHH-tag for purification. The resulting protein construct was 
expressed in BL21(DE3) at room temperature after induction with IPTG at an 
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OD(600 nm) of 0.6. Cells were resuspended in lysis buffer [20 mM Tris pH 8.0, 300 
mM NaCl, 20 mM imidazole pH 8.0, 1 mM PMSF, and 7 mM ß-mercaptoethanol (ß-
ME)] with 0.1 % Triton X-100, 0.4 mg/mL lysozyme, 0.05 mg/mL RNase A and 0.02 
mg/mL DNase I and lysed by sonication. The clarified lysate was loaded onto Ni-
NTA agarose (Qiagen) and eluted with a stepwise imidazole gradient of 50 mM, 100 
mM, 150 mM, 200 mM, and 300 mM imidazole. β-ME and EDTA (7 mM and 10 
mM, respectively) were immediately added to each elution fraction. Fractions 
containing TRPV4-ARD were diluted 1:5 with 20 mM HEPES pH 8.0 and 5 mM 
DTT, and loaded onto a HiPrep 16/10 S FF column (GE Healthcare) and eluted with a 
NaCl gradient. Relevant fractions were pooled, and dialyzed against 10 mM Tris pH 
8.0, 300 mM NaCl, 5 mM DTT, and 10 % glycerol. The TRPV4-ARD protein was 
concentrated to 7-10 mg/mL with a Vivaspin centrifugal concentrator (10,000 
MWCO; VivaScience), and stored at -80 °C.  
2.4.12 Co-immunoprecipation 
These experiments were completed in our laboratory at the Neurogenetics Branch 
(NINDS, NIH, Bethesda). HEK293 cells were co-transfected with 0.5 µg of pcDNA3 
expressing human PACSIN1, PACSIN2 or PACSIN3 (gifts of M. Plomann, Cellular 
Neurobiology Research Group, Center for Biochemistry, University of Cologne, 
Cologne, Germany) and 0.5 µg Flag-TRPV4. The transfection was performed using 
the Fugene6 (Roche) and Optimem. The Fugene6 was added to Optimem and let sit 
for 5 minutes. This amount of DNA was then added, and the solution was incubated at 
room temperature for at least 20 but no longer than 40 minutes, and was then added to 
the cells. Each construct was done in duplicate. At 24 h, cells were washed once and 
harvested after with 1 ml of PBS and cleared. Cell pellets were obtained after 
spinning the harvested solution for 3 minutes. Cell pellets were re-suspended in 200 
µl of lysis buffer containing a protease. An aliquot of 20 µl was taking out for the 
input, and the remaining cell lysates were incubated with anti-Flag M2 (Sigma) for 6 
h followed by overnight incubation with Dynabeads Protein G (Dynal). The beads 
were washed 3 times with 500 µl lysis buffer, and proteins were denaturized by 
adding 4X dye and heating at 95 °C for 5 min. Bound proteins were separated by 
SDS-PAGE, and analyzed by immunoblotting with antibodies to PACSIN3, 
PACSIN2 and PACSIN1 (gifts of M. Plomann), respectively. TRPV4 
immunoprecipitation was verified by immunoblotting with anti-Flag M2.  
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2.4.13 Protein binding assays 
This experiment was performed in Dr. Rachelle Gaudet‟s laboratory. Wild-type and 
mutant human TRPV4-ARDs, including the N-terminal proline-rich region (residues 
136–397), were expressed and purified as the chicken Trpv4-ARD.  
Mouse Pacsin3-Sh3 domain (residues 361–424; single difference between mouse and 
human PACSIN3-SH3 is V362A; cDNA provided by S. Heller) was cloned into NdeI 
and NotI sites of pET21-C6H, expressed in BL21 (DE3) cells induced with 0.4 mM 
isopropyl-β-d-thiogalactopyranoside at room temperature. Cells were lysed by 
sonication in lysis buffer (20 mM Tris-HCl, pH 8.0, 300 mM NaCl, 20 mM 
imidazole, pH 7.0, and 1 mM phenylmethylsulfonyl fluoride) with 0.1 % Triton X-
100, 0.2 mg/ml lysozyme, 50 μg/ml RNase A and 25 μg/ml DNase I. The cleared 
lysate was loaded onto Ni-NTA (Qiagen) and eluted with steps of 25, 50, 100, 150 
and 250 mM imidazole pH 7 in lysis buffer, adding 10 mM EDTA at pH 8.0 and 1 
mM dithiothreitol (DTT) after elution. Relevant fractions were pooled, dialyzed, 
purified on Superdex75 (GE Healthcare) in 10 mM Tris-HCl, pH 8.0, 50 mM NaCl, 1 
mM DTT, and concentrated to >20 mg/ml in centrifugal filters. For PACSIN3-SH3 
interaction assays, samples contained 25 nmol TRPV4-ARD with or without 37.5 
nmol PACSIN3-SH3 in 125 μl pre-incubated for >30 min, and 100 μl were loaded 
onto a Superdex75 10/30 column (GE Healthcare) in 20 mM Tris, pH 7.0, 150 mM 
NaCl, 1 mM DTT at 4 °C. Calmodulin-agarose binding assays were performed 
essentially as described (Phelps, Wang et al. 2010).  
2.5 Statistical analysis 
Data were analyzed using Excel (Microsoft) and the Strathclyde electrophysiology 
suite (University of Strathclyde, Glasgow). Data significance was estimated using 
paired and unpaired student‟s t-Tests, where appropriate. Data are reported as means 
or standard error of the mean. 
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3 Results 
3.1 Patients 
3.1.1 General findings 
Family F1  
From the 25 family members evaluated, seven were found to be affected. The mode of 
inheritance was vertical, suggesting a dominant model, but no male-to-male 
transmission was seen. This may be explained by the fact that the founder, a female, 
had only one son who is unaffected and four daughters. In addition, from her eight 
grandchildren born from affected parents, four were males, and only one was affected. 
This affected grandson had no offspring. 
Clinical findings 
The age of onset was highly variable, with the earliest occurring before one year and 
the latest yet known at 44 years of age. This variability was seen in the disease course, 
and no relationship was seen between the age of onset and disease severity (as shown 
in the case presentations below). The clinical variability between the proband and her 
mother can be appreciated in Figure 15. Weakness and atrophy in lower extremities 
were the first reported symptoms in all but one. Altered voice and shortness of breath 
with stridor in variable degree were seen in all the affected individuals. These 
symptoms were worse on exertion or excitement. Absent or reduced tendon reflexes 
were seen in all patients. Minimal to moderate sensory loss was seen in all but one, 
and was more prominent in the most affected family members. All sensory modalities, 
including pin-prick, light touch, temperature sense, vibration sense, and 
proprioception were affected. However, vibration sense was the most affected 
modality. Five patients reported bladder urgency or urinary incontinence, and two 
complained of progressive hearing loss. The most affected patient had subtle facial 
weakness consistent with orbicularis oculi and oris muscle weakness. None of the 
patients presented with upper motor neuron involvement or memory decline. Two of 
them underwent tracheotomy (at 20 months and 18 years of age) because of the 
seriousness of the symptoms resulting from the laryngeal muscles paralysis. One 
unaffected individual (IV.5) of 41 year-old was complaining of raspy voice which she 
said started few months prior her visit, but had no other neurological symptoms such 
as muscle weakness or atrophy or breathing difficulties. Her neurological exam was 
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normal. In addition, her other family members had also normal neurological 
examination. 
 
Figure 15 Phenotypic characteristics of family F1.   
Marked variability of disease severity is demonstrated by mild, late-onset weakness 
with mild atrophy in hands and feet in subject F1.III.2, but severe quadriparesis, 
generalized muscle atrophy, scoliosis, and respiratory failure in her daughter, subject 
F1.IV.4. Written consent was obtained to publish these photographs. 
Laboratory findings 
Muscle/nerve biopsy 
The biopsy was done in individual IV.4 when she was at age 13 (Figure 16), about 
five years after disease onset. The source of the specimen was the right gastrocnemius 
muscle and sural nerve, a sensory nerve in the leg easily accessible to biopsy. Tissue 
sections were stained with hematoxylin, eosin, toluidine blue, and visualized by light 
and electron microscopy. Findings are detailed below in the figure legend. 
Muscle sections showed severe denervation atrophy, and near end-stage muscle. Type 
I and type II fibres were both involved, and there was fibre type grouping. 
Peripheral nerve sections of the sensory sural nerve showed a slight decrease of 
myelinated fibres with apparently well preserved axons indicating much more severe 
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involvement of motor nerves innervating muscles than sensory nerves. Endoneural 
connective tissue was mildly increased. There were occasional axonal swellings. 
 
                      
                      
Figure 16 Muscle and nerve biopsy.  
a) Light microscope images of hematoxylin and eosin-stained sections of 
gastrocnemius muscle biopsy from subject F1 IV.4 demonstrating profound 
denervation atrophy of muscle. Scale bar, 10 μm. b) Toluidine blue–stained section of 
sural nerve shows mild loss of large, myelinated sensory axons. Scale bar, 10 μm. c) 
Electron microscopy of sural nerve confirms mild loss of large and small myelinated 
axons and unmyelinated axons. Scale bar, 10 μm. d) Arrow demonstrates a rare axon 
undergoing Wallerian-like axonal degeneration. Scale bar, 2 μm. 
Nerve conduction studies and Electromyogram 
In general, NCS showed normal conduction velocities (above 38 m/s at all recorded 
sites), but low compound motor and sensory action potential amplitudes in all affected 
individuals who underwent this evaluation. The wide range of variability seen in the 
disease severity was reflected in the NCS by the fact that the more affected patients 
also had the lower amplitudes. NCS were consistent with the phrenic nerve 
involvement in all patients except the youngest patient who showed the mildest limb 
weakness and sensory symptoms. Individual IV.5, whose clinical examination was 
normal, also had normal NCS and normal EMG. Needle EMGs showed muscle 
membrane instability and motor unit remodelling, which is consistent with an active 
and chronic denervation/reinnervation of peripheral muscles. 
Laryngoscopy 
a b 
c d 
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Five of the patients underwent laryngoscopy that showed bilateral laryngeal muscles 
paralysis with the left side being more affected in most cases. Generally, both 
abductor and adductor muscles were affected with a variable degree of severity. 
Laryngoscopy performed in the unaffected family member (IV.5) with raspy voice 
showed no vocal fold paralysis, but revealed inflammation of her vocal cords, which 
likely accounted for her raspy voice. 
Audiological examination  
Ear-Nose-Throat (ENT) examination was performed in two patients who were 
complaining decreased hearing acuity. Findings were consistent with grossly intact 
hearing to loudly spoken voice and Weber was midline. Rinne was inverted bilaterally 
suggesting conductive hearing loss. A superior retraction pocket with squamous 
debris was found in the left ear in one individual. A middle ear effusion with opaque 
TM was also noted on the left. Her audiogram showed bilateral reduced hearing in 
high frequencies compatible with a sensorineural hearing loss and a cholesteatoma on 
the left as confirmed by flattened tympanograms.  
Family F02  
Clinical findings 
Five individuals were seen in the Neurogenetics clinic at NIH. Three of them had a 
history of distal atrophy and weakness, hoarseness of voice and/or breathing 
difficulties with stridor on exertion. These symptoms were variable in term of 
severity. The clinical exam confirmed the motor symptoms, and showed reduced 
vibration and pin-prick senses and disturbance in the proprioception. These signs were 
more prominent in the distal limbs, and the legs appeared to be more affected than the 
arms. Scoliosis and high arches were noted in some patients. Two patients reported 
bone abnormalities including osteoarthritis and frequent fractures. They were put on 
calcium supplement because of poor bone density. Bladder urgency or incontinence 
was reported by four affected subjects. Eight complained of progressive hearing loss 
that was documented by an audiological examination.  
Three other unaffected members were examined in our neurogenetics clinic at NIH, 
and had normal neurological examination. 
Laboratory findings 
Nerve conduction studies/EMG 
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In this family, NCS showed normal conduction velocities at all recorded sites (>38 
m/s in general), but low compound motor and sensory action potentials amplitudes. 
As expected, the peroneal nerve was the most affected. When both phrenic nerves 
were evaluated, the left side nerve was almost always more affected than the right 
side. The involvement of the phrenic nerve was seen in all patients. Fluoroscopic and 
EMG studies of the diaphragm was performed in two patients, and revealed that the 
movement of one or both hemidiaphragms was impaired.  
Unaffected individuals who underwent this exam had normal electrophysiological 
examination. 
Laryngoscopy  
Laryngoscopy showed bilateral laryngeal muscle paresis with the left side more 
affected. The abductor muscle appeared to be paralyzed in most patients, but in some 
patients both the abductor and adductor were paralyzed, explaining the stridor and 
hoarseness of voice reported by patients. In most of the patients, laryngeal 
videoendoscopy noted no observable movements of the left vocal fold which 
remained stationary in an “off-centre” (paramedian) position. The right vocal fold had 
reduced, but present, opening (abductor) and closing (adductor) function. In addition, 
the airway was reduced up to 60 % in size. 
Audiogram  
The audiological exam showed bilateral hearing loss involving high frequencies in all 
affected individuals with a wild range of severity. Patients who complained of 
progressive hearing loss were not able to hear at 500Hz and 4000Hz bilaterally, when 
tested at both 25dB and 40dB. Acoustic emittance indicated normal middle ear 
mobility and pressure with normal acoustic reflexes bilaterally. Grossly, all examined 
patients with reduced hearing had good speech discrimination. 
Family F03 
This is a family in which three individuals, a mother and her son and daughter, 
presented with limb weakness and atrophy, breathing difficulties, and skeletal 
deformities. No affected individual was reported in earlier generations. However, the 
proband‟s father died when he was 35 year-old. The cause of death was reported to be 
tuberculosis.  
Clinical findings 
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The mother (III.7) and daughter (IV.4) first presented with shortness of breath and 
stridor at age 2 and 12, respectively, whereas the son (IV.3) had gait abnormality as 
first symptom at age 3. They all presented with muscle weakness and atrophy in 
extremities later (at age 7 for the mother and son, and age 12 for the daughter) with a 
variable severity, and hoarseness of voice. They had high arches and hammer toes. 
The mother and her son developed scoliosis. The mother underwent tracheostomy at 
age 3, and a laser ablation surgery on vocal folds was done on her son and daughter at 
age 13. The disease course has been slowly progressive. One patient (IV.3) reported a 
bilateral progressive decrease in his hearing, whereas his mother (III.7) was 
complaining of right ear hearing loss. None of the affected individuals reported 
urinary symptoms. 
Another family member (III.5) of 51 of age was seen recently in our Neurogenetics 
clinic, and his physical examination showed minor signs of peripheral neuropathy 
including high arches, twitching in calves muscles, and minimal reduction in his 
vibration sense and pin-prick in lower extremities. He was not actively dyspneic 
during the examination and did not report any breathing difficulties on exertion but 
was diagnosed with sleep apnoea for which he is being followed up.  
Laboratory findings 
Nerve conduction studies 
Motor and sensory nerves amplitude potentials were decreased with normal distal 
latencies and conduction velocities. Like the other families, the peroneal nerve was 
most affected, and phrenic nerve was involved. EMGs revealed significant muscle 
membrane instability in a distal predominant pattern. Myotonic discharges were 
present, particularly in the tibialis anterior muscle. Motor units action potentials were 
of prolonged duration and increased amplitudes, consistent with a neurogenic process. 
Nerve conduction studies of the individual III.5 were overall normal except for a drop 
in his sural nerve action potentials from 14 to 7 over 10 years.  
Laryngoscopy 
Laryngeal muscles weakness was seen in all the affected individuals who underwent 
this examination with various level of severity. Findings ranged from breathiness to 
limited inspiration abduction bilaterally with no adduction on the left, and restriction 
of the airway. Laryngoscopy was done on individual III.5 when he was 40 years old, 
and was within normal limits. 
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Audiogram 
Audiological examination of the mother showed normal hearing for speech, slight 
conductive hearing loss, hypomobile middle ear system on left consistent with healed 
tympanic membrane perforation. Individual IV.3 was complaining of bilateral hearing 
loss, and his audiological examination confirmed a bilateral reduction in high 
frequencies hearing which is consistent with a sensorineural hearing loss. 
Radiological evaluation 
Spine radiographs of individual IV.3 showed convex left thoracic scoliosis of about 
40 degrees between the thoracic vertebra T3 and T9. Chest X-ray of individual III.5 
was consistent with an elevation of the left hemi-diaphragm with sub-diaphragmatic 
air distended bowel. His inspiration and expiration films showed no movement of 
either diaphragm. The heart is displaced to the right from the elevated left hemi-
diaphragm. Although he was complaining of sleep apnoea and has hemi-
diaphragmatic paralysis, his phrenic NCS were normal, suggesting that this symptom 
that this symptom may be of different origin. Another patient, IV.4, had a slightly less 
right diaphragmatic excursion noted during inspiration and expiration. The mother, 
III.7, had normal chest X-ray. No evidence of bone deformation to suggest 
abnormality of development was seen in these patients nor did we see abnormal bone 
density. 
Family F4 
Clinical findings 
The clinical examination of this family showed weakness and atrophy in extremities, 
though milder than in the families described above. Two patients in the younger 
generation presented scoliosis and high arches. Sensory loss affecting vibration, 
touch, cold and pin-pick sensation were very mild. All patients had difficulties with 
breathing on exertion and this constituted the predominant symptom. The high 
variability in the disease severity between different family members seen in the other 
families was also observed in this family. Patients reported no bladder symptoms. One 
patient was complaining of unilateral hearing loss.  
Laboratory findings 
Nerve conduction studies and EMG 
NCS were limited to the peroneal and sural nerves. The peroneal motor conduction 
studies were significant for reduced amplitude on the right side and a prolonged distal 
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motor latency in the left side, with normal conduction velocities. On the right side, the 
minimal F latency was also prolonged. The sural sensory conduction studies were 
significant for the presence of borderline reduced amplitude for age on both sides, but 
peak latencies and sensory conduction velocities were within normal limits. This is 
consistent with a diffuse axonal peripheral neuropathy, although focal neuropathy is 
possible, especially given the findings on the left. However, there was no phrenic 
nerve involvement in any of the affected individuals.  
EMG studies performed in the tibialis anterior muscle only showed chronic partial 
denervation/reinnervation of distal muscles. 
Laryngoscopy  
Speech recording indicated the presence of stridor upon inhalation, and intermittent 
breathiness and intermittent raspiness during phonation. Flexible fiberoptic 
nasolaryngoscopy of affected individuals revealed bilateral vocal fold paralysis, 
especially with regard to abduction, which was more pronounced in the left side. The 
airway was reduced to 3-4 mm. Under examination via stroboscopic lighting, normal 
muscosal waves and vocal fold vibration were also noted. 
Audiogram  
Audiological examination of the patient who was complaining of hearing loss showed 
mild hearing loss in the right ear and features consistent with a tympanic perforation. 
Radiological evaluation 
Chest X-rays comparing inspiratory and expiratory films were done in one patient, 
and showed symmetric motion of the diaphragm, suggesting no diaphragm paralysis. 
However, a thoracic levoscoliosis was noted. In addition, an asymmetry of the upper 
ribs, particularly the second and third anterior ribs on the left, was also seen. 
In summary, all five families presented with clinical and laboratory findings 
consistent with an axonal neuropathy as well as other clinical features seen in CMT 
2C. However, none of the patients in family F3, F4 and F5 presented with urinary 
incontinence. In addition, families F4 and F5 did not present clinical or laboratory 
findings consistent with bilateral sensorineural hearing loss or diaphragm involvement 
as seen in the other families. The clinical, laryngological and electrophysiological 
findings of some family members are summarized in Tables 4, 5 and 6. 
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Table 4 Summary of the clinical features in CMT2C patients. 
                         Clinical examination findings  
 Age Sex Age of First symptom Arm weakness Leg weakness Sensory  Hearing  
Skeletal 
deformities 
Patient  (yr)  onset 
(yr) 
 
Proximal Distal Proximal Distal 
loss loss 
F1 III.2 
 
71 F 44 Foot weakness None Mild None Moderate Minimal Yes HT 
F1 IV2 
 
48 F 5 Foot weakness Mild Severe Mild Severe Mild  No HT,  PC 
F1 IV3 
 
46 F 5 Stridor Mild Moderate Mild Moderate Mild No HT, PC 
F1 IV4 
 
44 F 3 Foot weakness Severe Severe Severe Severe Moderate  Yes Scoliosis, PC  
F1 V1 
 
24 F 7 Foot weakness None Mild None Mild Mild  No HT, PC  
F1 V3 
 
20 F 5 Stridor None Mild None Mild Mild No HT, PC  
F1 V8 
 
18 M 2 Stridor None Mild None Mild Minimal No Slight HT 
F2 III11 
 
65 M 57 Hearing loss None Mild None Mild Minimal Yes HT, PC 
F2 III18 
 
61 M 34 Foot weakness Mild Moderate Mild Moderate Minimal Yes HT, PC 
F2 III22 
 
64 F 35 Foot weakness Mild Moderate Mild Severe Minimal Yes HT, PC 
F2 III23 
 
57 F 22 Foot weakness None Mild None Mild Minimal Yes HT, PC 
F2 III24 
 
49 F <2 Stridor Mild Moderate Mild Moderate Mild No HT, PC 
F2 IV2 
 
50 M 16 Hoarseness Mild Moderate Mild Moderate Mild Yes HT, PC 
F2 IV5 
 
53 M 28 Hoarseness None Mild None Mild Minimal Yes HT, PC 
F2 IV9 
 
31 F 5 Stridor None None None Mild None  No HT, PC 
F2 IV10 
 
29 M 5 Hoarseness None Mild None Mild Minimal Yes HT, PC 
F2 IV12 
 
29 F 2 Stridor Moderate Severe Moderate Severe Mild No Scoliosis, HT, PC 
F3 III7 
 
50 F 2 Stridor  Minimal  Moderate  Minimal  Severe  Mild  No  Scoliosis, HT, PC 
F3 IV3 
 
24 M 3 Foot weakness None  Mild  None Moderate  Minimal  Yes  Scoliosis, HT, PC 
F3 IV4 22 F 12 Stridor  None  Minimal None  Minimal  Minimal  No  HT, PC 
        HT: hammer toes, PC: pes cavus 
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Table 5 Summary of laryngological examination findings in CMT2C patients. 
Patients Age 
(y) 
Dyspnea Aspiration Dysphonia Vocal fold 
adduction 
Vocal fold 
abduction 
Comments 
Left Right Left Right 
F1 III2 71 - + - 1 1 1 1 Raspy voice 
F1 IV2 48    0 1 0 1  
F1 IV3 46 + + + 0 1 0 1 High-pitched voice 
F1 IV4 44 + + + 0 0 0 0 Tracheostomy at age 18, permanent ventilation 
F1 V8 19 + - + 0 0 0 1 Husky voice, arytenoidectomy at age 2 
F2 III11 65    1 2 1 2  
F2 III18 61    >1 >1 1 1  
F2 III22 64 + + + >1 >1 <1 1 High-pitched reduced volume voice 
F2 III23 57 + + + 0 1 0 1 Stridor  
F2 III24 49 + + + 0 1 0 1 High-pitched voice with tremor, faint stridor 
F2 IV2 50    1 2 1 2  
F2 IV5 53    0 1 0 1  
F2 IV9 31    0 1 0 1  
F2 IV10 29    1 2 0 1  
F2 IV12 29 +  + 0 0 0 0  
F3 III7 50 + - + 0 0 0 0 Tracheostomy at age 3, arytenoid tie-back age 14  
F3 IV3 24 + - + 0 0 0 0 Laser ablation surgery at age 13 
F3 IV4 22 + - + 1 1 1 1 Laser ablation surgery at age 13 
Vocal fold movement: 2 = normal, 1 = impaired mobility, 0= immobile; +: present, -: absent 
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Table 6 Summary of nerve conduction studies findings in CMT2C patients 
 
Patients  Median Ulnar Peroneal Sural Phrenic 
SNAP 
Amp (uV) 
(N≥15) 
APB CMAP 
Amp (mV) 
(N≥4.5) 
SNAP 
Amp (uV) 
(N≥15) 
ADM CMAP 
Amp (mv) 
(N≥4.5) 
EDB CMAP 
Amp (mV) 
(N≥2.5) 
SNAP 
Amp (uV) 
(N≥6) 
Right 
Amp (mV) 
(N> 0.6) 
F1 III2 13 4.9 18 7.0 2.1 ND 0.5 
F1 IV3 5 0.4 3 0.1 Absent 9 Absent 
F1 IV8 20 12.4 ND ND 4.1 13 0.6 
F2 III22 11 8.5 ND ND 0.2 4 Absent 
F2 III23 10 5.1 17 ND 1.3 6 Absent  
F2 III24 ND ND ND 0.9 1.2 (TA) ND Absent  
F2 IV2 ND ND ND ND ND ND Absent  
F3 III7 3 4.5 2 1.5 0.3 Absent  Absent  
F3 IV3 7 2.2 ND ND ND 7 ND 
F3 IV4 ND 7.1 ND ND ND ND ND 
             Amp: amplitude; SNAP: sensory nerve action potential; CMAP: compound motor action potential; APB: abductor pollicis brevis;  
             ADM: abductor digiti minimi; EDB: extensor digitorum brevis; uV=microvolts, mV=millivolts, ND: not done, TA: tibialis anterior; N= normal 
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3.1.2 Case presentations: 
Patient IV.4, Family F1 (Figure 10): Proband of family F1, this 43-year old 
wheelchair bound woman was the most severely affected in her family. Her past 
medical records showed that pregnancy, labour, delivery, and her early developmental 
milestone histories were normal including the fact that she walked at 11 months. At 
the age of 6, however, she first began having problems running, keeping up with the 
other children, going upstairs and performing other motor tasks involving mainly the 
lower extremities. Since onset, she has experienced progressive weakness involving 
all four extremities, lower extremities slightly greater than the upper extremities, and 
distal limb slightly greater than proximal. At that time she had no numbness or 
tingling, and no bowel or bladder problems. She was losing weight, fatiguing easily, 
and progressively developed scoliosis. At age 13, she was hospitalized for acute 
pneumonitis, and went into respiratory distress for which she underwent surgery for 
tracheal and bronchial aspiration. However, her chest x-ray was completely normal. 
The same year she was hospitalized in a neurology department where her examination 
revealed marked and diffuse muscle wasting, weakness more pronounced distally and 
mild sensory loss. Her voice was hypophonic and high-pitched with slight inspiratory 
stridor. She was also noted to have some fasciculations of her tongue. Tendon reflexes 
were absent throughout. Her NCS showed low sensory and especially motor nerve 
responses, but normal conduction velocities, suggestive of an axonal type of 
peripheral neuropathy. Electromyography revealed widespread chronic neurogenic 
atrophy. Her muscle biopsy showed severe denervation, atrophy and near end stage 
muscle. Both type I and type II fibres were involved. Peripheral nerve sections 
showed slight decrease of myelinated fibres with apparently well preserved axons but 
occasional axonal swelling. Laryngoscopy revealed a left vocal fold paralysis. These 
findings led her physician to the diagnosis of Charcot-Marie-Tooth type 2 disease.  
She was hospitalized for another episode of acute pneumonitis at age 15, and her 
chest X-ray showed left lower lobe pneumonia. 
At age 16 she was seen by an orthopedic surgeon for her progressive scoliosis. A left 
low thoracic curve measured forty degrees, which was worse compared to what had 
been seen three years earlier when it was seventeen and later twenty-two degrees.  
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On examination, she was slightly cachectic and appeared to have marked weakness of 
both distal and proximal musculature including trunk and hip musculature. She had 
slight cavus and varus deformities of her feet. Her speech was noticed to be quite 
abnormal. Her walking was unsteady, and a cane had been advised. 
At age 18, her general examination showed her to be very slender with minimal 
subcutaneous tissue. She had a mid-thoracic and lumbar spine scoliosis with lumbar 
lordosis. Her neurological examination showed a hoarse voice and intermittent stridor 
while talking. There was obvious atrophy of the margins of her tongue and quite 
prominent fasciculations. She had bilateral foot drop, and she could not dorsiflex her 
feet against gravity, and a bilateral pes cavus foot deformity was noted. A progression 
of the scoliosis was noted from forty degrees two years earlier to forty three degrees. 
Her vocal fold paralysis became bilateral. Because of her progressive laryngeal 
disease and repetitive pulmonary infections, a tracheostomy was recommended and 
was performed a few months later. She was put on ventilator as needed, but relied on 
it more and more over time. In 2000, she was hospitalized for 6-8 weeks, and was 
given a jejunal tube after swallowing test showed severe dysphagia. Since then, she 
noticed a dramatic loss of weight and became very weak. In the last two years, since 
her father‟s death, she has had to be in bed more, which she believed made her weaker 
because he was her care-giver.  
During her recent evaluation she complained of having to stay longer than usual on 
ventilation. She could get off the ventilator just for a couple of hours during the day, 
and had to stay on it all night. She noticed urinary incontinence and diarrhoea. Her 
voice was barely audible, therefore she uses an amplifier. Her neurological 
examination showed a very weak patient with no movement in the limbs. Pin-prick, 
temperature, light touch and vibration, although difficult to assess because of the 
patient‟s condition, seemed to be reduced in the distal part of the limbs. Tendon 
reflexes were absent throughout. She wore a chest brace without which we see a 
marked scoliosis. 
She had slight weakness of facial muscles, and some fasciculations in her tongue and 
mentalis. Her cognition was intact. Her neck muscles were strong enough to allow her 
to use her computer with her head. 
Late in 2006, she was seen by an ENT for decreasing hearing, aural fullness, and 
occasional tinnitus since irrigations for cerumen disimpaction on the left ear. An 
audiogram was performed and showed significant bilateral conductive hearing loss 
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and flattened tympanograms on the left. A conductive hearing loss was noticed on 
sensorineural testing.  
Placement of bilateral myringotomy tubes was performed after which she noticed an 
improvement in her hearing. No NCS were done because she was seen at home. 
Patient III.2, Family F1 (Figure 10): A 73-year old woman, mother of the proband, 
was found to have areflexia, but normal strength and sensory tests at age 44 when she 
was being evaluated because of her family‟s disease. Prior to that time she had no 
complaints. Her EMG was abnormal. The NCS were normal, but the needle 
examination showed diffuse neurogenic abnormalities. A moderate decrease in distal 
vibratory sense in addition to a raspy voice was additionally noticed at the age of 53 
during another physical exam. Over the past few years, she developed hoarseness of 
voice, difficulty of breathing on exertion, and pain in the distal legs after a long day of 
activity. She noticed weakness in extremities and increasing number of falls. Her 
recent neurological examination showed mild weakness and wasting in distal muscles. 
Tendon reflexes were absent at the ankles and reduced elsewhere. There was no 
skeletal deformity, and the facial muscles were intact. Her NCS showed axonal type 
abnormalities (normal nerve conduction velocity and low CMAP and SNAP) more 
prominent in lower limbs with mild prolonged distal latency in the right phrenic 
nerve. She had poor heel and toe walking, and Romberg sign was positive. EMG 
showed active denervation in the tibialis anterior muscle and the first dorsal 
interosseus muscle in addition to chronic denervation changes in the proximal arm 
and legs muscles. Her laryngological examination showed vocal fold paresis more 
prominent on the left than on the right side.  
Patient IV.3, Family F1 (Figure 10): A 46-year old woman who had shortness of 
breath and stridor in her childhood. At 18 years old, she had NCS and EMG that 
showed normal conduction velocities and low to borderline amplitude in motor 
responses, and very prominent chronic neurogenic motor unit discharges. The lower 
limbs were more affected. The sensory responses were within normal limits, including 
the sural and forearm median nerves. At age 22, while pregnant with her second child, 
she had a check-up that showed she had bilateral vocal fold paresis with the left side 
completely paralyzed. A tracheotomy was suggested for the delivery because she has 
been very short of breath and had to be given oxygen during her first delivery. 
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In 2006, at age 46, her neurological examination showed weakness in all limbs, worse 
distally, and wasting in forearms, hands and feet. She had slightly high arches and 
hammer toes. Her shortness of breath was noticeable and worse on exertion. Her NCS 
showed evidence of diffuse sensorimotor polyneuropathy due to axonal loss with 
phrenic nerve involvement. Laryngoscopy showed bilateral vocal fold paralysis. 
Patient V.8, Family F1 (Figure 10): A 19-year old young man whose birth and 
neonatal histories were normal. He was admitted in the hospital at 20 months of age 
when his parents became aware of stridor and difficulty of breathing present with 
excitement and vigorous activity. These symptoms became prominent over ten 
months. A laryngoscopy showed that the vocal folds were in a keyhole type position 
with the anterior tips of the vocal fold processes touching each other, leaving space 
anteriorly as well as posteriorly. The general examination was normal and the child 
was let go home. Two months later, he was brought back to the hospital because the 
stridor was becoming permanent with several gasping episodes. The respiratory rate 
was 55/s and the stridor was audible, worse with excitement. He weighed 10.7 kg. 
Neurological examination did not reveal any weakness or atrophy. His EMG 
reportedly showed a spinal muscular atrophy process. Another laryngoscopy was 
performed and it revealed a bilateral vocal folds paralysis in a paramedian position 
with an approximately 2 mm glottic opening. Following this procedure a tracheotomy 
tube was placed. At age 2 he had an arytenoidectomy and 2 months later the 
tracheotomy tube was removed. Since then he has not been complaining of any major 
symptoms, but X-ray done later showed a mild scoliosis. 
In 2006, at 19 years old, his neurological examination showed only mild weakness in 
foot dorsiflexion bilaterally, high arches and slight hammer toes, and some wasting of 
hand intrinsics and the EDB (extensor digitorum brevis). Sensory signs were minor, 
with only slight decrease in proprioception and vibration in toes. Tendon reflexes 
were absent throughout. He had poor heel walking, but normal toe and tandem walk. 
His NCS was borderline normal, but the EMG showed muscle denervation and 
reinnervation that the examiner interpreted to be due to an early stage polyneuropathy. 
The laryngoscopy showed bilateral vocal fold paralysis affecting the left side more 
than the right. 
Patient V.1, Family F1 (Figure 10): This is a 24-year old woman who complained of 
hoarseness of voice and weakness in the extremities. These symptoms started at 7 
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year old and have evolved progressively over time. She becomes short of breath and 
has loud breathing in inspiration on exertion. She has difficulties with running and 
taking stairs. Her physical examination showed slight to moderate weakness in 
extremities and neck flexors. Atrophy in the thenar and hypothenar eminences were 
noticed in addition to high arches. Sensory loss to cold, vibration and pin-prick was 
noticed in the extremities up to the level of the wrists and knees. Reflexes were absent 
throughout. She was unable to walk on the heels or the toes, and a slight sway was 
seen at Romberg. Because she was seen at home, no electrophysiological or 
laryngological studies were done. 
Patient III.23, Family F2 (Figure 11): A 64-year old woman who was first seen in the 
neurogenetics clinic at NIH in 2000 for weakness and atrophy in extremities and 
speech difficulties. Her symptoms began around age 38 with weakness and wasting of 
the muscles in her hands and distal lower extremities. She has noticed shortness of 
breath with exertion over the past five years. She has difficulties climbing stairs. She 
was noticed to have osteoporosis and scoliosis at age 20, and has been on calcium 
supplementation since. She has had two fractures in her left leg. Her neurological 
examination showed good facial strength, moderate muscle weakness and atrophy 
more marked in extremities, and reduced vibration sensation in toes. Tendon reflexes 
were absent throughout. Her nerve conduction studies showed low amplitude but 
normal motor nerve conduction velocity in the ulnar and peroneal nerves. The radial 
sensory nerve conductions had borderline conduction velocity, but low amplitude. 
The sural sensory nerve action potential was absent. The right phrenic nerve 
conduction was also absent. Her audiological examination was consistent with 
bilateral sensorineural hearing loss. Her ENT examination showed a high pitched 
voice with reduced volume. Laryngoscopy showed a reduced abduction of both vocal 
folds (the left side greater than right). The adductor function of her vocal folds was 
also affected to a lesser degree. 
Patient III.22, Family F2 (Figure 11): A 49-year old woman who was first seen in the 
neurogenetics clinic at NIH in 2000 reported to having difficulty breathing while 
nursing, and history of stridor as a child. As a child her running was slow, and she 
would quickly become short of breath. She presented with weakness in legs that 
became progressively bothersome over years, and later developed weakness in the 
hands. Her voice has also become weaker over time. She also has a history of 
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osteoarthritis, and is on calcium supplementation. Her neurological examination 
showed high arches, and hammer toes. She was noted to have weakness and atrophy 
of the limbs, with the distal parts being more affected. She had decreased vibratory 
and pin-prick sensation at toes. Her nerve conduction studies and laryngological 
examination were quite similar to her aunt‟s (F2 III.22). 
She has a 29-year old daughter (Patient IV.12, Figure 11) who is severely affected. 
She is very weak and needs to use a negative pressure ventilator at night because of 
her laryngeal paralysis. She had severe scoliosis at age 3, and underwent spine 
surgery because of that. 
Patient III.7, Family F3 (Figure 12): This is a 50-year old woman who developed 
stridor and falls at age 2. She underwent a tracheostomy at age 3, which remained in 
place until age 14 when she had a right vocal fold tie back surgery. She was left with 
a breathy voice, but denies significant change in her voice since then. She has had 
distal limb weakness since the age of 7. Over the years there has been slow 
progression. She has worn ankle-foot orthoses (AFOs) braces for 13 years, but admits 
to ongoing tripping and falling once a week. Although she has hand weakness, she 
can button, open jars and turn keys, unless her hands are cold at which point she feels 
her hands become completely paralyzed. She develops intermittent paraesthesias and 
numbness in the right second and third fingers. Otherwise, she denies sensory 
symptoms. She has a mild scoliosis. She has mild right-sided hearing loss. 
Her neurological examination showed facial weakness. She had mild upper thoracic 
curvature. There was an atrophy and weakness in forearms and legs, but worse in the 
lower limbs. She was unable to walk on her heels or her toes and the Romberg sign 
was present. Cold sensation was absent below the knees and 5 % reduced in the 
hands. Vibration was moderately and slightly reduced at the toes and hands, 
respectively. Pin-prick was reduced to midshin and slightly in hands. Tendon reflexes 
were absent throughout.  
Patient III.3, Family F4 (Figure 13) (proband): A 35-year old woman who was first 
seen in the neurogenetics clinic at NIH in 1998. Shortly after delivery, she was 
noticed to have a breathing problem for which she stayed in Intensive Care Unit for a 
few days. She has noticed that for all her life she has suffered from loud breathing 
sounds as well as from raspier voice than her peers. She did not notice limb weakness, 
although she does complain of difficulty with inclines and climbing stairs, but 
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primarily due to her breathing problem. She complains of twitching in her muscles, 
mainly in legs, arms, and face. She gives a history of having scoliosis and having to 
wear foot orthotics due to high arches. Her physical exam was consistent with a mild 
degree of thoracic levoscoliosis. Examination of extremities revealed thin feet with 
borderline elevated foot arch. The neurological examination showed mild weakness in 
the neck flexors, but no facial weakness was observed. There was only mild degree of 
weakness in the very distal foot muscles with toe extension and flexion. She had 
mildly decreased vibratory sensation in the toes. The rest of the sensory examination 
was normal. Deep tendon reflexes were absent. Her nerve conduction studies showed 
significantly reduced amplitudes in the peroneal motor nerve conductions, but normal 
conduction velocities. The sural sensory conduction studies were borderline-reduced 
amplitude for age. The phrenic nerve was not shown to be affected. Her 
laryngological examination showed bilateral vocal fold motion impairment, especially 
with regard to abductory motion in both sides (the left side appearing to be more 
affected). Her chest X-ray showed normal symmetric diaphragm motion. 
Her 60-year old father (Patient II.2, Figure 13) has a history of shortness of breath 
since childhood, but never sought a medical evaluation until his daughter developed 
more severe symptoms. His neurological examination revealed very mild weakness in 
the very distal parts of hand and feet, and discrete pin-prick, temperature and 
vibration sensation loss in the distal parts of lower limbs. Reflexes were diminished or 
absent throughout. His laryngological examination showed a left vocal fold paralysis. 
His chest X-ray showed no asymmetry in the diaphragm motion. Audiological 
examination was normal. 
Patient IV.1, Family F4 (Figure 13): A 5-year old girl who presented breathing 
difficulties and stridor at birth. Subsequently, she was intubated and at one month of 
age she had a tracheostomy tube inserted. She later developed scoliosis, for which she 
wears a brace. The neurological examination showed generalized hypotonia, reduced 
to absent sensory loss, and absent reflexes throughout. Her laryngoscopy showed 
bilateral vocal fold paralysis. 
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3.2 Genetic analysis: 
3.2.1 Linkage analysis/Fine mapping 
As stated above, the gene for CMT2C was previously mapped to chromosome 12q24. 
To confirm that the families we report here also map to this locus, we performed a 
genetic analysis using 12 polymorphic markers covering the previously described 
region between polymorphic markers D12S84 and D12S1023. We performed a 
parametric and nonparametric analysis of the genotyped data, and found linkage to 
this region in three of the four families.  
Family F1: The region of linkage was located at 12q24.11 with a genetic distance of 
118-119 cM (Marshfield). The LOD score without the three unaffected who had the 
disease haplotype was 3.6, which shows a significant linkage. The haplotype 
reconstruction matched the disease status except in three supposedly unaffected 
individuals who carry the disease haplotype (Figure 17). The haplotype of one of 
them was inferred since that individual was not genotyped. The region of linkage in 
this family spanned from markers D12S84 to D12S1343 with a recombination 
occurring in the telomeric region between markers D12S1343 and D12S1023. This 
recombination took place in the second genotyped generation, between the affected 
founder and one of her affected daughters. No further recombination occurred in the 
subsequent generation. This region spans 2.8 Mb, and has 46 labelled genes according 
to NCBI.  
Genotyping for one individual did not work; therefore he is not represented on the 
haplotype in Figure 17. 
Family F2: This is a branch of a family analyzed in a previous study (Klein, 
Cunningham et al. 2003). The region of linkage in this family was located at 
12q24.11-12q24.21 with a genetic position of 118-123 cM. The LOD score for this 
family was close to 7. The haplotype reconstruction matched the disease status except 
for two supposedly unaffected family members who had the disease-bearing allele. 
They were not considered affected because of inconclusive findings in their 
neurological examination in addition to a lack of neuro-electrophysiological and 
laryngological studies to confirm those minor findings. A review of their medical 
records showed that they had reduced to absent reflexes and questionable weakness in 
the extremities, suggesting that they may be affected.  
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The haplotype analysis showed that two recombinations had occurred in this family. 
The first one took place in the downstream region in the second generation of one 
branch of the family, between markers D12S1341 and D12S1023. This recombination 
was also seen in the third generation of another branch. The second recombination 
took place in the upstream region in the second generation of another branch of the 
family, between markers D12S84 and D12S105. This recombination appeared also in 
the fourth generation of another branch. By taking the recombinations into account in 
this family the region of linkage spanned from markers D12S105 to D12S1341 
(Figure 18). There were 86 annotated genes in this region which is 5.5 Mb large 
(NCBI). A review of the analysis reported in this family showed that region has been 
slightly narrowed; this may be due to the rearrangement of the markers we noticed in 
this region since the first report (Klein, Cunningham et al. 2003). 
Family F4: the region of linkage was located at 12q24.11-12q24.13 with a genetic 
position at 118-120 cM (Marshfield). The LOD score was estimated to about 1, which 
was the maximum one could get because of the small number of analyzed samples. 
The haplotype reconstruction matched the disease status with the disease-linked 
haplotype seen in the affected members only. A recombination occurred in the 
telomeric region of the chromosome in the second genotyped generation between 
markers D12S811 and D12S1023. This region spanned from markers D12S84 to 
D12S811 (Figure 19). This region is about 5 Mb, and has 84 labelled genes (NCBI). 
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Figure 17 Haplotype reconstruction for family F1.  
Note that all the patients have the disease allele (light blue). Three unaffected have also the disease allele (illustrating incomplete penetrance in 
individual III.2 and her mother (see Figure 10) or new mutation from individual 32 to 489). 
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Figure 18 Haplotype reconstruction for family F2. 
The disease allele (pale pink) segregates according to the disease status. Three individuals carrying this allele (6327, 6335, and 6336) were found 
later to be clinically affected. 
 113 
 
 
Figure 19 Haplotype reconstruction for family F4.  
Note that all the affected have the disease allele (pale purple). 
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The additive LOD score from the analysis of all three families was about 11 (Figure 
20), giving us strong evidence that this locus is likely to contain the disease-causing 
gene for CMT2C.                                   
                                
Figure 20 LOD score curve for family F1 and F2.  
The plateau blue curve represents family F1 and the plateau pink curve represents 
family F2. The yellow curve represents the combined LOD score for these two 
families. Note that family F4 that has a LOD score of about 1 is not represented here. 
X axis: the region covered by markers D12S84 and D12S1023, Y axis: LOD score. 
 
When data from all three families were combined, the haplotype reconstruction 
narrowed down the region of interest to about 2.6 Mb, between markers D12S105 and 
D12S1343 (Figure 21). Family F2 defines the upper border and F1 defines the lower 
border. This region contains 40 annotated genes of which 38 are protein-coding 
(NCBI Mapviewer), and 35 are, in various levels, expressed in the nervous system. 
Twenty eight of these expressed genes have a known function, and four of them are 
involved in diseases, but none of them is of interest for the nervous system. The 
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ataxin 2 gene (ATXN2) was excluded by this analysis as did previous studies through 
fine mapping as well as sequencing. 
 
 
 
 
 
  D12S84           7                         6                      4 
  D12S105         1                         2                      2 
  D12S1583       5                         7                      6 
  D12S1339       4                         2                      2 
  D12S1343       3                         2                      3 
  D12S1344       6                         1                      4 
  D12S1616       1                         3                      3 
  D12S145         2                         2                      2 
  D12S811         6                         9 
  D12S1341       6                         1 
  D12S354         1                         4 
  D12S1023       2                         2 
  
Figure 21 Summary of linked regions in family F1, F2, and F4.  
Only the disease allele is represented here. Note that family F2 defines the upper 
border (marker D12S105) and family F1 defines the lower border (marker 
D12S1343). Family F4, apart from being linked, did not narrow the previous region of 
linkage. The green square represents the region from the first linkage study (Klein, 
Cunningham et al. 2003), the blue represents the region from the second linkage study 
in different families (McEntagart, Reid et al. 2005), and red represents our results. 
 
3.2.2 SNP arrays analysis 
SNP arrays analysis was performed to look for possible duplications or deletions in 
the two families (F1 and F2) where linkage with microsatellite markers was used. 
This analysis was focused on the region of interest found with the linkage analysis, 
and no copy number variation was seen. 
Whole genome scan using SNP array in family F5 excluded the 12q24.11 locus 
(Figure 22).  In fact the affected mother passed on different alleles to her affected sons 
for the same markers (SNP). This is not consistent with disease status in this family 
   F2 IV12 F1 V3  F4 IV1  
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because the affected sons should inherit the same allele from their mother.    
             
Figure 22 Part of the haplotype reconstruction in family F5.  
The haplotype reconstruction is showing that the TRPV4 locus was excluded in 
family F5. Note that the arrow is showing one of the SNPs for which the affected 
mother gave a different allele to her affected sons at the same marker position.  
3.2.3 Selection of candidate genes 
The candidate genes selection approach within the mapped region defined earlier 
allowed us to choose a first set of candidate genes to be sequenced.  
CUTL2 
The first gene that was considered as primary candidate was the cut-like homeobox 2 
gene (CUTL2 or CUX2). It has three conserved domains: homeodomains that are 
DNA binding domains involved in the transcriptional regulation of key eukaryotic 
developmental processes (transcription repressor activity), an Smc domain that 
functions as chromosome segregation ATPases that play a role in cell division and 
chromosome partitioning, and CUT domains that are DNA-binding motifs which can 
bind independently or in cooperation with the homeodomain, often found downstream 
of the CUT domain (Gene Ontology Annotation [GOA] Database, EMBL-EBI). 
CUX2 spans a 316528 bp long genomic region, is transcribed into a 6841 bp long 
mRNA, and has 22 exons that code for 1486 amino acids (NCBI, Entrez Nucleotide 
database).  
Arguments for CUX2 being a candidate gene: 
- Expression: Cux-2 in mouse is expressed exclusively in the central and peripheral 
nervous system and may encode a transcription factor that is involved in neural 
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specification in mammals (Quaggin, Heuvel et al. 1996; Gingras, Cases et al. 2005). 
Another study has found that CUX-2 functions at multiple levels during the spinal 
cord neurogenesis.  
- Interaction and homology: CUX2 has a common cellular localization with the ataxin 
1 (ATXN1) gene (NCBI, Aceview), and some homology with dynactin 1 (DCTN1) 
and the neurofilament light polypeptide (NEFL) genes (UCSC Human Gene Sorter) 
which are known to cause spinocerebellar ataxia, distal hereditary motor neuropathy 
with vocal fold paralysis and both axonal and demyelinating hereditary motor and 
sensory neuropathies, respectively. 
The possibility of CUX-2 for being a candidate gene for susceptibility to bipolar 
disorder was also suggested (Jacobsen, Elvidge et al. 2001).  
TCTN1 
The tectonic 1 gene encodes a member of the tectonic family of secreted and 
transmembrane proteins. This gene has one conserved domain (DUF1619 
superfamily) of unknown function. TCTN1 has three transcript variants that code for 
different length of proteins. The total genomic DNA is 35056 bp, and the longest 
isoform codes for 592 amino acids. The orthologous gene in mouse is required for 
formation of most ventral cell types.  
Arguments for TCTN1 being a candidate gene: 
- TCTN1 is expressed in both the central and peripheral nervous systems, though this 
expression is not the highest when compared to other organs. 
- Studies in Tectonic mutant mice showed that Tectonic is required for formation of 
the Sim1-expressing V3 interneurons, and Tectonic mutants also display a variable 
reduction in the number of Islet1/2-positive motor neurons (Reiter and Skarnes 2006). 
VPS29 
The vacuolar protein sorting 29 homolog (S. cerevisiae) gene belongs to a group of 
vacuolar protein sorting (VPS) genes that, when functionally impaired, disrupt the 
efficient delivery of vacuolar hydrolases. The protein encoded by this gene is a 
component of a large multimeric complex, termed the retromer complex, which is 
involved in retrograde transport of proteins from endosomes to the trans-Golgi 
network. This VPS protein may be involved in the formation of the inner shell of the 
retromer coat for retrograde vesicles leaving the prevacuolar compartment. Other 
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functions of this gene include metal ion binding, phosphoserine phosphatase activity 
and zinc ion binding (NCBI, Entrez Gene). 
Arguments for VPS29 being a candidate gene: 
- Expression: this gene is expressed in brain, nerve and spinal cord, though the 
expression is not higher than in other organs including parathyroid, bladder and bone 
marrow (NCBI, Unigene). But no expression data is available in the GNF SymAtlas 
v1.2.4 for this gene. 
- Although no animal model is available to date to show the implication of this gene 
in the nervous system phenotype, it seems to be sharing the same function as another 
gene (DCTN1) involved in hereditary peripheral neuropathy with vocal fold paralysis; 
which is, as stated above, the retrograde transport of proteins from endosomes to the 
trans-Golgi network. 
GIT2 
The G protein-coupled receptor kinase interacting ADP-ribosylation factor (ARF) 
GTPase-activating protein (GAP) 2 (ArfGAP 2) encodes a member of the GIT protein 
family, which interact with G protein-coupled receptor kinases and possess ARF GAP 
activity. GIT proteins traffic between cytoplasmic complexes, focal adhesions, and 
the cell periphery, and interact with Pak interacting exchange factor beta (PIX) to 
form large oligomeric complexes that transiently recruit other proteins. GIT proteins 
regulate cytoskeletal dynamics and participate in receptor internalization and 
membrane trafficking. This gene has been shown to repress lamellipodial extension 
and focal adhesion turnover, and is thought to regulate cell motility. 
Arguments for GIT2 being a candidate gene: 
- Expression: GIT2 in expressed in the nervous system; however this expression does 
not exceed the median seen in other organs (NCBI Unigene, GNF SymAtlas v1.2.4). 
- Studies have suggested pathogenic roles for GIT proteins in Huntington's disease, a 
disease due to a damage of nerve cells of basal ganglia and cerebral cortex (Hoefen 
and Berk 2006). 
ACACB 
Acetyl-CoA carboxylase (ACC) is a complex multifunctional enzyme system. ACC is 
a biotin-containing enzyme which catalyzes the carboxylation of acetyl-CoA to 
malonyl-CoA, the rate-limiting step in fatty acid synthesis. ACC-beta is thought to 
control fatty acid oxidation by means of the ability of malonyl-CoA to inhibit 
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carnitine-palmitoyl-CoA transferase I, the rate-limiting step in fatty acid uptake and 
oxidation by mitochondria. ACC-beta may be involved in the regulation of fatty acid 
oxidation, rather than fatty acid biosynthesis. ACACB also functions as ATP binding. 
Arguments for ACACB being a candidate gene: 
- Expression: ACACB is expressed in the central and peripheral nervous system 
although not at higher level than the other organs. 
- ACACB is expressed in hypothalamus neurons, but mutant Acetyl-CoA 
Carboxylase 2 mice did not show obvious neurological abnormalities other than those 
seen in hypothalamus damage (feeding control) (Loftus, Jaworsky et al. 2000; Abu-
Elheiga, Matzuk et al. 2001). However this does not rule out a presence of 
neurological signs in these mice because more often investigators are focused on the 
organs and symptoms of their particular interest. 
ANKRD13A 
The ankyrin repeat domain 13A gene contains a conserved domain that is made up of 
ankyrin repeats which mediate protein-protein interactions in very diverse families of 
proteins. This gene is made of 15 exons, is transcribed into an mRNA that is 3910 bp 
long which is translated into a protein that consists of 590 amino acids. 
Arguments for ANKRD13A: 
- Expression: this gene is expressed both in the central and the peripheral nervous 
system, though not at higher level than the other organs (NCBI Unigene, GNF 
SymAtlas v1.2.4). 
- Studies of animal models have shown that ankyrins are expressed in the peripheral 
nervous system, especially in axons, and along with other proteins participate in the 
axonal and dendritic morphogenesis (Yamamoto, Ueda et al. 2006). Ankyrins also 
interact with other genes involved in diseases affecting the nervous system in animal 
models (Zhou, Opperman et al. 2008).  
FLJ40142 
The genomic region of the FLJ40142 gene is 26518 bp long leading to a 1946 bp long 
mRNA. This gene codes for 135 amino acids long protein but has no known function 
(Entrez Gene, NCBI). 
Arguments for FLJ140142: 
- Expression: this gene has its highest expression in the nervous system (Unigene: 
NCBI, GNF SymAtlas v1.2.4). 
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Other genes of interest including ARPC3, ANAPC7, UBE3B, ATP2A2 and KCTD10 
were considered after the first set. 
3.2.4 Mutation detection by Sanger sequencing 
The coding regions of selected candidate genes, including the likeliest candidates, 
were sequenced, and no significant sequence variants have been seen. We then 
proceeded with sequencing the coding region of all the remaining genes within the 
region of interest. Forward and reverse primers were designed for the remaining 
exons, and set in 96-well plates for a faster PCR processing.  
We found two heterozygous sequence variants in the exon number 5 of the TRPV4 
gene. The first change is a cytosine to tyrosine transition, and was seen in family F1 at 
coding position 805 (c.805C>T) (Figure 23a). This change leads to the amino acid 
substitution arginine to cysteine at position 269 (R269C). Next, we sequenced the rest 
of the family members, and found that all the affected individuals carried the 
sequence variant, and none of the unaffected individuals, except the two who carry 
the disease-haplotype, had it. The second change, seen in family F2, is a guanine to 
adenine transition at coding position 806 (c.806G>A) (Figure 23b). This sequence 
variation gives the amino acid substitution arginine to histidine at position 269 
(R269H). Here also we screened all available family members for this mutation, and 
found that all the affected had the sequence change and none of the unaffected 
individuals showed it. Family F4 did not show any significant sequence change in the 
TRPV4 gene nor in any of the other genes within the linked region; pointing toward a 
genetic heterogeneity which is a characteristic feature of Charcot-Marie-Tooth 
diseases.  
After these findings we have screened families F3 and F5 for the TRPV4 gene, and 
found no significant sequence variants. We subsequently screened 132 patients for 
this gene, and two heterozygote sequence variants have been found in two patients. 
The first one lies at the end of exon number 4 at coding position 694, and is a cyteine 
to tyrosine transition (c.694C>T) (Figure 23c), leading to the amino acid substitution 
arginine to cysteine at position 232 (R232C). Additional exploration of the family 
history showed that the patient had an affected father. The second change, located in 
the C-terminal region of the gene, was found in the exon number 16 at coding position 
2560, and is an Adenine to Guanine transition (c.2560G>A) (Figure 23d).  
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This missense nucleotide variant gives the amino acid change aspartic acid to 
asparagine at position 854 (D854N). 
The R269 residue lies at the tip of the 3
rd
 ankyrin repeat domain (ANK) of the chicken 
TRPV4 ankyrin repeats domain structure. The R269 residue is conserved in a wide 
range of species from human to fish. Moreover, the R269 residue constitutes the first 
arginine of one of the four TRPV4 endoplasmic reticulum (ER) retention motifs 
(RGR).  
The R232 residue is located in the second ankyrin repeat domain. This residue is also 
highly conserved in different species from human to fish, and is in a predicted exon 
splicing enhancer (ESE) SR protein binding site (SF2/ASF (IgM-BRCA1)), and the 
R232C change destroys this site with a score above the threshold. 
                              
                                     
Figure 23 Chromatographs representing the mutations found by Sanger sequencing.  
Asterisks are showing: a) heterozygous sequence variant c.805C>T in family F1, b) 
heterozygous sequence variant c.806G>A in family F2, c) heterozygous sequence 
variant c.694C>T from the CMT2 cohort study, d) heterozygous sequence variant 
c.2560G>A from the CMT2 cohort study 
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3.2.5 Exome sequencing 
Because screening of family F3 and F4 for the TRPV4 gene was negative we 
performed whole exome sequencing using one affected individual in each family. We 
first excluded all known CMT-causing genes and analyzed the rest of the data. 
Although not perfect because it does not cover the whole coding genome, exome 
sequencing has become a useful tool in identifying mutation in small families with 
suspected hereditary disorders. This sequencing revealed a single nucleotide sequence 
variant in the TRPV4 gene in family F3. The sequence variant is located in the exon 
number 3 at the coding nucleotide position 557, and is a transition of guanine to 
adenine (c.557G>A) (Figure 24a). This missense mutation leads to the substitution of 
arginine to glutamine at the amino acid position 186 (R186Q). This variant was 
missed by previous Sanger sequencing because it was at background noise level 
(Figure 24b). We have designed new primers to amplify and sequence the exon 3 to 
confirm this change and check for segregation. All affected individuals in family F4 
had the sequence variant which was not seen in the unaffected individuals. Individual 
III.5 does not have the mutation (Figure 24c), confirming that he is not affected with 
CMT2C, though he presented some subtle symptoms. 
The R186 residue lies at the end of the first ankyrin repeat domain, and the R to Q 
change is non conservative. Unlike R269, R186 is not part of an ER retention motif. 
                
Figure 24 Chromatographs showing the mutation missed by Sanger sequencing and 
found by exome sequencing.  
a) heterozygous sequence variant c.557G>A clearly visible when primers that do not 
contain SNP were used to amplify the genomic DNA, b) the sequence variant is not 
apparent (the “A” variant peak is comparable to the background noise), c) 
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chromatograph of individual III.5 (the sequence variant is not seen). Note that primers 
used in Figures 24a and 24c are same and different from Figure 24b. 
3.3 Functional studies 
3.3.1 Expression analysis  
Quantitative RT-PCR 
Expression of TRPV4 was shown in ventral horn and dorsal root ganglia nerves and 
in cartilage. In order to confirm the presence of TRPV4 in these tissues, we quantified 
TRPV4 transcript by qRT-PCR in human spinal cord ventral and dorsal horn, tracheal 
cartilage, and knee cartilage primary chondrocytes (Figure 25a). TRPV4 transcript 
was expressed in all of these tissues but the expression level was much higher in 
cartilaginous tissues.  
Five TRPV4 splice variants were cloned in human tracheal and bronchial epithelial 
cells (Arniges, Fernandez-Fernandez et al. 2006), although two of them were already 
described (the full-length TRPV4 cDNA called isoform A; GenBank number 
NM_021625 and the TRPV4 cDNA lacking exon number 7 called isoform B, 
GenBank number NM_147204; Δ384–444 amino acids). The other three are the 
TRPV4-C variant which lacks exon 5 (number DQ59644; Δ237–284 amino acids), 
TRPV4-D that presents a short deletion inside exon 2 (number DQ59645; Δ27–61 
amino acids), and TRPV4-E (number DQ59646; Δ237–284 and Δ384–444 amino 
acids) that is produced by double alternative splicing lacking exons number 5 and 
number 7. Although distinct TRPV4 transcript isoforms lacking exon number 5 and/or 
exon number 7 have been described (Arniges, Fernandez-Fernandez et al. 2006), we 
detected no evidence of variable expression of spliced isoforms lacking exon number 
5 or number 7 in the different tissues. 
To confirm these results, we performed a regular PCR using cDNA from different 
human tissues, including brain, spinal cord, trachea, liver, pancreas, kidney, and 
primers located within exon number 4 and number 8 of the TRPV4 cDNA to amplify 
exon 5 and 7. PCR products were visualized on agarose gel. In all lanes, two bands 
were identified (Figure 25b). Sequencing of these bands revealed the full length 
transcript and the one lacking exon number 7 in all tissues. No other deletion was seen 
elsewhere in the cDNA sequence. However, the band corresponding to the transcript 
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lacking exon number 7 seemed stronger than the full length in the nervous system 
tissues. The variant lacking exon 5 was not seen.   
 
      
Figure 25 Quantification of TRPV4 transcript by quantitative RT-PCR.  
a) in control human lymphoblast lines (n=4), human dorsal spinal cord (n=3), ventral 
spinal cord (n=3), and tracheal cartilage (n=3) using qRT-PCR primers specific for 
following exon regions: exons 3–4, exons 5–6, exons 7–8, exon 5, and exon 7. There 
was no evidence of variable expression of TRPV4 transcript isoforms containing exon 
5 or exon 7 in spinal cord compared to cartilage tissues. Values are normalized to the 
first tracheal cartilage sample. Data is averaged; error bars, s.e.m. b) amplification of 
TRPV4 full-length cDNA from kidney (K), lung (L), spinal cord (SC), foetal brain 
(FB), and brain (B). Arrows denote full length TRPV4 and Δ7 TRPV4. Note that Δ7 
TRPV4 appears stronger in nervous system tissues.  
Immunohistochemistry (IHC) 
TRPV4 has been shown to be expressed in DRG neurons where it is postulated to 
play a role in nociception. The expression and function of TRPV4 in motor neurons 
has not been previously well characterized. One previous study reported TRPV4 
immuno-reactivity in human spinal cord motor neurons and ventral root (Facer, 
Casula et al. 2007).  In addition, in situ hybridization indicates that TRPV4 mRNA is 
expressed in large ventral horn neurons of the adult mouse spinal cord (see Allen 
Institute for Brain Science Spinal Cord Atlas:  
http://mousespinal.brain-map.org/imageseries/show.html?id=100017703). We further 
examined the expression of TRPV4 protein in mouse spinal cord and DRGs by IHC. 
TRPV4 protein was expressed in ChAT positive spinal motor neurons, but was absent 
in TRPV4 knock-out mice tissues (Suzuki, Mizuno et al. 2003) confirming the 
specificity of the staining.  
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These data indicate that full-length TRPV4 are expressed in both sensory and motor 
neurons (Figure 26).    
 
 
             
Figure 26 TRPV4 expression in mouse spinal cord ventral horn motor neuron.  
TRPV4 is expressed at low level in mouse spinal cord ventral horn motor neuron. a) 
TRPV4 staining is evident in ChAT-positive motor neurons in WT mice. b) TRPV4 is 
absent when immunostaining is performed under identical conditions, except that 
TRPV4 primary antibody is omitted. c) Reduced TRPV4 staining is evident in 
knockout mice. Scale 20 µm. 
 
3.3.2 Analysis of WT and mutant TRPV4 in transfected mammalian cells  
Cell surface localization 
Full-length TRPV4, TRPV4-A, and the one lacking a portion of exon 2, TRPV4-D, 
were shown to traffic to the surface membrane while TRPV-B, TRPV4-C, and 
TRPV4-E, that all have deletion of part of the ankyrin repeat domains were retained 
in the ER (Arniges, Fernandez-Fernandez et al. 2006). The ankyrin domain of the 
TRPV4 protein has been hypothesized to be important for normal TRPV4 protein 
tetramerization and cellular trafficking by same investigators (Arniges, Fernandez-
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Fernandez et al. 2006). Biogenesis of TRPV4 involves oligomerization in the ER and 
transfer to the Golgi for subsequent maturation. In order to evaluate whether the 
R269C and R269H mutants altered the normal trafficking of TRPV4, we transfected 
different mammalian cell lines with WT and mutant TRPV4, and examined the 
distribution of TRPV4 protein by IHC. In HeLa cells, mouse WT, R269C, and R269H 
TRPV4 were all expressed predominantly in the cell cytoplasm and at the cell surface 
membrane with no differences seen between WT and mutant forms of TRPV4 (Figure 
27). In cells, expressing high levels of transfected protein, TRPV4 was present in 
small, rounded inclusions in the cell cytoplasm which partially co-localized with 
EEA1, an early endosome marker (Figure 28). When stained with the Golgi marker, 
GM130, we have seen the same result (Figure 28). These inclusions appeared more 
abundant and bigger in mutant TRPV4-transfected cells. In HEK 293 cells, human 
WT and mutant TRPV4 was predominantly present in the cell cytoplasm with surface 
localization less prominent than in HeLa cells (Figure 27). In order to check whether 
mutant TRPV4 was retained in the ER or in the Golgi, we stained cells with ER 
markers. There was little co-localization with the ER marker, calnexin. This indicates 
that mutant TRPV4 was not sequestered in the ER or in the Golgi. In DRG neurons, 
TRPV4 was prominently localized to the distal neurites of these cells, but again no 
difference was seen in cells expressing WT or mutant forms of the protein.   
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Figure 27 The CMT2C mutations do not change TRPV4 trafficking.  
In HeLa and HEK293 cells, WT, R269C, and R269H are localized to the cell 
cytoplasm and cell surface membrane. Note the inclusions in both wild-type and 
mutant TRPV4 expressing cells. Both WT and mutant TRPV4 show little co-
localization with the endoplasmic reticulum (ER) marker, calnexin, and the Golgi 
marker, GM130, and there was no difference in cell surface localization. Scale bars 10 
µm. 
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Figure 28 Staining of transfected HeLa cells with ER and Golgi markers.  
Note that there is little or no co-localization between TrpV4 and ER (EEA1) and 
Golgi (GM130) markers. Scale bar 10 µm. 
 
Cell surface biotinylation 
In order to further examine the association of WT and mutant TRPV4 with the cell 
plasma membrane, we isolated cell surface biotinylated proteins from HeLa cells 
expressing mouse WT, R269C, or R269H TRPV4. Immunodetection of TRPV4 
proteins showed appropriately sized bands for TRPV4 in 10 % of whole cell extract 
inputs and extracts after streptavidin isolation. Protein loading was controlled by 
immunodetection of β-actin, which showed appropriate depletion after isolation of the 
membrane fraction. No differences were seen in the amount of TRPV4 expressed at 
the cell surface membrane in cells expressing WT or mutant forms of TRPV4 (Figure 
29). Similar results were seen in HEK 293 cells expressing human WT and mutant 
forms of TRPV4 (data not shown). 
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Figure 29 Immunodetection of TRPV4 proteins in HeLa cells.  
Immunodetection of TRPV4 proteins shows appropriately sized bands for TRPV4 in 
10 % of whole cell extract inputs and the biotinylated fraction. Arrows denote 
glycosylated, full length and Δ7 TRPV4. There was no difference in the amount of 
wild-type compared to mutant TRPV4 in the membrane fraction (biotinylated 
fraction). However, the glycosylation pattern is slightly different (the upper band, 
which correspond to the glycosylated protein is stronger in wild-type. Shown is one 
representative blot of four independent experiments.  
 
Endoplasmic Reticulum stress 
To further investigate mutants TRPV4 cellular localization, we checked levels of 
genes activated during sequestration of genes in the ER. There was no increase in the 
expression of these genes in HEK 293 cells expressing mutant TRPV4 (Figure 30). 
This confirms that mutants TRPV4 are not retained in the ER, as shown by previous 
experiments. 
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Figure 30 Mutant TRPV4 is not retained in the ER. 
The ER stress genes HSPA5, HSP90B1, and GADD45A were measured by qRT-PCR 
in HEK 293 cells expressing empty vector, WT TRPV4, and mutant forms of TRPV4 
for 48 hours. Data are normalized to the GADD45A pcDNA3.1 value. No difference 
in expression of ER stress genes is seen in cells expressing mutant forms of TRPV4 
protein. 
 
Cell death assays 
Because TRPV4 is calcium permeable ion channel and Ca
2+
 overload is known to 
cause cell death, we performed cell death assays to assess the effect of mutants 
TRPV4 in cell viability. Although R269C and R269H TRPV4 showed no 
abnormalities of intracellular trafficking or cell surface expression, HEK 293T cells 
expressing mutant human TRPV4 showed evidence of cellular toxicity and death that 
increased with time (Figure 31a). At 24 hours, the percentage of dead cells was 4.0 % 
in WT TRPV4 expressing cells, but 11.0 % for R269C TRPV4 (p<0.01) and 11.4 % 
for R269H TRPV4 (p<0.01). By 48 hours, 1.8 % were dead in WT TRPV4-
expressing cells, 29.3 % dead for R269C (p<0.0001), and 24.9 % dead for R269H 
(p<0.0001). The addition of ruthenium red (RR), a non-specific TRP channels 
inhibitor, completely blocked this toxicity (Figure 31b) suggesting that cell toxicity 
relates to abnormal function of the TRPV4 channel. The same toxicity was seen in 
DRGs (Figure 31c). 
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Figure 31 Mutant TRPV4 causes cell toxicity in non-neuronal and in neuronal cells.  
a) HEK293 cells expressing R269C and R269H mutants show an increase in the 
number of dead cells (red channel is EthD-1 stain) at 48 h; this increase is prevented 
by the TRP channel blocker ruthenium red (RR). Green channel is calcein-AM stain 
for live cells. Scale bar, 200 μm. b) Quantification of cell death in HEK293 cells 
indicates a time-dependent increase in cell death that is blocked by the TRP channel 
blocker ruthenium red (RR). *P < 0.01, **P < 0.001. Data in (a) and (b) are averaged 
from three independent experiments; error bars, s.e.m. c) DRG neurons were 
transfected with wild-type and mutant forms of TRPV4 (green). At 16 h, some cells 
expressing mutant forms of TRPV4 show evidence of early cellular toxicity with a 
collapsed cytoplasm. The nuclear DAPI stain is blue. Scale bar, 40 μm. d) 
Quantification of propidium iodide uptake in DRG neurons expressing wild-type and 
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mutant TRPV4 reveals a marked increase of cell toxicity in mutant expressing cells at 
48 h. *P < 0.0001. 
To further evaluate TRPV4 hyperactivity and cell death we used two TRPV4 specific 
blockers: a genetic modification in the transmembrane domain and a chemical 
compound (Figure 32). A TRPV4 pore mutation, M680K, was shown to reduce or 
block TRPV4 Ca
2+
 permeability. HEK 293 cells tansfected with constructs containing 
both M680K and R269C or R269H variants showed less toxicity (Figure 32a).  
Moreover, relative fluorescent units were reduced (Figure 32c), supporting less 
calcium entry into the cell. RN1734 is a chemical compound that was recently 
identified as specific TRPV4 inhibitor. When used, this compound also had a similar 
effect as the M680K mutant (Figure 32b and 32d).  
 
Figure 32 CMT2C mutations cause cell death that is prevented by TRPV channel 
blockers.  
Increased cell death and intracellular calcium levels caused by the CMT2C mutations 
are mitigated by the TRPV4 inactivating channel pore mutation, M680K, and the 
TRPV4 channel inhibitor, RN1734. Quantification of cell death in HEK293 cells at 48 
hours in WT, R269C, or R269H TRPV4-expressing cells compared to a) WT/M680K, 
R269C/M680K, or R269H/M680K TRPV4-expressing cells and b) TRPV4-
expressing cells treated with the TRPV4 inhibitor, RN1734 at 10μM. *p<0.001. 
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Quantification of intracellular calcium levels by Fluorometric Imaging Plate Reader 
(FLIPR) in HEK293 cells expressing the TRPV4 mutants c) and treated with RN1734 
for 24 hours d). *p<0.05. Data in a, b are averaged from three independent 
transfections, data in c, d are averaged from 4 independent transfections, error bars, 
s.e.m. 
Xenopus oocytes expressing mutants TRPV4 also showed toxicity. When we 
expressed TRPV4 in Xenopus oocytes incubated in normal frog‟s Ringer solution, 
mutant forms of TRPV4 caused obvious toxicity within 12 hours with characteristic 
pigmentation of the vegetal pole (Figure 33).  This was observed in WT-expressing 
oocytes occasionally, but appeared more frequently and earlier in mutant-expressing 
oocytes. Overt oocyte cell death was witnessed at 48 hours for WT and mutants, but 
not water-injected oocytes. Although WT TRPV4 was toxic to the cells, this toxicity 
was much less than in mutants-transfected cells. Incubation of TRPV4-expressing 
oocytes in a Ca
+2
-free solution prevented obvious cell toxicity. This toxicity was 
reversed when oocytes were exposed to ruthenium red (Figure 33).  
 
 
Figure 33 Mutant TRPV4 toxicity in Xenopus oocytes is blocked by ruthenium red.  
Note the characteristic black pigmentation (vegetale pole) in R269H and R269C 
transfected oocytes in normal solution but absent when oocytes are exposed to 
ruthenium red (RR). 
 134 
3.3.3 Electrophysiology  
Because TRPV4 is an ion channel, we wanted to evaluate the effect of R269C and 
R269H mutants in the channel function. As stated above, when we expressed TRPV4 
in Xenopus oocytes incubated in normal frog‟s Ringer solution, mutant forms of 
TRPV4 caused obvious toxicity within 12 hours making electrophysiological studies 
difficult. We then incubated TRPV4-expressing oocytes in a Ca
+2
-free solution that 
prevented obvious cell toxicity and thus subsequent electrophysiology experiments 
were therefore performed in Ca
+2
-free solution. Whole cell currents measurement of 
oocytes expressing R269C and R269H TRPV4 showed a 2.5 fold increase in channel 
currents compared to WT under resting conditions (18 ºC) (Figure 34a). Addition of 
ruthenium red at 10 μM significantly reduced wild-type, R269H and R269C currents 
by 53 %, 52 % and 48 %, respectively (P < 0.05). TRPV4 is a heat activated ion 
channel (Watanabe, Vriens et al. 2002). We measured heat-activated mutant and wild-
type expressing oocytes and measured currents. In the heat-activated state (38 ºC), 
both wild-type and mutant TRPV4 channel currents increased 2-3 fold above their 
constitutive levels, with mutant channel currents remaining 2-3 fold higher than wild-
type (Figure 34a). It was also known that 4α-phorbol didecanoate (4α-PDD) is a 
specific agonist of TRPV4 (Watanabe, Davis et al. 2002). When the TRPV4 channels 
were activated by 4α-PDD, currents were increased by 3.1 fold in mutant-expressing 
oocytes compared to WT expressing oocytes (Figure 34b & c). Increasing temperature 
in the oocytes pre-incubated with 4α-PDD resulted in a further increase in channel 
activity (Figure 34b & c).  
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Figure 34 The R269C and R269H mutations cause increased TRPV4 channel activity 
in Xenopus oocytes.  
a) Wild-type and mutant TRPV4 were expressed in Xenopus oocytes, and currents 
were measured at 18 °C and after heating to 38 °C. Currents obtained at −100 mV 
were normalized to currents in wild-type at 38 °C. Basal and stimulated channel 
activities of both mutants were significantly increased compared to wild-type (P < 
0.006). Data are averaged from the number of experiments per condition shown in the 
columns; error bars, s.e.m. *P < 0.006. b) Representative current ramps obtained after 
preincubation in 5 μM 4αPDD (obtained from clamping cells from −100 to +100 mV 
in 500 ms). c) Summary of the data obtained in b. Currents obtained at −100 mV were 
normalized to wild-type at 18 °C. *P < 0.05. 
 
To confirm these electrophysiological results in mammalian cells, we transfected 
HEK 293 cells with human wild-type and mutants TRPV4 constructs. As seen in 
Xenopus oocytes, higher basal currents were observed in HEK293 cells transfected 
with R269C or R269H mutants as compared to wild type (Figure 35). Here also, HEK 
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293 cells were activated by 4α-PDD before currents measurement, and enhanced 
responses were observed in R269C and R269H expressing cells. Hypotonicity was 
also shown to activate TRPV4 channel (Liedtke, Choe et al. 2000). In addition to 
using 4-α-PDD to activate mutants and wild-type expressing HEK 293 cells, we used 
hypotonic stimulation, and saw greater currents in mutants TRPV4 expressing cells as 
compared to wild-type. 
 
 
Figure 35 The R269C and R269H mutants cause increased TRPV4 channel activity 
in HEK293 cells.  
Constitutive, 4αPDD-, and hypotonicity-activated currents in HEK293 cells 
expressing R269C or R269H TRPV4 are higher than in wildtype. a) Time courses 
showing constitutive currents, stimulation with 4αPDD (red bar) and inhibition with 
ruthenium red (RR; black bar). Reductions of >50% are observed in -100 mV currents 
before and after RR application (WT, 50%; R269C, 53%; R269H, 64%; all are 
significant p<0.05). b) Current-voltage relationship of constitutive (1) and 4αPDD-
activated (2) currents from time courses in (a). c) Summarized data from constitutive 
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and 4αPDD-activated currents. R269C showed greater variability in current values 
and a trend to larger currents than WT TRPV4. d) Time courses showing constitutive 
currents, stimulation with hypotonic solution (200 mOsm, blue bar), and 4αPDD (red 
bar). e) Current-voltage relationship of constitutive (1) and hypotonicity-activated (2) 
currents from time courses in (d). f) Summarized data from constitutive and 
hypotonicity-activated currents. In (a) and (d), currents at –100 (black) and +100 mV 
(red) were obtained from voltage ramps applied every 2 s. In (c) and (f), means ± 
s.e.m are shown and compared with WT values (*, p<0.05; number of cells (n) in 
legend). For (d-f), whole-cell configuration was established in standard extracellular 
solution, then exchanged to 320 mOsm solution, which has the ionic strength of 200 
mOsm solution but osmolality of standard solution, causing a negative shift of 
junction potential (-12.6 ± 0.3 and -16.0 ± 0.2 mV in 320 and 200 mOsm solutions, 
respectively (n=5)), and negative shift of reversal potential in (e). Untransfected 
HEK293 cells show endogenous volume-regulated anion channel (VRAC) activity, 
which develops and recovers slowly (several minutes) and is down-regulated by 
TRPV4 over-expression (1). To minimize possible contamination by remaining 
VRAC activity, hypotonic stimulation was limited to 60 sec and TRPV4 expression 
was confirmed by 4αPDD stimulation. 
3.3.4 Cell calcium measurement 
As Ca
2+
-permeable channel, TRPV4 hyperactivation would lead to cell Ca
2+
 overload 
and cause cell death. In fact, studies have associated TRPV4 hyperactivity to 
intracellular calcium increase (Krakow, Vriens et al. 2009). We therefore performed 
calcium measurement using two techniques. Intracellular calcium levels were elevated 
in the mutant TRPV4 compared to the WT (Figure 36a & b). This calcium uptake 
caused by the TRPV4 mutations was inhibited by the inactivating pore domain 
mutation, M680K, and by the TRPV4 specific blocker, RN1734 (Figure 36a & c). 
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Figure 36 HEK293 cells expressing mutant TRPV4 have higher basal calcium levels 
than WT expressing cells.  
a) Representative images of transfected HEK293 cells (circled) loaded with the 
fluorescent calcium indicator, Fura 2. Transfected cells were identified by their 
expression of the fluorescent marker mCherry. Under basal conditions, when cells 
were perfused with standard extracellular buffer, TRPV4- transfected cells had 
elevated intracellular calcium concentrations, as demonstrated by an increased Fura 
ratio. Furthermore, cells expressing the mutant TRPV4 channels, R269C and R269H, 
had higher levels of intracellular calcium when compared to cells transfected with WT 
TRPV4. When transfected cells were incubated in the presence of 10 μM of the TRP 
channel blocker ruthenium red (RR), the TRPV4-mediated increase in calcium 
concentration was blocked. Scale bar = 50 μm. b) Quantification of baseline Fura 
ratios in TRPV4- or vector-transfected HEK293 cells. n = 7-10 coverslips from three 
independent transfections. c) Quantification of baseline Fura ratios in the presence or 
absence of ruthenium red. n = 5 coverslips. Error bars s.e.m. *p<0.01, **p<0.001. 
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3.3.5 Chicken TRPV4-ARD structure determination 
This was performed using data collection and refinement statistics in the table below 
(Table 7). The 2.3-Å crystal structure of the chicken Trpv4 ankyrin repeat domain 
(ARD) (Figure 37) shows a typical hand-shaped structure with a concave palm 
surface formed by inner helices and fingers and a convex surface representing the 
back of the hand. Arg269 is located at the base of finger 3 on the convex surface. In 
addition, the Arg269 residue side chain is exposed and well positioned to mediate 
protein-protein interactions that may be critical to TRPV4 function. 
 
                        
Figure 37 Localization of CMT2C and skeletal dysplasia TRPV4 mutations in the 
chicken Trpv4 ankyrin repeat domain crystal structure.  
The R269C and R269H substitutions are located in the ankyrin repeat domain (ARD) 
of the TRPV4 protein. a) Primary structure of the TRPV4 protein, with the positions 
of the CMT2C-associated (Arg269; blue arrowhead) and skeletal dysplasia–associated 
(Krakow, Vriens et al. 2009)
 
(green arrowheads) mutations indicated below. b) 
Ribbon diagram of the chicken Trpv4 ARD, with the location of the Arg269 residue 
(Arg255 in chicken sequence) depicted as a blue sphere and the Ile331 and Asp333 
residues (Ile317 and Asp319 in chicken sequence, respectively) previously shown to 
be mutated in skeletal dysplasia as green spheres. 
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3.3.6 Protein binding assays and co-immunoprecipitation 
One study has shown that PACSINs (1, 2, and 3) bind to TRPV4, and that PACSIN 3 
affects the endocytosis of TRPV4 (Cuajungco, Grimm et al. 2006). Therefore, we 
completed co-immunoprecipitation studies with wild-type and mutant TRPV4. 
HEK293 cells were co-transfected with PACSIN1, PACSIN2, or PACSIN3 and either 
FLAG-WT TRPV4, FLAG-R269C TRPV4, FLAG-R269H TRPV4. After 
immunoprecipitation (IP) using anti-FLAG antibody, bound proteins were separated 
by SDS-PAGE and analyzed by immunoblotting with antibodies to PACSIN1, 2, or 3. 
The TRPV4 IP was verified by immunoblotting with anti-FLAG antibody. We found 
that there is no change in interaction between all PACSINs and mutant TRPV4 
(Figure 38a, b & c).  
Another study has shown TRPV4 interaction with calmodulin through its ARD 
(Phelps, Wang et al. 2010). We performed binding assays, and found no disruption in 
interaction between calmodulin and CMT2C mutant TRPV4 compared to skeletal 
dysplasias mutant TRPV4 or wild-type TRPV4 (Figure 38d). 
 
Figure 38 The CMT2C TRPV4 mutations do not influence TRPV4 interaction with 
PACSINs 1-3 or Ca2+-calmodulin.  
a) The CMT2C mutations do not reduce co-immunoprecipitation of TRPV4 with 
PACSINs1-3. (b,c) Interactions of isolated TRPV4-ARD with the isolated PACSIN3 
SH3 are unchanged by CMT2C mutations. b) Representative size exclusion 
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chromatography traces of PACSIN3 SH3 domain alone (grey; the same trace is shown 
on all graphs for reference), HsTRPV4-ARD alone (black) or the HsTRPV4-
ARD/PACSIN3-SH3 mixture (red). Elution volumes for each peak are indicated. 
Traces are representatives of at least two experiments. c) Coomassie-stained SDS-
PAGE gels of the elution fractions (elution volumes 10.1 to 16.1 ml) of the 
chromatography experiments shown in (b). d) Coomassie-stained gel shows wildtype 
and mutant TRPV4-ARD loaded (left) and bound to calmodulin-agarose in the 
presence of Ca
2+
 or EGTA. The normalized amount of protein recovered (average +/- 
standard deviation) is plotted below, from three independent experiments, showing no 
significant differences between WT and the mutants.  
 
 
 
 
 
 142 
4 Discussion 
4.1 Clinical and laboratory findings 
Patients with CMT2C present with axonal-type features with high variability in age 
of onset and disease course. 
CMT2C is a peripheral neuropathy characterized by distal muscle wasting and 
weakness, mild sensory impairment and prominent vocal fold and diaphragm 
involvement (Dyck, Litchy et al. 1994). We report five families presenting with 
clinical, electrophysiological and laryngoscopical features of CMT2C including distal 
more than proximal limb muscle weakness and atrophy, sensory loss, reduced to 
absent tendon reflexes, and laryngeal and diaphragmatic muscles weakness. In 
addition to these previously described findings, sensorineural hearing loss and urinary 
incontinence were observed in many patients in families F1, F2 and F3. However, 
sensorineural hearing loss and urinary incontinence were not reported in any patient 
of families F4 and F5. Moreover family F4 showed subtle or no sensory involvement 
and no diaphragmatic involvement during NCS; suggesting that these two families 
may be different clinical entities or manifesting the variability seen in the CMT2C 
sub-type. 
Ages of disease onset were highly variable, ranging from 1 to 53 years. Although the 
variability in the age of onset and disease severity seen in this study is seen in other 
types of CMT patients, this pattern seems to occur frequently in CMT2C. Other 
studies also emphasized the variability in the disease progression and expression as a 
key feature of CMT2C (Dyck, Litchy et al. 1994). This variability between 
generations does not reflect the anticipation pattern seen in nucleotide repeat disorders 
like polyglutamine diseases or fragile X or myotonic dystrophy because some patients 
in the younger generations (family F1 V.8) appeared to be less affected than their 
parents (family F1 IV.3). Two patients did not report any symptoms. The first patient, 
a 71-year old mother of three affected sibs was found to have absent tendon reflexes 
throughout, and mild husky voice when evaluated at 53 years. The second patient 
(Family F1, V.2) is a son of an affected woman and brother of two affected young 
ladies. He was not complaining of any symptom related to CMT2C. When examined 
he had hammer toes and slight pes cavus, reflexes were absent in ankle and reduced in 
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knees, and vibration sense was slightly decreased in lower limbs. Although NCS and 
laryngological studies were not performed, he was found to having the TRPV4 
mutation running in his family.  
His cousin (Family F1, V.8), although suffering from early laryngeal muscle 
paralysis, showed few signs when examined 18 years later, suggesting that the disease 
may be generally milder in men or supporting the characteristic clinical variability 
seen in previously reported CMT2C families. Other CMT2C studies reported 
individuals with no complaints, but were found to be affected during clinical 
examination. Dyck P. J. et al. (Dyck, Litchy et al. 1994) reported an 80 year-old 
female with no complaints but who had weakness and atrophy in hand, legs and feet, 
and decreased to absent reflexes on examination. She also manifested hoarse voice at 
times after lengthy talk. In addition her NCS was abnormal. 
On the opposite side, a 54-year old male (Family F3, III.5), although having no major 
complaints, was suspected to be affected because  his medical history was consistent 
with long standing high arches, cramps and fasciculations in calves, and recently sleep 
apnoea for which he is seeing a doctor. Moreover, his neurological examination 
revealed subtle distal sensory loss, and chest X-rays showed hemidiaphragm paralysis 
while NCS, especially the phrenic nerve, and EMG did not reveal any sign of chronic 
neuropathy but median nerves entrapment, making the diaphragmatic paralysis 
unlikely to be of neurodegenerative origin. Although these findings are subtle, there 
was still a possibility that he may be affected, but, as discussed below, he did not have 
mutation in the TRPV4 gene as his affected family members.  
The clinical and electrophysiological examination of the youngest patient in family F1 
showed little signs of worsening since his first months of life. This is consistent with 
results from some studies which report that some patients with CMT stabilize over 
years (Pareyson, Scaioli et al. 2006). 
Vocal fold and diaphragm paralysis are characteristic and most common features 
in CMT 2C patients. 
Stridor, breathing difficulties on exertion, and hoarseness of voice were the most 
frequent initial and predominant symptoms and were present in almost all patients. 
But, ultimately, all these symptoms were present at the late stage of their disease. 
Laryngeal paralysis primarily involving abductor muscles (opening) leads to air 
obstruction that manifests symptomatically by stridor (Holinger, Vuckovich et al. 
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1979; Young and Harper 1980). On the other hand, laryngeal paralysis involving 
adductor muscles (closing) leads to breathing difficulties and risk for aspiration 
(Mace, Williamson et al. 1978; Pridmore, Baraitser et al. 1992), and hoarseness of 
voice. Although breathing difficulties can be due to laryngeal adductor muscles 
paralysis, diaphragmatic and intercostal muscles paralysis seen in this disease can also 
cause this symptom. Another symptom that may cause breathing difficulties is severe 
thoracic deformity that may be seen in CMT patients. 
Although an unusual clinical feature, vocal fold paralysis has been described in other 
hereditary motor and sensory neuropathy sub-types. Axonal neuropathies caused by 
mutations in the GDAP1 gene (CMT4A and CMT2K) are associated with vocal fold 
paralysis (Baxter, Ben Othmane et al. 2002; Cuesta, Pedrola et al. 2002; Birouk, 
Azzedine et al. 2003; Stojkovic, Latour et al. 2004). These CMT sub-types, unlike 
CMT2C, are autosomal recessive, although some CMT2K cases are autosomal 
dominantly inherited (Chung, Kim et al. 2008). Symptoms linked to vocal fold 
paralysis were also reported in some demyelinating CMT sub-types, including 
CMT1A, CMT2A2, HNPP-PMP22, and CMT1D (Thomas, Marques et al. 1997; 
Pareyson, Taroni et al. 2000).  
But in all these CMT variants, symptoms related to vocal fold paralysis appear in few 
patients only whereas in CMT2C vocal fold paralysis is a central clinical feature 
present in all patients. In addition, symptoms are not limited to hoarseness of voice, 
albeit respiratory difficulties appeared in the third decade in some families (Stojkovic, 
Latour et al. 2004). Except in two of these families (Azzedine, Bolino et al. 2003; 
Stojkovic, Latour et al. 2004), diaphragm paralysis was not associated with these 
diseases, and in one of them the diaphragm paralysis was not symptomatic. 
Sensorineural hearing loss was reported in several patients in these diseases but 
urinary incontinence was absent.  
Stridor and breathing difficulties were reported in other hereditary neurological 
disorders. In distal spinal and bulbar motor neuropathy (dSBMA) caused by mutations 
in the Dynactin 1 (DCTN1) gene (Puls, Jonnakuty et al. 2003; Puls, Oh et al. 2005), 
stridor and breathing difficulties are first and predominant symptoms. However, 
CMT2C and dSBMA have several clinical and laboratory differences. Distal spinal 
and bulbar muscular atrophy is an autosomal dominant hereditary motor neuropathy 
in which the disease starts later, ranging from 23 to 39 years. Although ages of onset 
are highly variable in CMT2C, in most cases the disease starts within the first decade. 
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In dSBMA, limb weakness starts with hands, and lower limbs are usually affected 
several years later. While bulbar involvement is a prominent symptom in dSBMA, 
only one patient in the families studied here, the most affected, presented with subtle 
facial weakness. In addition, there is no sensory loss in dSBMA, nor were reported 
diaphragm paralysis, bilateral hearing loss or urinary incontinence. 
Dyspnoea on effort and hoarseness of voice were reported in another large kindred 
affected with distal motor neuropathy (HMN7A) (Young and Harper 1980). In this 
family, the disease usually started with hand weakness, and progressed to lower limbs 
years later. Laryngeal symptoms appeared later in the disease course, but in some 
cases they preceded limb weakness. The gene for this disease was mapped to 
chromosome 2q14 (McEntagart, Norton et al. 2001), but the disease-causing gene is 
still not identified. Although CMT2C and HMN7A share some clinical features, there 
is no urinary incontinence in HMN7A, and sensation is normal. 
Patients with CMT2C, like in most CMT variants, have normal life expectancy. But 
these symptoms, air obstruction and breathing difficulties, are potentially life-
threatening, and shorten patients‟ life expectancy. In fact, a 46-year old patient in 
family F1 has died of respiratory failure whereas her 77-year old affected mother who 
has less laryngeal muscle paralysis is still alive. This shortened life expectancy was 
also seen in other neurological diseases with vocal fold involvement discussed above 
(Puls, Oh et al. 2005). Patients with severe respiratory difficulties underwent surgery. 
Tracheostomy was performed in few of them after they lived a better life. Vocal fold 
tie back or arytenoidectomy were usually performed to liberate air way. This 
procedure was beneficial to all it was performed on. In fact one of our patients who 
underwent surgery was playing French horn when we last saw him, 17 years after his 
surgery.   
Limb weakness and atrophy, and not facial involvement, are also common signs in 
CMT 2C. 
Foot weakness and walking difficulties were the second most reported symptoms in 
the families we investigate here. One patient who had noisy breathing within his first 
year of life presented minimal foot weakness when evaluated at age 18. In the 
classical CMT presentation, foot weakness and walking difficulties are first and most 
common symptoms. However, in some CMT sub-types, including the autosomal 
dominant CMT2D due to the GARS gene mutation, symptoms start with hand 
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weakness. As in the classical CMT presentation, distal lower limb weakness worsened 
over time in the patients described here, and upper limbs became affected later in the 
disease course. Skeletal deformities consistent with pes cavus, hammer toes, and 
scoliosis were reported in several patients, mostly in patients with very early onset. 
However, some patients with early onset presented mild or no skeletal deformities, 
supporting the variability in the disease severity in this disease. These symptoms are 
characteristic of the classical CMTs, and inversely correlated to the age of disease 
onset. 
Several patients reported worsening of muscle weakness in the cold (“cold 
paralysis”), which is an intriguing symptom given that TRPV4 is known to be 
activated by increased temperature.  
This symptom could relate to motor neuronal function or possibly to abnormalities of 
vasoregulation known to be controlled in part by TRPV4.  
Sensory loss is a characteristic feature of CMT. Almost all patients studied here 
presented with some sensory loss. While most patients had minimal sensory loss, few 
had mild to moderate sensory loss, and only one was moderately affected. Two 
patients in family F1 had no sensory loss. In general, sensory loss seen in the classical 
CMT is more pronounced than what we have seen in the patients studied here, and 
decreased or absent vibration sense was the predominant sensory loss.  
Facial weakness, seen in some previous CMT 2C reports (Dyck, Litchy et al. 1994), 
was not apparent in our study; except in the most affected patient in family F1 (IV.4) 
who presented minimal facial weakness. Although rarely seen in CMT cases, facial 
weakness was reported in some CMT variants such as CMT 4G (Rogers, Chandler et 
al. 2000). But it is in dSBMA that facial weakness represents a characteristic feature 
present in all patients (Puls, Oh et al. 2005). 
Patients with CMT2C also present with sensorineural hearing loss and urinary 
incontinence. 
Several patients from three families studied here had hearing loss and urinary 
incontinence.  The hearing loss was documented by ENT examination, and showed 
that patients with hearing impairment had a bilateral sensorineural hearing loss. These 
are distinctive features since there were not reported in previous CMT2C reports 
(Dyck, Litchy et al. 1994; Donaghy and Kennett 1999; Santoro, Manganelli et al. 
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2002; McEntagart, Reid et al. 2005). Hearing loss can be due to the auditory nerve 
dysfunction secondary to the degeneration of all peripheral nerves as it is reported in 
several CMT sub-types (CMT1D, CMT1E, CMT2E/CMT1F, CMT1X, CMT2A2, and 
HMSNIV). But in CMT2C, this symptom may also relate to TRPV4 dysfunction 
because TRPV4 has been shown to express in hair cells, spiral ganglion, and stria 
vascularis in the cochlea (Liedtke, Choe et al. 2000). In these tissues, TRPV4 may be 
involved in transduction of acoustic stimuli (Kim, Chung et al. 2003; Mutai and 
Heller 2003; Nilius, Vriens et al. 2004). Moreover, TRPV4 knockout mouse have 
bilateral sensorineural hearing loss (Suzuki, Mizuno et al. 2003). Urinary 
incontinence was not reported in other CMT variants. Thomas P. K. et al. (Thomas, 
Marques et al. 1997) have reported CMT1A patients with weakness of the pelvic floor 
muscles resulting in faecal incontinence. However, there was no urinary incontinence, 
and none of the patients studied here reported faecal incontinence.  
Some patients presented unilateral hearing loss, and audiological examination showed 
features consistent with tympanic injury or other causes unrelated to their 
neurological disease.  
Urinary incontinence is also likely secondary to TRPV4 dysfunction as TRPV4 is 
expressed in bladder epithelium (Yamada, Ugawa et al. 2009). Studies have suggested 
that TRPV4  may play a role in sensing of bladder pressures (Gevaert, Vriens et al. 
2007). In addition, impairments of bladder voiding was shown in the knockout mouse 
(Suzuki, Mizuno et al. 2003; Tabuchi, Suzuki et al. 2005; Gevaert, Vriens et al. 2007).   
Electrophysiological studies in CMT 2C patients show axonal-type findings with 
often phrenic nerve involvement. 
NCS were consistent with an axonal-type involvement. Motor and sensory, 
conduction velocities were normal, especially the median nerve (>38 m/s) whereas 
compound motor action potentials were low. This was in contrast with demyelinating-
type CMT in which conduction velocities were generally low. However, in some 
mildly affected patients, NCS were normal or minimally disturbed. This is another 
distinctive feature of CMT1 because in this form of CMT NCS show almost always 
abnormalities, and can appear years before first symptoms appear (Pareyson, Scaioli 
et al. 2006). The peroneal nerve was the most affected consistent with the CMT 
distribution; which was first called peroneal muscular atrophy. One patient had 
prolonged distal latency and slow conduction velocity with normal amplitude of the 
 148 
left median motor and sensory nerve, respectively. This pattern is not characteristic of 
CMT2. Her medical history revealed symptoms in her left hand consistent with a 
median nerve entrapment explaining the NCS results in that side. Phrenic nerve 
involvement was seen in all but one affected patients in families F1, F2, and F3. In 
addition to the slight phenotypic difference, NCS of some patients in family F4 was 
not quite typical of what is seen in CMT2C. In fact, NCS in family F4, although 
raised the possibility of an increased susceptibility to physical injury such as seen in 
more diffuse polyneuropathies, was significant for the presence of bilateral 
asymmetric and probably of a different nature peroneal nerve abnormalities; which 
could be supportive of bilateral focal peroneal nerve lesions. In addition, NCS family 
F4 did not show phrenic involvement. All these together may raise the possibility of 
family F4 being a different peripheral neuropathy entity, at least from CMT2C. In 
family F5, though, phrenic nerve compound motor action potentials (CMAPs) were 
not recorded. Phrenic nerve involvement was reported in other CMT variants 
(CMT1E, and CMT4A) (Sevilla, Cuesta et al. 2003), but no symptoms related to 
phrenic nerve dysfunction were seen albeit abnormal NCS. Stojkovic et al. (Stojkovic, 
Latour et al. 2004) reported two affected individuals with hemi-diaphragm paralysis 
but phrenic nerve action potentials were not recorded. EMG showed muscle 
membrane instability and motor unit remodelling even in the mildly affected 
individuals suggesting a chronic muscle denervation and reinnervation.  
Quantitative sensory testing performed in one patient showed a decrement in CMAP 
after cooling. This pattern is suggestive of a channelopathy consistent with the genetic 
and electrophysiological findings discussed below. 
Vocal fold paralysis in CMT 2C shows a length-dependent pattern with left muscles 
being more affected in the beginning of the disease.  
Laryngoscopy was done in few of our patients, and showed laryngeal muscles 
paralysis with the left laryngeal muscles being more affected. In patients evaluated at 
earlier stage of their disease, left laryngeal muscles were only affected. This pattern of 
vocal fold paralysis evolution was seen in the previously reported CMT2C families 
(Dyck, Litchy et al. 1994; Donaghy and Kennett 1999; Santoro, Manganelli et al. 
2002; McEntagart, Reid et al. 2005). The presence of bilateral laryngeal muscle 
paralysis of both abductor and adductor muscles could explain the stridor and 
hoarseness of voice present in these patients, except in family F4 where only abductor 
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muscle paralysis was seen. CMT2C is a length-dependent axonal neuropathy. In 
neurodegenerative diseases in which symptoms appear in length-dependent pattern, 
muscles innervated by longer nerves appear to be first affected. Therefore, left 
laryngeal muscles were often first paralyzed because the left recurrent nerve, which 
innervates those muscles, is longer than the right side nerve. This pattern of left 
laryngeal muscles being more affected than the right ones at the early stage of the 
disease is seen in other neurodegenerative diseases, including the distal hereditary 
motor neuropathy (HMN7A) (Young and Harper 1980). However, in the distal spinal 
and bulbar muscular atrophy (dSBMA) (Puls, Oh et al. 2005), there is an early 
bilateral laryngeal paralysis. 
Vocal fold paralysis is seen in other CMT sub-types, including CMT2K, CMT4A, 
CMT1A, CMT2A2, HNPP-PMP22, and CMT1D, but this symptom appears in few 
patients only whereas in CMT2C vocal fold paralysis is a core symptom present in all 
patients, and sometimes is the only symptom. In addition, vocal fold paralysis is 
unilateral and rarely involves both sides. 
CMT2C patients show skeletal deformities and diaphragm paralysis. 
Spinal radiographs showed skeletal deformities in some patients. This symptom 
appears generally in CMT patients with early onset. However, not all patients who 
presented symptoms at early age had spinal deformity; supporting the clinical 
variability seen in this disease. However there were no bone morphology or density 
abnormalities. Chest X-rays showed asymmetric diaphragm in few patients due to the 
phrenic nerve paralysis. This symptom is common in CMT2C families as it was 
reported in previous studies (Dyck, Litchy et al. 1994; Santoro, Manganelli et al. 
2002). Other hereditary neurological disorders including the autosomal recessive 
CMT 2 due to the GDAP1 gene reported this symptom in two patients (Azzedine, 
Bolino et al. 2003; Stojkovic, Latour et al. 2004). 
Mutations in TRPV4 were shown to cause bone diseases including autosomal 
dominant Brachyolmia and Spondylometaphyseal Dysplasia, Kozlowski Type 
(SMDK) and Metatropic Dysplasia (Rock, Prenen et al. 2008; Krakow, Vriens et al. 
2009). Others have later reported TRPV4 mutations in skeletal dysplasias families 
(Camacho, Krakow et al. 2010).  
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The brachyolmias are a heterogeneous group of skeletal dysplasias of unknown 
aetiology that primarily affect the spine. At least three types of brachyolmia have been 
described (Shohat, Lachman et al. 1989) with different pattern of inheritance. The 
Type 1 (Hobaek and Toledo forms) and Type 2 (Maroteaux type) brachyolmias are 
inherited in an autosomal recessive fashion (Fontaine, Maroteaux et al. 1975; Toledo, 
Mourao et al. 1978; Horton, Langer et al. 1983; Shohat, Lachman et al. 1989). Type 1 
brachyolmia forms are characterized by scoliosis, platyspondyly with rectangular and 
elongated vertebral bodies, overfaced pedicles and irregular, narrow intervertebral 
spaces. In addition, the Toledo form has characteristic features such as corneal 
opacities and precocious calcification of the costal cartilage. Type 2 brachyolmia is 
distinct from type 1 by rounded vertebral bodies and less overfaced pedicles. Type 3 
brachyolmia is an autosomal dominant form with severe kyphoscoliosis and flattened, 
irregular cervical vertebrae (Gardner and Beighton 1994). SMDK is primarily 
characterized by postnatal short stature and significant kyphoscoliosis leading to 
progressive deformity. Other clinical findings include normal facies, a short neck, 
pectus carinatum, and genu varus (Nural, Diren et al. 2006). The radiographic 
phenotype includes odontoid hypoplasia, platyspondyly with vertebral bodies 
described as resembling an „„open staircase,‟‟ overfaced vertebral pedicles, short 
square ilia, flat acetabular roofs, wide proximal femoral epiphyseal plates, 
metaphyseal irregularities, and markedly delayed carpal bone ossification (Lachman 
2007).  
First described in 1966 (Maroteaux, Spranger et al. 1966), metatropic dysplasia often 
present with shortened limbs and a long, narrow trunk in the newborn period that 
evolves into a severe, progressive kyphoscoliosis (Leet, Sampath et al. 2006). 
Affected individuals have a distinctive facies with a prominent forehead and squared-
off jaw (Kannu, Aftimos et al. 2007). The radiographic findings in metatropic 
dysplasia are characteristic and include wafer-like vertebral bodies in newborns, a 
halberd-shaped pelvis, irregular calcanei and tali, brachydactyly with delayed carpal 
ossification, and flared or „„mushroomed‟‟ proximal and distal metaphyses of the 
femora leading to a „„dumbbell-shaped bone‟‟ (Lachman 2007). Cervical myelopathy, 
and stenosis leading to significant neurologic sequelae were reported in metatropic 
dysplasia patients (Shohat, Lachman et al. 1989; Leet, Sampath et al. 2006), but these 
result in symptoms consistent with upper motor neurons involvement that clinically 
differ to peripheral neuropathy. Although some CMT sub-types present with 
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pyramidal signs, these were not reported in the families we studied here or in the other 
CMT2C families described elsewhere. Interestingly, some of these patients present 
with respiratory difficulties and sensorineural deafness (Kannu, Aftimos et al. 2007; 
Genevieve, Le Merrer et al. 2008). These symptoms are also seen in CMT2C patients 
but the physiopathology, at least for the breathing difficulties, may be different. The 
respiratory difficulties in metatropic dysplasia are due to the kyphoscoliosis and 
narrowed thorax whereas in CMT2C this symptom result from diaphragmatic and/or 
the accessory respiratory muscles paralysis. In CMT2C hearing loss occurs probably 
because of intrinsic auditory nerve degeneration while in metatropic dysplasia it may 
be due to stapedial bone deformity compressing the acoustic nerve. However, both 
can have the same physiopathology because of the expression of TRPV4 in hair cells. 
No bone deformities or cartilage abnormalities comparable to those seen in 
brachyolmia and other skeletal dysplasias caused by TRPV4 mutations (Rock, Prenen 
et al. 2008; Krakow, Vriens et al. 2009) were seen in the patients we studied here. 
Skeletal deformities seen in CMT families including the ones studied here are not due 
to abnormal bone morphology; rather they are due to muscle weakness that fails to 
sustain joints. Nonetheless, there is a possibility of overlap between these two entities 
as shown in two studies that reported cases of CMT2-type peripheral neuropathy 
associated with skeletal dysplasia-type symptoms (Chen, Sul et al. 2010; Zimon, 
Baets et al. 2010).  
The mutation identified in this single case was reported to cause autosomal dominant 
brachyolmia (V620I) (Rock, Prenen et al. 2008). This residue lies on the pore domain 
of TRPV4, where most of the brachyolmia and spondylometaphyseal dysplasia, 
Kozlowski type (SMDK) and Metatropic Dysplasia mutations clustered. In addition, a 
recent study reported two CMT2C families with short stature in which they identified 
TRPV4 mutations. Interestingly, the family with mild neuropathy and pronounced 
short stature had mutation in the pore domain of TRPV4 (S542Y) while the family 
with severe neuropathy and less remarkable short stature had a mutation in the 
ankyrin repeat domain (R315W) (Chen, Sul et al. 2010). The latter mutation was also 
previously reported in a CMT2C family (Auer-Grumbach M., 2010). 
Mutations in TRPV4 were described in other neurological disorders including 
congenital distal spinal muscular atrophy (SMA) and scapulo-peroneal SMA 
(SPSMA) in two independent studies (Auer-Grumbach, Olschewski et al. 2010; Deng, 
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Klein et al. 2010). Although these disorders share some features with CMT2C, these 
neuropathies are phenotypically different. Congenital distal SMA is characterized by 
more proximal than distal muscle weakness and atrophy with minimal or no sensory 
symptoms. However, laryngeal muscle and diaphragm involvement are not features 
seen in congenital distal SMA, although some studies reported congenital SMA with 
diaphragm paralysis (Bertini, Gadisseux et al. 1989). SPSMA is characterized by a 
scapulo-peroneal distribution of weakness and atrophy, congenital absence of 
muscles, and laryngeal palsy as seen in CMT2C. The latter symptom is a 
characteristic feature that is present in all CMT2C patients, while congenital absence 
of muscles, specifically the deltoid, was reported in only few patients (Dyck, Litchy et 
al. 1994; McEntagart, Reid et al. 2005). None of our patients reported congenital 
absence of muscles.  
But, urinary incontinence and hearing loss were not reported in these diseases. 
How do mutations in the same gene causes defects in different selected parts of the 
nervous system needs to be addressed in future studies.   
4.2 Genetic analysis 
CMT 2C is genetically heterogeneous  
The gene for CMT2C was mapped to chromosome 12q23-24 (Klein, Cunningham et 
al. 2003), and this locus was later confirmed and narrowed by another study 
(McEntagart, Reid et al. 2005). The genetic analysis of families studied here also 
found evidence for linkage in this locus with a cumulative LOD score of about 10. By 
combining linkage data from all families we were able to reduce the region of interest 
from 3.9 Mb to 2.6 Mb.  
From the haplotype reconstruction it appears that all the affected individuals in 
families F1, F2, and F4 have the disease-bearing allele. Three supposedly unaffected 
individuals in family F1 (the mother of the founder II.2 and her 71 year-old sister III.4 
and son IV.6) also carry the disease-related allele, although the genotype for the 
founder‟s mother was inferred. Family members F1 III.4 and F1 IV who were seen in 
this study had no complaints, and their clinical examination was completely normal, 
although electrophysiological and laryngological studies were not done on them. This 
may be due to an incomplete penetrance or the high variability in the age of onset and 
the severity seen in this disease. In their studies, Dyck P. J. et al. (Dyck, Litchy et al. 
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1994) and Klein C. J. et al. (Klein, Cunningham et al. 2003) reported similar pattern. 
They also reported about an asymptomatic individual with a normal clinical and 
laboratory examination but had the disease-bearing allele. But, another likely 
explanation could be that this may be a new mutation arising between the affected 
founder (Fig. 1, individual III.2) and her mother. This is consistent with the family 
history because no information was gotten from family members suggesting that one 
of the affected founder‟s parents or other relatives in the older generations were 
affected. However, the founder‟s mother was reported to have absent reflexes, and her 
EMG showed peroneal involvement at age 71. Based on these findings, it cannot be 
ruled out that she was not affected due the high variability seen in other families. The 
haplotype reconstruction in the family F1 was most helpful because it narrowed down 
the previous region of linkage due to the recombination that took place in the 
telomeric border of the region of interest. This recombination excluded about 26 
genes including the ATXN2 gene from the last mapping study in this locus 
(McEntagart, Reid et al. 2005). 
The haplotype reconstruction matched well the disease status in the other two linked 
families. Linkage analysis done in family F5 excluded the 12q24.11 locus, suggesting 
genetic heterogeneity within the CMT2C sub-type. 
The chromosome 12q24 locus is a “hot-spot” for many neurological disorders. 
Scapuloperoneal muscular dystrophy (SPMD) is an autosomal dominant 
neurodegenerative disorder characterized by a myopathic syndrome. Symptoms 
develop in the legs first, and manifest with foot-drop and a gait disturbance, and 
shoulder girdle weakness develops at a later stage of the disease. Mild facial muscles 
weakness may develop in some patients (Todman and Cooke 1984). Wilhelmsen K. 
C. et al. have mapped the gene causing scapuloperoneal muscular dystrophy in a large 
family to chromosome 12q21-22 (Wilhelmsen, Blake et al. 1996).  
Scapuloperoneal muscular atrophy (SPSMA) is the neurogenic form of the syndrome 
described above. SPSMA is an autosomal dominant disorder characterized congenital 
absence of muscles, progressive scapular and peroneal atrophy, laryngeal palsy, and 
progressive distal weakness and atrophy (DeLong and Siddique 1992). The gene for 
SPSMA was mapped to chromosome 12q24.1-24.31 (Isozumi, DeLong et al. 1996), 
and the disease-causing gene was identified recently (Deng, Klein et al. 2010). 
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Distal hereditary motor neuropathy type II (dHMNII) is an autosomal dominant 
neuropathy characterized by weakness and atrophy in distal lower limbs but upper 
limbs can be affected later. This disease is close to CMT1 or CMT2 but there is no or 
little sensory loss (Timmerman, Raeymaekers et al. 1992). The gene for dHMNII was 
mapped to chromosome 12q24 (Timmerman, De Jonghe et al. 1996), and the disease-
causing gene was identified later by same group (Irobi, De Jonghe et al. 2004).  
Congenital distal spinal muscular atrophy (SMA) is an autosomal dominant non-
progressive SMA characterized by weakness and atrophy in distal limbs, but proximal 
limbs can be affected in the severely affected individuals (Fleury and Hageman 1985). 
The gene for this disorder was mapped to chromosome 12q (van der Vleuten, van 
Ravenswaaij-Arts et al. 1998), and the gene was recently found (Auer-Grumbach, 
Olschewski et al. 2010). 
Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominant disorder that 
manifests with cerebellar ataxia, Parkinsonian symptoms and oculomotor impairment. 
Gispert, S. et al. mapped the gene for SCA2 to chromosome 12q24 (Gispert, Twells et 
al. 1993). Three years later, Pulst S. M. et al. identified CAG repeats in the ATXN2 
gene in this locus (Pulst, Nechiporuk et al. 1996). 
Recently, an autosomal dominant hereditary spastic paraplegia (SPG36) was mapped 
to chromosome 12q23-24 (Schule, Bonin et al. 2009). Hereditary spastic paraplegias 
are characterized by spasticity mostly in lower leading gait difficulties, but can be 
complicated by other features including urinary dysfunction, ocular impairment and 
mental disability. In SPG36, the clinical presentation can be complicated by 
peripheral neuropathy. 
SCA2 and SPG36 affect the central nervous system, but some degree of peripheral 
nervous system involvement is seen as well. Because all these diseases are linked to 
chromosome 12q, this region might be important in the development or function of 
the nervous system. Further studies of this region could prove useful in determining 
its role in the neurogenesis, especially the peripheral nervous system. 
4.3 Gene sequencing 
TRPV4 is mutated in CMT 2C 
Sequencing of candidate genes selected within the region of interest failed to identify 
any significant sequence variant. This selection was based on function and expression 
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of the genes. We then undertook sequencing all the genes within that region, and 
identified two sequence variants in the TRPV4 gene. TRPV4 is expressed at low level 
in neurons but was found to be mutated in three of the five CMT2C families studied 
here and in two non characterized CMT2 index patients. This proves that, although 
this method has worked in other cases, gene expression level in targeted tissues may 
not be the appropriate way to select for candidate genes in a linked region. Two 
missense mutations characterized here were located in the same codon but predict 
different amino acid substitutions, R269C and R269H, respectively. This residue is 
located in the third ankyrin repeat in the intracellular N-terminal region of the TRPV4 
protein, and may play a specific role in TRPV4 function. Screening of the two 
supposedly unaffected individuals in family F1 revealed that they carried the 
mutation. This makes it less likely that this mutation be a new mutation in this family. 
Sequencing of TRPV4 in families F3, F4 and F5 did not show any significant 
sequence variant, supporting the possible genetic heterogeneity in this disease as 
suggested above. However, exome sequencing revealed a single nucleotide change in 
the TRPV4 gene in family F3, R186Q. With standard Sanger sequencing we could not 
first see this sequence variant. A review of the chromatographs showed a very low 
peak of the mutant variant at the level of the background noise. This is likely due to 
the fact that primers used to amplify this region of the gene contained SNPs, with one 
having a frequency of 0.049. It was shown that when a primer that contains SNP is 
used to amplify a region it can lead to monoallelic amplification. This emphasizes the 
advantage of the technique used by exome sequencing. In fact there were 131 reads 
across the sequence variant with 79 reads for the wild-type allele and 52 for the 
mutant allele. When this region of TRPV4 was amplified with different primers, the 
mutation appeared well, and segregated with disease status in the family (Family F3). 
However, individual III.5 did not have the mutation. This is possible because he did 
not have any clear clinical or laboratory findings in favour of CMT. Although his 
chest X-rays showed hemi-diaphragmatic paralysis, his phrenic nerve conduction 
velocity and amplitude were normal, suggesting that his sleep apnoea may be of 
different origin. The R186 is also located in an ankyrin repeat domain, at the end of 
the first ARD. 
Only about 1 % of genome is translated into protein, and the majority of Mendelian 
disorders are caused by mutations in this part of the genome. In recent years, 
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researchers have developed a technique that capture and sequence this part of the 
genome, making discovery of monogenic diseases mutations easier. Our study 
emphasizes the importance of targeted capture sequence, and has added to growing 
list of mutations found by exome sequencing. However, this technique also has its 
limitations. Not all the exome is covered, leaving the possibility of false negative 
findings. As in Sanger sequencing, G-C rich regions are hard to sequence using the 
targeted capture sequencing, and repeat regions are not sequenced at all. With the 
technology improving and the cost of exome sequencing going down, high throughput 
capture sequencing will be a valuable tool to uncover new genes and establish 
diagnosis of genetic disorders. 
Screening of 132 families with unspecified CMT2 revealed two other sequence 
variants in TRPV4 (R232C and D854N), suggesting that mutations in this gene are 
not as uncommon as one would expect. Further cohort studies may reveal new 
mutations in this gene. 
Other researchers have reported TRPV4 mutations in CMT2C families and other 
neurodegenerative diseases including scapuloperoneal spinal muscular atrophy 
(SPSMA), and congenital spinal muscular atrophy (Auer-Grumbach, Olschewski et 
al. 2010; Chen, Sul et al. 2010; Deng, Klein et al. 2010; Zimon, Baets et al. 2010) 
discussed below.  
TRPV4 mutations also cause skeletal dysplasias 
Mutations in the TRPV4 gene have been previously associated with autosomal 
dominant skeletal dysplasias. Brachyolmia is caused by R616Q and V620I mutations 
(Rock, Prenen et al. 2008), and later, the D333G and I331F mutations have been 
identified in the 5
th
 ankyrin repeat in single patients with spondylometaphyseal 
dysplasia Kozlowski type and metatropic dysplasia, respectively (Krakow, Vriens et 
al. 2009).  
More recently, other TRPV4 mutations were reported in other metatropic dysplasias 
families (Camacho, Krakow et al. 2010).  
Of the 11 mutations identified in 19 families with skeletal dysplasia, only three are 
located in the ankyrin repeat domains (Krakow, Vriens et al. 2009; Camacho, Krakow 
et al. 2010) while only two of the mutations identified in CMT2C/SPSMA/SMA 
families are localized in the transmembrane domain (Chen, Sul et al. 2010; Zimon, 
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Baets et al. 2010), and those families with transmembrane domain mutations have 
some symptoms related to bone abnormalities. 
Several cases of single gene mutations causing different diseases, in some cases in 
different organ systems, were reported in the literature. We will discuss some of them 
here. 
ANO5 mutations cause Gnathodiaphyseal dysplasia and limb-girdle muscular 
dystrophy and Myoshi muscular dystrophy 3. 
Gnathodiaphyseal dysplasia (GDD) is an autosomal dominant disease characterized 
by frequent bone fractures in adolescence and purulent osteomyelitis of jaws during 
adult life (Akasaka, Nakajima et al. 1969). This disease was found to be caused by 
mutations in the ANO5 gene in 2004 by Tsutsumi et al. (Tsutsumi, Kamata et al. 
2004). Recently, other researchers identified mutations in the ANO5 gene in 
consanguineous families with limb-girdle muscular dystrophy type 2L (LGMD2L) 
and distal Myoshi muscular dystrophy 3 (MMD3) (Bolduc, Marlow et al. 2010). 
LGMD2L is an autosomal recessive LGMD characterized by prominent asymmetrical 
quadriceps femoris and biceps brachii weakness and atrophy. Symptoms start between 
11 and 50 years, and the disease severity is variable. MMD3 is characterized by 
asymmetric distal weakness in lower limbs; mostly calf muscles leading to the 
inability to stand on tiptoes. While mutations in the N-terminal tail of ANO5 were 
seen in LGMD2L and MMD3 only, mutations of the transmembrane domain were 
seen in ganthodysphyseal dysplasia, and LGMD2L and MMD3. 
ANO5 is a calcium-activated chloride channel with unknown function. Although 
functional analyses showing the effect of these mutations on the channel function are 
not available, it is still striking that mutations in the same gene cause diseases in 
different organ systems. Further experiments may be needed to differentiate the effect 
of the mutations in the channel function or its interaction with other proteins.  
Dynactin 1 mutations in distal hereditary motor neuropathy type VIIB and in Perry 
syndrome. Distal hereditary motor neuropathy type VIIB (dHMNVIIB) is an 
autosomal dominant motor neuron disease characterized by an adulthood onset of 
breathing difficulties due to vocal fold paralysis, progressive facial weakness, and 
weakness and atrophy in hands. Lower limb weakness and atrophy develop later in 
the disease course. There is no sensory involvement. Puls I. et al. found mutations in 
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the dynactin 1 (DCTN1) gene in a large family afflicted with dHMNVIIB (Puls, 
Jonnakuty et al. 2003).  
Perry syndrome is an autosomal dominant neuropsychiatric disorder that starts in the 
late fifties. The disease starts with psychiatric symptoms including mental depression, 
sleep disorder, exhaustion and severe weight loss. Later, Parkinsonian symptoms 
develop. Death occurs by respiratory failure (Perry, Bratty et al. 1975). In 2009, 
Farrer M. J. et al. (Farrer, Hulihan et al. 2009) identified five heterozygous mutations 
in the DCTN1 gene in eight Perry syndrome families. 
Although both dHMNVIIB and Perry syndrome present with symptoms involving the 
nervous system, these two diseases are separate because they affect different parts of 
the nervous system; dHMNVIIB affects peripheral nerves while Perry syndrome 
affects the central neurons system. In vitro functional expression studies in both 
disorders indicated that mutations in DCTN1 resulted in decreased microtubule 
binding and intracytoplasmic inclusions. However, how mutations in DCTN1 cause 
both diseases is still not clear. 
Sodium channel, voltage-gated, type IX, alpha subunit (SCN9A) mutations cause 
primary erythermalgia, paroxysmal extreme pain disorder, and congenital indifference 
to pain. 
Primary erythermalgia is an autosomal dominant disorder characterized by childhood 
onset of episodic symmetrical red congestion, vasodilatation, and burning pain of the 
feet and lower legs provoked by exercise, long standing, and exposure to warmth 
(Mandell, Folkman et al. 1977). Relief is obtained with cold (Michiels, te Morsche et 
al. 2005). In 2004, Yang F. et al. (Yang, Wang et al. 2004) identified mutations in the 
SCN9A gene in affected members of a Chinese family with primary erythermalgia 
and in a sporadic case. Other researchers reported mutations in other families, later 
(Dib-Hajj, Rush et al. 2005; Michiels, te Morsche et al. 2005). 
Paroxysmal extreme pain disorder (PEXPD), formerly known as familial rectal pain, 
is characterized by paroxysms of rectal, ocular, or submandibular pain with flushing 
(Fertleman, Baker et al. 2006). Fertleman C. R. et al. have identified eight missense 
mutations in the SCN9A gene in 11 families and two sporadic cases of PEXPD 
(Fertleman, Baker et al. 2006). 
Although these two entities are characterized by pain and are allelic, Fertleman C. R. 
et al. suggested that they have distinct underlying biophysical mechanisms. 
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Carbamazepine is a drug that is efficient in PEXPD but not in primary erythermalgia. 
Moreover, in vitro electrophysiological studies have shown that carbamazepine 
selectively block persistent current associated with PEXPD mutants but not primary 
erythermalgia mutants, confirming that each of these disorders represents separate 
class of peripheral neuronal sodium channelopathy.  
Congenital indifference to pain also called 'channelopathy-associated insensitivity to 
pain' is characterized by painless injuries beginning in infancy but otherwise normal 
sensory modalities. Perception of passive movement, joint position, and vibration are 
normal, as are tactile thresholds and light touch perception. Reflexes and autonomic 
responses are also normal. The first case was described in 1932 (Dearborn 1932). Cox 
J. J. et al. first identified three distinct homozygous mutations in the SCN9A gene in 
three Pakistani families with congenital indifference to pain (Cox, Reimann et al. 
2006). Subsequently, Goldberg Y. P. et al. (Goldberg, MacFarlane et al. 2007) 
identified 10 homozygous mutations in nine families. In vitro functional expression 
studies have shown that the mutations in congenital indifference to pain cause loss of 
function.  
Although these diseases affect the same organ system, it is still striking that mutations 
in the same gene cause different diseases, especially in the case of primary 
erythermalgia or paroxysmal extreme pain disorder and congenital indifference to 
pain. 
Lamin A/C (LMNA) mutations cause Charcot-Marie-Tooth type 2B1, limb-girdle 
muscular dystrophy type 1B, autosomal dominant Emery-Dreifuss muscular 
dystrophy (EDMD), and mandibuloacral dysplasia with type A lipodystrophy 
(MADA). 
As described above, Charcot-Marie-Tooth type 2B1 is an axonal neuropathy 
characterized by distal lower limb muscles weakness and atrophy, but in some cases 
proximal muscles are affected (Bouhouche, Benomar et al. 1999). In 2002, De 
Sandre-Giovannoli et al. (De Sandre-Giovannoli, Chaouch et al. 2002) identified a 
homozygous mutation in the LMNA gene in three consanguineous families. 
Limb-girdle muscular dystrophy type 1B (LGMD1B) is an autosomal dominant 
muscular dystrophy associated with cardiomyopathy (van der Kooi, Ledderhof et al. 
1996). The disease is characterized by symmetrical weakness in the proximal lower 
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then upper limb muscles. Muchir A. et al. identified mutations in the LMNA gene in 
three LGMD1B families (Muchir, Bonne et al. 2000). 
The classic EDMD is an X-linked disorder caused by mutations in the emerin gene 
(Emery 1989), and characterized by myopathic changes in certain skeletal muscles 
and early contractures at the neck, elbows, and Achilles tendons, as well as cardiac 
conduction defects. Autosomal dominant EDMD is characterized by slowly 
progressive muscle weakness with scapulo-ilio-peroneal distribution and late-onset 
cardiomyopathy. Bonne G. et al. have identified mutations in the LMNA gene in five 
families with autosomal dominant EDMD (Bonne, Mercuri et al. 2000). 
Mandibuloacral dysplasia with type A lipodystrophy (MADA) is an autosomal 
recessive disorder characterized by growth retardation, craniofacial anomalies with 
mandibular hypoplasia, skeletal abnormalities with progressive osteolysis of the distal 
phalanges and clavicles, and pigmentary skin changes (Young, Radebaugh et al. 
1971). Novelli G. et al. (Novelli, Muchir et al. 2002) first identified homozygous 
mutations in the LMNA gene in nine families with MADA. 
Although LGMD1B and EDMD are due to muscle involvement, CMT2B1, and 
MADA more, are diseases of different organ systems. But yet mutations in the 
LMNA gene are associated with all these diseases. 
Other disorders as diverse as dilated cardiomyopathy type 1A (CMD1A), familial 
partial lipodystrophy type 2 (FPLD2), Hutchinson-Gilford progeria syndrome 
(HGPS), Slovanian type heart-hand syndrome, and LMNA-related congenital 
muscular dystrophy can be also due mutations in the LMNA gene. 
This chapter underscores the complexity of gene regulation and expression in the 
different organ systems, a process that is still not well known. 
4.4 Functional studies 
TRPV4 is expressed in peripheral nerves. 
TRPV4 is a non selective cation channel that was shown to be expressed in the 
nervous system. Studies have reported TRPV4 to be expressed in motor neurons 
(Facer, Casula et al. 2007), ventral root (Facer, Casula et al. 2007), and dorsal root 
ganglion (DRG) neurons (Liedtke, Choe et al. 2000). In addition, in situ hybridization 
studies show Trpv4 mRNA expression in ventral and dorsal horn neurons of adult 
mouse spinal cord tissue (Allen Institute for Brain Science Spinal Cord Atlas). We 
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have confirmed TRPV4 expression in the spinal cord using Trpv4 knockout (Suzuki, 
Mizuno et al. 2003) and wild type mice by immunohistochemistry (IHC), and in 
human adult dorsal and ventral spinal cord, and in tracheal cartilage. Furthermore, 
quantitative RT-PCR showed TRPV4 expression in the nervous system. However, 
compared to cartilage, TRPV4 was about 95 % less expressed in the nervous system. 
This high expression in cartilage was shown by previous studies (Rock, Prenen et al. 
2008).  
To date, all the genes implicated in CMTs have been shown to play a major role in the 
peripheral nerve structure or function. To our knowledge, TRPV4 is the second ion 
channel reported to cause CMT. KCC3, a potassium chloride cotransporter was 
reported to cause hereditary motor and sensory neuropathy associated with agenesis 
of the corpus callosum (Uyanik, Elcioglu et al. 2006). KCC3 was localized in the 
brain and the spinal cord, and KCC3 knockout mouse showed peripheral nerves 
hypomyelination. Although the function of TRPV4 in the nervous system is not 
known, as a calcium channel, TRPV4 may play a role in the axonal degeneration; a 
process that implicates calcium influx. In addition, as discussed below, dysregulation 
of calcium homeostasis has been implicated in some neurodegenerative disorders. 
TRPV4Δ7 expresses more in the nervous system by RT-PCR but qRT-PCR found 
no difference in exon 7 levels in different tissues  
At least five TRPV4 splice variants cloned in human tracheal and bronchial epithelial 
cells have been reported in the literature (Arniges, Fernandez-Fernandez et al. 2006). 
Quantitative RT-PCR using cDNA using primers flanking TRPV4 exon 7 did not 
show any differential expression in tissues including cartilage, spinal cord, peripheral 
nerves, and kidney. When we amplified TRPV4 cDNA from different human tissues 
including brain, spinal cord, trachea, liver, and kidney, only two bands were 
visualized in each. There was no difference in size between tissues. Moreover, 
sequencing of these bands revealed that the smaller band lacked exon number 7 while 
exon number 5 was present in all. However, the band corresponding to the splice 
variant lacking exon 7 was stronger in tissues from the nervous system. It is possible 
that the mutations we describe here impact more TRPV4Δ7 function, which is more 
expressed in neurons. Although a weak argument, this difference could account for 
TRPV4 mutations causing diseases in different organ systems. Heterologous 
experiments described here were conducted using TRPV4 full-length. It will be 
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interesting to perform experiments with the shorter splice variant, and compare 
mutations described here to those found in bone diseases. 
CMT 2C mutations lead to increased channel activity 
TRPV4 is a non-selective cation channel that lets Ca
2+
 into cell. Ca
2+
 is an essential 
intracellular signal in neurons regulating neurite outgrowth, synaptogenesis, synaptic 
transmission, and plasticity, but excessive influx of Ca
2+
 has also long been associated 
with neurodegeneration (Mattson 2007). The mutations found here were shown to 
cause increased channel activity leading to calcium overload. This calcium overload 
likely causes cell toxicity as shown in different cell models including Xenopus 
oocytes, HEK293 cells, and, most importantly, dorsal root ganglia. Although TRPV4 
is expressed at rather low level in nerve tissues, in vitro functional expression studies 
have shown that abnormal TRPV4 function could still cause neuronal cell death as 
evidenced by DRG toxicity. When exposed to ruthenium red, mutants and wild-type 
expressing oocytes showed reduced currents up to 53 %. In the presence of ruthenium 
red, increased calcium levels and cell death were blocked, suggesting that calcium 
overload and cell death was due to TRPV4 hyperactivity. However, because 
ruthenium red is non-specific TRP channels blocker, its blocking activity may not be 
limited to TRPV4 channel only. In addition, ruthenium red can also be toxic to cells. 
To investigate the specificity of TRPV4 currents and exclude ruthenium red for 
causing cell death, we used the specific TRPV4 inhibitor RN-1734, and found that 
calcium overload and cell death were reversed, confirming the specificity of TRPV4 
currents. In addition, the TRPV4 pore-inactivating substitution M680K, which is 
known to reduce calcium entry into the cell (Voets, Prenen et al. 2002) also reduced 
cell calcium content and cell death when co-expressed with mutant TRPV4.  
Together, these data indicate that cell calcium overload and cell death is due to 
aberrant activity of the TRPV4 channel. However, as discussed below, increased 
channel activity could not be accounted for by changes in TRPV4 channel subcellular 
localization as shown by analysis of surface incorporation of TRPV4 by cell surface 
biotinylation and wild-type and mutant TRPV4 expressed in cells from the HeLa and 
HEK293 lines that showed similar spatial distributions. 
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Mutant TRPV4 display similar cellular localization compared to wild-type, and is 
not retained in the ER. 
TRPV4 protein contains four endoplasmic reticulum (ER) retention or retrieval 
motifs, two in the intracellular N-terminal region (
122
RWR and 
269
RGR) and two in 
the C-terminal tail (
816
RLR and 
819
RDR). The R269 residue constitutes the first 
arginine of the second motif as seen above. These motifs are known to play a role in 
protein trafficking from the endosome to the membrane (Zerangue, Schwappach et al. 
1999). In fact, Zerangue N. et al. have shown in ATP-sensitive K
+
 channels that ER 
retention or retrieval motif is required at multiple stages of KATP assembly to restrict 
surface expression to fully assembled and correctly regulated octameric channels. 
They have shown that when tetrameric channels assemble, ER retention or retrieval 
motifs are internalized, thus leading these channels to traffic to the cell membrane. 
When assembly is prevented, ER retention or retrieval motifs are exposed; therefore 
channel subunits are retained in the ER leading to low expression of these channels.  
TRPV4 channels form a functional homotetrameric channel. Assembly occurs in the 
ER, and the channel is trafficked to the Golgi where it undergoes further maturation 
(Arniges, Fernandez-Fernandez et al. 2006). Arniges M. et al. have shown that when 
they delete part of TRPV4 ankyrin repeat domains, the protein remains in the ER, and 
mutation of the first arginine of any of the four ER motifs did not modify the 
localization of TRPV4, to say TRPV4 was retained in the ER (Arniges, Fernandez-
Fernandez et al. 2006).  
In addition, ER markers did not show any overexpression suggestive of ER stress. 
Although different in design, our results are consistent with those of Arniges et al. in 
that ER motif mutation did not modify the cellular localization TRPV4. Based on the 
results Arniges et al. found, we can extrapolate that the mutations we found here did 
not disturbed the ankyrin repeat domains in such a way to disturb TRPV4 assembly 
and cell surface localization.  
TRPV4 mutations are also found in bone diseases. 
During our study, mutations in TRPV4 were reported in patients with bone disease 
(Rock, Prenen et al. 2008; Krakow, Vriens et al. 2009; Camacho, Krakow et al. 2010; 
Dai, Kim et al. 2010; Nishimura, Dai et al. 2010). Some of these mutations were 
shown to increase basal and stimulated channel activity, perhaps via direct alteration 
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of the S5 pore domain (Rock, Prenen et al. 2008). TRP channels operate within 
macromolecular complexes (Clark, Middelbeek et al. 2008), and the ankyrin motifs 
are likely critical mediators of protein-protein interactions that regulate TRP channel 
localization and activity. The R269 residue localized to the convex face of the 
TRPV4-ARD may mediate distinct interactions with yet-to-be identified regulatory 
partners particularly important for TRPV4 function in peripheral neurons. Although 
the R232C and R186C mutations were not studied functionally, R232 and R186 along 
with the other residues mutated in other neurological disorders (Auer-Grumbach, 
Olschewski et al. 2010; Deng, Klein et al. 2010) are located on the same face as R269 
in the chicken Trpv4 ARD structure, suggesting that they may also play a role in 
TRPV4 interaction with other proteins important for the nervous system. Moreover, 
the R232 lies in a splicing enhancer site where the R232C may disrupt splicing and 
disorganize the ankyrin repeat domain, thus disrupting TRPV4 assembly or activity. 
The D854 residue is located in the C-terminal part of the protein, a region that has 
been shown to play a role in the plasma membrane localization of the TRPV4 
(Becker, Muller et al. 2008). In fact, their study, Becker D et al. showed that deletion 
of the C-terminal part of TRPV4 protein up to the 844
th
 amino acid did not traffic to 
the membrane but a deletion to the 855
th
 amino acid of TRPV4 protein did. Mutation 
at residue D854 may lead to untrafficked TRPV4, therefore causing toxicity to 
neuronal cells and CMT2C phenotype. No other mutation has been found in this 
region, raising the possibility that this sequence variant may not be disease-causing. 
Heterologous expression studies of the D854N mutation in cell models could give 
insights into its impact in TRPV4 function. 
TRPV4 mutations in CMT 2C lie on the opposite face of that of skeletal dysplasias 
mutations in the chicken TRPV4 ankyrin repeat domain crystal structure. 
The TRPV4 protein has distinct domains, including six transmembrane segments with 
a putative ion pore region between S5 and S6, an intracellular N-terminal domain 
containing six ankyrin repeats and an intracellular C-terminal domain. Ankyrin repeat 
motif is a short sequence of about 33 amino acids residues which forms an anti-
parallel helix-turn-helix structure followed by a β-hairpin loop. Often, more than three 
repeats are found in tandem and stack together to yield a hand-shaped domain with a 
concave palm surface formed of the inner helices and fingers, and a convex surface 
analogous to the back of the hand (Gaudet 2008). 
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Ankyrin repeats mediate protein-protein interactions, some of which have been shown 
to modulate TRPV4 activity (Phelps, Wang et al. 2010). The 2.3-Å crystal structure of 
the chicken Trpv4 ankyrin repeat domain (ARD) shows the typical hand-shaped 
structure with a concave palm surface formed by inner helices and fingers, and a 
convex surface representing the back of the hand. Arg269 is located at the base of 
finger 3 on the convex surface, opposite the palm surface harbouring all described 
skeletal dysplasia mutations in the ARD (Krakow, Vriens et al. 2009) (Figure 39a). 
Most convincingly, all reported TRPV4 mutations found in CMT2C or SPSMA or 
congenital SMA (Auer-Grumbach, Olschewski et al. 2010; Chen, Sul et al. 2010; 
Deng, Klein et al. 2010; Landoure, Zdebik et al. 2010) are located in the opposite side 
of those identified in bone diseases (Krakow, Vriens et al. 2009; Camacho, Krakow et 
al. 2010) (Figure 39b). Other non-reported TRPV4 mutations found in distal SMA 
patients also localize to same face as R269, R186, R315, and R316. This may suggest 
that residues on these faces may play an important role in TRPV4 interaction with 
proteins important for the nervous system or the skeleton. 
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Figure 39 Surface representation of the chicken TRPV4 ARD showing neurological and bone diseases mutations.  
a) Arg269 in blue and Ile331 and Asp333 in green. Residues that differ between chicken and human TRPV4 are yellow, demonstrating that the 
palm and finger regions are conserved. b) Green and represent mutations in bone diseases and blue and purple represent mutations in 
neurological disorders. Note that they are in opposite faces. 
 167 
CMT 2C mutations do not disrupt TRPV4 protein folding or its interaction with 
PACSIN 1, 2, and 3. 
When compared, the TRPV1, TRPV2 and TRPV6 structures (Jin, Touhey et al. 2006; 
Lishko, Procko et al. 2007; Phelps, Huang et al. 2008) show a conserved backbone 
structure at the position Arg269, although the arginine residue is not conserved in 
other TRPV channels (Figure 40). This suggests that the R269C and R269H 
substitutions are unlikely to disrupt the protein folding, but the Arg269 side chain is 
exposed and well positioned to mediate protein-protein interactions that may be 
critical to TRPV4 function. The cytoskeletal modulating proteins, PACSINs 1-3, have 
been shown to bind the N-terminus of TRPV4 and modulate its membrane 
localization and function. When interaction with PACSIN 3 is disrupted, TRPV4 
shows increased channel activity (Cuajungco, Grimm et al. 2006). PACSIN 1 is 
nervous system-specific (Modregger, DiProspero et al. 2002) and altered interaction 
with this or another such factor could account for the tissue specificity of the CMT2C 
phenotype. ATP and calmodulin have been shown to bind to TRPV4 through a 
conserved binding site in the ARD, and that ATP and calmodulin participate in the 
sensitivity and adaptation profiles of TRPV4 (Phelps, Wang et al. 2010). 
However, binding assays and co-immunoprecipitation experiments did not show 
changes in the interaction of mutant TRPV4 with known protein partners such as 
calmodulin and PACSIN 1, 2, and 3, confirming that the CMT2C-associated 
mutations do not grossly disrupt TRPV4 protein folding. Further experiments are 
needed to define whether specific intermolecular or intramolecular interactions are 
affected by the Arg269 substitution. 
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Figure 40 Comparisons of the chicken TRPV4 ARD structures to that of other TRPV 
proteins.  
a) Carbon α traces of the superimposed TRPV4 ankyrin repeat domain structures, 
Chains A (blue), B (cyan), C (light green), D (dark green) of crystal form I and A 
(orange) and B (yellow) of crystal form II. They superimpose readily with pairwise 
root mean squared deviations (rmsd) ranging from 0.31 to 0.71. The largest 
differences are in the tip of finger 3 (white arrowhead) as observed in TRPV218. The 
side chain of R255 (R269 in human TRPV4) is shown (black arrowhead). b) 
Stereodiagram of the weighted 2Fo-Fc electron density map in proximity to R255 
(R269 in human TRPV4; arrowhead) of chain A. c) Ribbon diagram of the 
superimposed structures of chicken TRPV4 (blue; carbon α of R255 shown as a 
sphere), rat TRPV1 (yellow; 2PNN16), rat TRPV2 (green; 2ETB18 and mouse 
TRPV6 (cyan; 2RFA19). Again, the largest observed structural differences are at the 
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tip of finger 3 (white arrowhead). d) Zooming into the base of finger 3 at the convex 
face of the molecule. The backbone positions of residues structurally equivalent to 
R255 (R269 in human TRPV4) are conserved, although the side chains of these 
residues differ. Colouring is the same as in (c). 
 
Activating TRPV4 mutations cause other neurological disorders 
In SPSMA TRPV4 mutations caused increased channel activity and calcium overload 
(Deng, Klein et al. 2010). In this study, HEK293 cells were used for both 
electrophysiological and cell calcium measurement experiments. However, in the 
other study that reported congenital distal SMA and CMT2C (Auer-Grumbach, 
Olschewski et al. 2010) there was a decreased channel activity and calcium uptake, 
and TRPV4 mutants proteins surface localization was reduced. This study used HeLa 
cells that do not have endogenous TRPV4. TRP channels are known to interact with 
PIP2 (Nilius, Owsianik et al. 2008). PIP2 is a recruiter of TRPV4 and an inhibitor of 
its activity. Because ankyrin repeat domain are typical PIP2 binding sites, ankyrin 
domain mutations diminish the channel‟s ability to interact with the phospholipid. In 
HeLa and other cells that lack endogenous TRPV4, the transfected mutant protein is 
unable to find the membrane without binding PIP2, and thus remains in the 
cytoplasm. The lack of trafficking of TRPV4 to the membrane can explain its loss of 
function seen in the second study. On the other side cell types such as HEK293 cells 
contain endogenous wild-type TRPV4, and the mutant and wild-type proteins 
sometimes may come together in mixed tetramers. The interaction of wild-type 
TRPV4 and PIP2 is sufficient to recruit the complex to the plasma membrane. In this 
case the PIP2 cannot bind to the mutant channel meaning that it does not effectively 
inhibit TRPV4 mutant, thus causing the gain of channel function. Another possible 
explanation of the discrepancies can be the difference in the compensatory 
mechanisms of the different cell types. 
4.5 Calcium and neurodegeneration 
Several studies have demonstrated the role of calcium ions in several cellular 
processes including muscle contraction, transmitter release, cell proliferation, gene 
transcription, and cell death (Berridge, Bootman et al. 2003). In neurons, under 
physiological conditions, Ca
2+
 plays an important role in the regulation of neurite 
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outgrowth and synaptogenesis, synaptic transmission and plasticity, and cell survival. 
Neurons are excitable cells that rapidly transfer electrochemical signals in a highly 
controlled spatio-temporal manner. Ca
2+
 is critical in mediating many intracellular 
physiological responses of neurons to chemical and electrical stimulation. TRPV4 is 
ligand-gated channel, and the influx of Ca
2+
 through ligand-gated channels in the 
plasma membrane is a critical signal for the release of neurotransmitter from 
presynaptic terminals and for responses of the postsynaptic neuron (Hartmann and 
Konnerth 2005). In normal conditions, intracellular Ca
2+
 concentration increases only 
transiently, second to a few minutes. This transient increase does not affect neurons. 
However, in pathological conditions such as in neurodegenerative disorders, neurons 
can no longer control Ca
2+
 fluxes and recover from Ca
2+
 overload, leading to their 
damage. Two organelles play a critical role in the Ca
2+
 homeostasis; endoplasmic 
reticulum (ER) and mitochondria are sites of Ca
2+
 regulation. 
The role of dysregulation of calcium homeostasis in the pathogenesis of slow 
progressing neurodegenerative diseases was shown in different studies. We will talk 
about diseases that are clinically and physiopathologically close to CMTs.  
Huntington‟s disease: Huntington‟s disease (HD) is an autosomal dominant 
neurodegenerative disease characterized by motor and psychiatric symptoms. The age 
of onset ranges from 20 to 50 years, and symptoms manifest as chorea and dementia 
due to a selective and progressive loss of medium spiny neurons in the striatum.  HD 
is caused by a dominant negative effect the abnormal expansion of Huntingtin protein 
(Ht). Some studies have shown that mutant Ht disrupts mitochondrial Ca
2+
 
homeostasis (Panov, Gutekunst et al. 2002), and associates directly with the inositol 
triphosphate receptor (IP3R) in the ER and is able to sensitize this receptor to its 
activation by IP3R (Tang, Tu et al. 2003). Other studies have implicated mutant Ht in 
N-methylo-D-aspartate receptors (NMDARs) hypersensitivity and an increase in Ca
2+
 
influx (Sun, Savanenin et al. 2001). All these lead to Ca
2+
 accumulation over time that 
can eventually trigger the opening of the permeability transition pore in mitochondria 
and neuronal death. 
Other hereditary neurological disorders in which Ca
2+
 signalling play a role in the 
pathogenesis are autosomal dominant spino-cerebellar ataxias (SCA). SCAs are 
neurodegenerative disorders that start between 30 and 50 years, and are characterized 
by cerebellar ataxia associated with pyramidal and extrapyramidal signs and 
symptoms, dementia, ophthalmoplegia and pigmentary retinopathy, and peripheral 
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neuropathy (Zoghbi 2000). These symptoms progress slowly over years. Signs of 
Ca
2+
 involvement in the pathogenesis of SCAs are downregulation of several neuronal 
genes highly expressed in Purkinje cells and involved in Ca
2+
 signalling or 
homeostasis in SCA-1 mutant mice. Among these genes are the calbindin-D28k and 
paralbumin (Vig, Subramony et al. 2000), and IP3R and SERCA2 (Lin, Antalffy et al. 
2000). Another Ca
2+
 channel associated with Purkinje cells degeneration is the 
voltage-operated Ca
2+
 channel CACNA1A gene (Pietrobon 2002). 
The closest disease to CMTs in which Ca
2+
 dyshomeostasis was shown to play a role 
in the pathogenesis is the amyotrophic lateral sclerosis (ALS). ALS is characterized 
by loss of cortical, spinal and bulbar motor neurons. Symptoms include muscle 
weakness, breathing and swallowing difficulties, and limbs spasticity (Rowland and 
Shneider 2001). Only 10 % of ALS cases have a genetic component, and the 
superoxide dismutase gene (SOD1) is most commonly mutated gene in this 
neurodegenerative disorder (Strong and Gordon 2005). Although the mechanism 
leading to degradation of motor neurons in this disease is not established, intracellular 
Ca
2+
 dysregulation was suggested by different studies. Glutamate excitotoxicity, Ca
2+
 
dependent formation of protein aggregates, and Ca
2+
-evoked mitochondrial 
dysfunction are believed to play a role in the mechanism (Van Den Bosch, Van 
Damme et al. 2006). Studies have shown that spinal motor neurons do not express the 
Ca
2+
 binding proteins parvalbumin and calbindin D28k that are Ca
2+
 sequestrators 
(Ince, Stout et al. 1993) and that they have a high proportion of α-amino-3-hydroxy-5-
methylisoxazole-4-propionate acid receptors (AMPARs), receptor-operated channels, 
lacking the GluR2 subunit. This favours Ca
2+
 permeability of these channels 
(Carriedo, Yin et al. 1996), making these motor neurons highly sensitive to any 
potential excitotoxicity by either exogenous or endogenous factors. 
The role of Ca
2+
 dyshomeostasis was shown in other chronic neurological or 
neuropsychiatric diseases, including Alzheimer‟s disease, Parkinson‟s disease, 
glaucoma, epilepsy, and schizophrenia. 
Dysregulation in Ca
2+
 signalling was also shown to play a role in acute 
neurodegenerative diseases, including traumatic brain injury, brain stroke, and HIV 
dementia. 
In our study, we have proven that Ca
2+
 overload was toxic to HEK293 and HeLa 
cells, dorsal root ganglia (DRG) neurons, and Xenopus oocytes. TRPV4 channel 
hyperactivity was shown in Xenopus oocyte and HEK293 cells currents measurement. 
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The sustained TRPV4 channel hyperactivity may cause chronic increased Ca
2+
 entry 
into the neuronal cells that cannot handle it over a long period of time, leading to their 
destruction. But the mechanistic process by which hyperactivity of this channel 
become toxic to neuronal cells while it was showed to cause bone diseases in other 
studies is not fully understood. The only difference found, as stated earlier, is that 
skeletal dysplasias mutations mostly cluster in the transmembrane domain of the 
protein, and while CMT2C and other neurological disorders mutations cluster in the 
ankyrin repeat domain. Although some skeletal dysplasia mutations localize to the 
ARD, they lie in opposite face of that of neurological disorders mutations. This can 
lead to disruption of interaction with specific proteins important for each organ 
system. 
4.6 TRP channels and diseases 
TRP channels were discovered just over a decade ago, but there is an increased 
evidence of their implication or association in the genesis of diseases or pathological 
processes. 
Since their discovery, TRP channel have improved our understanding of molecular 
processes mediating Ca
2+
 entry into cells. As developed in their description above, 
TRP channels play a role in the cytosolic free Ca
2+ 
concentration. Ca
2+ 
signalling is 
very important in all cell types, thus dysfunctions in Ca
2+ 
channels cause or are 
associated with the pathogenesis of several diseases. 
Channelopathies are diseases caused by defect in genes encoding ion channels. The 
prevalence of monogenic channelopathies in neurology is 35:100,000 (Jurkat-Rott, 
Lerche et al. 2010). However, this number increases when susceptibility-related 
mutations are considered. To date, mutations in several TRP channels have been 
identified to cause disease. In addition, dysregulations of physiological functions 
mediated by ion channels that can contribute to the genesis of diseases or contribute to 
the progression of the disease have been described in the literature. 
Focal segmental glomerulosclerosis 
Focal segmental glomerulosclerosis (FSGS) is a human proteinuric kidney disease in 
which the podocyte foot processes and glomerular slit diaphragms of the glomerular 
filter lose their integrity between childhood and adulthood. Mutations in the TRPC6 
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gene were shown to be linked to FSGS (Kriz 2005; Winn, Conlon et al. 2005). 
Heterologous expression studies revealed an enhanced activity of three of the six 
mutants TRPC6. In the nephron, TRPC6 was shown to be expressed in the podocytes 
in the kidney glomerular filter (Reiser, Polu et al. 2005). Podocyte foot processes and 
the glomerular slit diaphragm form the glomerular filter and are an essential part of 
the permeability barrier in the kidney, which is defective in FSGS, making defects in 
TRPC6 a likely cause of this disease (Kriz 2005). Enhanced TRPC6 activity leads to 
Ca
2+
 overload of the podocyte that initiates cell death by apoptosis, or causes 
dysregulation that compromises the integrity of the permeability barrier (Reiser, Polu 
et al. 2005). 
Hypomagnesaemia with secondary hypocalcaemia 
Hypomagnesaemia with secondary hypocalcaemia (HSH) is an autosomal recessive 
disorder characterized by very low serum levels of Mg
2+
 and Ca
2+
. HSH occurs 
because of impaired intestinal Mg
2+
 absorption associated with renal Mg
2+ 
leak. 
Mutations in the TRPM6 gene were shown to cause HSH disease. Heterologous 
experiment have shown that TRPM6 protein forms a Mg
2+
-permeable channel, and is 
expressed in the brush-border membrane of the small intestine and in the apical 
membrane of renal distal convoluted tubule, both containing highly specialized cells 
responsible for Mg
2+ 
absorption and reabsorption (Voets, Nilius et al. 2004). 
Autosomal dominant polycystic kidney disease 
Polycystic kidney diseases are characterized by progressive development of large 
fluid-filled cysts that can occupy much of the mass of the abnormally enlarged 
kidneys, compressing and destroying normal renal tissue and impairing kidney 
function. Mutations in TRPP1 or TRPP2 genes lead to polycystic kidney disease. 
Under normal conditions, phosphorylated TRPP2 associates with TRPP1 and prevents 
nuclear translocation of Id2 which is a crucial regulator of cell proliferation and 
differentiation. TRPP1/TRPP2 mutations allow Id2 to translocate in the nucleus 
where it binds to E-proteins, switching off the activity of growth suppression proteins. 
This explains the hyperproliferative feature of autosomal dominant polycystic kidney 
disease (Li, Luo et al. 2005). 
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Mucolipidosis type IV 
Mucolipidosis type IV (MLIV) is an autosomal recessive neurodegenerative 
lysosomal storage disease. The disease manifests with severe psychomotor 
retardation, corneal opacity, retinal degeneration, strabismus, agenesis of corpus 
callosum, blood iron deficiency, and achlorohydria (Bach, Webb et al. 2005). MLIV 
is caused by mutations in the TRPML1 gene. The pathological mechanism of MLIV 
is not still fully understood.  Electron microscopy visualization of late endosomes and 
lysosomes showed abnormal storage of amphiphilic lipids and membranous materials 
in multiconcentric lamella together with granulated, water soluble substances (Bach 
2001). Heterologous experiments have shown that mutant TRPML1 channels retain 
physiological function, but are not affected by pH changes (Raychowdhury, 
Gonzalez-Perrett et al. 2004). In addition, mutant TRPML1 channels induce changes 
in the endocytotic transport of membrane components, including block to endocytotic 
route to final lysosome. Disturbed Ca
2+
 homeostasis has also been described in MLIV 
patient cells (LaPlante, Ye et al. 2004). 
Guamanian amyotrophic lateral sclerosis (ALS-G) and Guamanian Parkinsonism 
dementia (PD-G) 
As they are called, these diseases are seen with a relatively higher incidence on the 
Pacific Islands of Guam and Rato. These diseases are related and have features of 
ALS, Parkinson‟s disease and dementia. Mutations in the TRPM7 gene were found in 
25 % of the ALS-G/PD-G patients. The aetiology of ALS-G and PD-G is not 
elucidated but genetic and environmental factors seem to play a role in their 
occurrence. Interestingly, the incidence of these diseases is higher in environments 
that are deficient in Ca
2+
 and Mg
2+
, like the West Pacific. TRPM7 is ubiquitously 
distributed in most cells, and provides a pathway for Mg
2+
, Ca
2+
, and trace metal ions 
entry into the cell (Monteilh-Zoller, Hermosura et al. 2003). Studies have shown the 
important role of Mg
2+
 in cell progression and proliferation (Rubin 2005). The 
suggested mechanism for these diseases is an aggravation of the Mg
2+
 homeostasis by 
an increased sensitivity of TRMP7 to inhibition by Mg
2+
 in an Mg
2+
-deficient 
environment. This leads to decreased intracellular Mg
2+
 that may in turn contribute to 
the aetiology of the neurodegenerative diseases (Hermosura, Nayakanti et al. 2005). 
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Complete congenital stationary night blindness  
Congenital stationary night blindness (CSNB) is caused by defective signalling from 
photoreceptors to bipolar cells, and is characterized by a reduced or absent b-wave 
and a normal a-wave in the electroretinogram (ERG). Two types can be distinguished, 
the type 1 where there is a complete absence of rod pathway function (cCSNB) and 
the type 2 characterized by an impaired rod and cone pathway function (icCSNB). 
Mutations in the nyctalopin (NYX) and the metabotropic glutamate receptor 6 
(GRM6) genes were implicated in cCSNB. Postsynaptic defects in depolarizing or 
ON bipolar cell signalling was shown to cause cCSNB. TrpM1 was shown to be 
essential for the ON biopolar cell function, and had expression pattern similar to that 
of nyctalopin. In addition, screening of patients with cCSNB who are negative for 
NYX and GRM6 mutation revealed mutations in the TrpM1 gene (van Genderen, 
Bijveld et al. 2009).  
Another recent study has shown an association of loss-of-function nonsynonymous 
polymorphism in the TRPV4 gene with human hyponatraemia (Tian, Fu et al. 2009). 
Hyponatraemia is a disorder linked to disturbances in water balance. TRPV4 is 
involved in the osmoregulation and is activated by extracellular hypotonicity. As 
such, changes in TRPV4 structure or function may lead to diseases such as 
hyponatraemia.  
TRP channels are also involved in the mechanism of several pathological conditions. 
Pain is a pathological entity in which many TRP channels have been implicated. Pain 
is an unpleasant sensory and emotional experience associated with actual, or potential, 
tissue damage or described in terms of such damage (International Association for the 
Study of Pain: IASP). Pain is classified as nociceptive, neuropathic, and psychological 
depending on the origin. 
Several studies have shown the role of members of the TRP superfamily in the 
detection of acute noxious thermal, mechanical, and chemical stimuli. TRPV1 is the 
first TRP channels member to be implicated in the genesis of pain. Because of its 
expression in DRG, trigeminal ganglia, and nodose ganglia, in addition to its 
activation by heat, acid and pungent vanilloid compounds, TRPV1 have been shown 
to be a strong candidate for the detection and integration of noxious stimuli. In 
addition, TRPV1 knockout mice showed reduced response to noxious heat stimuli and 
complete indifference to pungent vanilloids (Caterina, Leffler et al. 2000). Other TRP 
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channel knockout mice, including TRPV3, TRPV4, and TRPA1 have shown reduced 
perception to noxious heat and cold (Moqrich, Hwang et al. 2005; Alessandri-Haber, 
Dina et al. 2006; Kwan, Allchorne et al. 2006). 
Neuropathic pains occur in chronic disease such as trigeminal neuralgia, diabetic 
neuropathy, post-herpetic neuralgia, late-stage cancer, amputation, or physical nerve 
damage. Members of the TRP channels superfamily were shown to be involved in the 
aetiology of neuropathic pain. Among these, TRPV1 and TRPV4 are most studied. 
Hypersensitivity of TRPV1 leads to thermal allodynia and hyperalgaesia. Another 
TRP member involved in neuropathic pain is TRPA1 which appears to be 
overexpressed in inflammation and nerve injury (Katsura, Obata et al. 2006). 
Itch is another symptom in which TRP channels are implicated. Itch is an irritating 
skin sensation causing the desire to scratch. This symptom is seen in several skin 
disorders, including psoriasis, eczema, and scabies. Some studies have shown the role 
of TRPV1 in the initiation of itch (Mohapatra, Wang et al. 2003). Other studies have 
shown that itching sensation may be due to activation of other temperature-sensitive 
TRP channels expressed in skin, keratinocytes, and sensory fibres including TRPV2, 
TRPV3, TRPV4, TRPA1, and TRPM8. It has also been shown that pruritogenic 
compounds such as eicosanoids can potently activate TRPV1 and TRPV4 (Watanabe, 
Vriens et al. 2003).  
TRP channels have been implicated in the pathophysiology of different systemic 
disorders. Activation of TRP channels can cause firing of action potentials in sensory 
fibres that is relayed to the spinal cord and can trigger efferent signals, such as 
autonomous reflexes. Activation of sensory fibres can also be directly translated via 
axon reflexes into vegetative responses, such as vasodilatation. Thus TRP channels 
can interfere via multiple pathways with organ function (Nilius 2007). Several TRP 
channel, especially TRPC and TRPM subfamilies, are involved in the inflammatory 
process. 
The study we present here adds to the growing list of diseases caused by ion channel 
dysfunction now recognized under channelopathies. We have shown functional 
evidences that R269C and R269H disrupted TRPV4 channel function, and caused 
intracellular calcium overload which led to cellular toxicity and death. 
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4.7 Channelopathies and therapeutic future  
Ion channels are proteins involved in many pathological processes. Their function can 
be regulated by different stimuli, mechanical, environmental or chemical. Therefore, 
it may be possible to reverse the effect of dysfunctional ion channel in organ systems 
by using the appropriate regulator. To date, several studies have demonstrated the 
positive effect of inhibiting or stimulating dysfunctional ion channels. 
Different studies have demonstrated the calming role of capsaicin in chronic pain, 
including post-herpetic neuralgia (Backonja, Wallace et al. 2008) and distal sensory 
polyneuropathy due to HIV infection (Simpson, Brown et al. 2008). The analgesic 
action of capsaicin is considered to be the consequence of its inhibitory effect on 
TRPV1, known to mediate pain. More recently, an oral administration of a novel 
compound (AS1928370) that is a TRPV1 antagonist was shown to reduce neuropathic 
pain in rats (Watabiki, Kiso et al. 2010) by inhibiting capsaicin-mediated inward 
currents.  
TRPA1 is also known to mediate pain, and is overexpressed in neighbouring 
uninjured nerves after nerve injury. An in vivo study has shown that a knock down of 
TRPA1 alleviates cold hyperalgaesia after spinal nerve ligation (Katsura, Obata et al. 
2006). 
Recently, it has been shown that activation of TRPM8 in sensory afferents of 
neuropathic and chronic pain rat models by either cutaneous or intrathecal application 
of pharmacological agents or by modest cooling causes inhibition of sensitized pain 
responses. 
In our study, mutations were shown to cause TRPV4 hyperactivation. A recent study 
has shown the inhibitory role of a small interfering RNA (siRNA) of mRNA levels, 
protein expression, and function of TRPV4 in DRG (Liu, Bi et al. 2010). Although the 
study did not investigate the clinical effect of TRPV4 inhibition, the use of 
synthesized siRNA could serve as potential treatment of TRPV4-related pathological 
conditions. A previous study had shown that painful peripheral neuropathy induced by 
taxol can be treated by gene silencing of TRPV4 (Alessandri-Haber, Dina et al. 2004). 
Another potential compound to try in animal model is RN1734 which is a specific 
TRPV4 antagonist that we showed block cell toxicity caused by TRPV4 
hyperactivation.   
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To date more than 35 % of marketed drugs target ion channels (Jurkat-Rott, Lerche et 
al. 2010), therefore, there is a high chance to identify or investigate known TRPV4-
blockers that may counteract the effects of the mutations we found here. 
4.8 Conclusion 
We characterized the clinical, electrophysiological, and pathological features of 
CMT2C in five families and confirmed the previously reported linkage by performing 
fine mapping. We were able to narrow down the region of linkage for this disorder 
from 3.9 Mb to 2.6 Mb. We excluded deletions or duplications in this region by SNP 
array analysis in three families. We identified five sequence variants in the TRPV4 
gene, three in three of the families described here, and two in CMT2-type cohort 
screening. Heterologous expression studies of two of the variants showed that mutants 
TRPV4 enhance channel activity leading to intracellular Ca
2+
 overload and cell death. 
TRPV4 is a cation channel known to play a role in fundamental cellular processes 
such as osmosensation, temperature sensation and mechanosensation. In this study, 
we have shown that CMT2C is associated with substitutions at the Arg269, Arg232, 
and Arg186 residues in the ankyrin repeat domain of the TRPV4 protein.  
This work uncovers a previously unrecognized role for TRPV4 in neurons and 
highlights the importance of this ion channel in normal peripheral nerve function. 
Together with the observations that disruption of TRPML1 causes the central nervous 
system lysosomal-storage disease mucolipidosis type IV (Venkatachalam, Long et al. 
2008), and that mutation of Trpc3 causes degeneration of cerebellar neurons in mice 
(Becker, Oliver et al. 2009), this study emphasizes the importance of TRP channels in 
the pathogenesis of neurodegenerative diseases. Most surprisingly, our data indicate 
that distinct alterations in this important ion channel result in strikingly different 
phenotypes that involve separate organ systems. 
To date, there is no disease modifying treatment for CMT 2C or any other hereditary 
neurological disorder. Identifying new proteins will improve our understanding of 
common pathways involved in CMTs, and will ultimately provide a basis to finding 
treatment for these diseases. Because treatment of pain targeting TRPV1 channels is 
showing satisfactory results, the future is promising for TRPV4-related diseases 
because several agents that have been shown to modulate TRPV4 function can be 
studied and tested for therapeutic effects. 
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4.9 Future directions 
Here we describe families with Charcot-Marie-Tooth type 2C that have mutations in 
the transient receptor potential vanilloid, superfamily, member 4 (TRPV4). Many 
questions remain and future and ongoing studies are focused in the following areas: 
1. What is the spectrum of neurological disease caused by TRPV4 mutations? Since 
our original study, several groups have reported other mutations in TRPV4 in both 
peripheral nerve disease and bone diseases. We have continued to evaluate other 
individuals who present with forms of CMT2 or distal SMA in order to further define 
the phenotypic spectrum of disorders associated with TRPV4 mutations.   
2. Why do some TRPV4 mutations cause peripheral nerve disease and others cause 
bone disease? Different mutations in TRPV4 cause forms of inherited skeletal 
dysplasia and inherited neuropathy, disorders affecting distinct organ systems. 
However, to date, all the described TRPV4 mutations appear to cause a gain of 
protein function resulting in increased constitutive and activated ion channel activity.  
The observation that the mutations cluster in particular anatomical locations of the 
TRPV4 protein suggest that there may be specific interactors and regulators important 
for TRPV4 channel activity in each of these organ systems. Our future objectives are 
to find potential interactors by performing co-immunoprecitation studies and mass 
spectrometry.  
3. What is the normal function of TRPV4 in motor neurons? 
4. Does TRPV4 mutation result in peripheral nerve degeneration in animal models 
and does pharmacological inhibition of TRPV4 ameliorate these defects? TRPV4 is 
an ion channel that is modulated by different stimuli, some of which inhibit its 
activity. Because the mutations found here lead to TRPV4 hyperactivation, we plan to 
test the inhibitory effect of some TRPV4-antagonists in CMT2C transgenic animals. 
For this, we plan to generate a fly and mouse model. Animal models have been used 
to better understand the pathogenesis of human diseases and to develop treatments for 
those diseases. To date, many compounds that are used to treat human diseases were 
developed from animal studies. This allowed researchers to test toxicity of drugs, and 
check their effect in reversing the disease or some symptoms without harm to human. 
Successful testing of these compounds in animal models may open the road towards 
clinical trials with the final objective of therapeutic intervention at patient level.  
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